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Introduction: Juvenile Idiopathic Arthritis (JIA) is among the most common chronic diseases of 
childhood. The cause of JIA is unknown but is suspected to occur in genetically susceptible 
children with some unidentified environmental exposure. Vitamin D, through its genetic or 
environmental influences, may regulate inflammation and immune responses in JIA. To date, no 
25 hydroxyvitamin D (25(OH)D) concentrations specific to children with JIA have been 
suggested. 
Objective. The overarching goal of this research was to understand how vitamin D affects 
disease activity in children who are suffering from JIA. The specific objectives were to: (1)  
Compare vitamin D status between healthy children and patients with JIA. (2) Determine vitamin 
D status and its association with disease activity and outcomes in children with JIA.  (3) Identify 
potential associations of vitamin D pathway gene polymorphisms and JIA. 
Methods. Data from the Biologically-Based Outcome Predictors (BBOP) Study, a prospective 
multi-center study of newly diagnosed Canadian children with JIA (n=186, 2007-2012) was 
analyzed. Blood samples were obtained at baseline and 6 months later to measure  25(OH)D)and 
plasma inflammatory cytokine concentrations. Saliva was collected for genetic analysis. Vitamin 
D-related factors (milk intake, season of measurement, supplementation and steroid use) and 
clinical data to define remission were recorded every 6 months for 2 years. 
First, BBOP children were compared to healthy children from the Canadian Health 
Measures Survey (CHMS). 25(OH)D concentrations, vitamin D related factors, measures of 
inflammation, and anthropometric measurements were evaluated. Longitudinal analysis then 
explored whether 25(OH)D and related factors could predict disease activity in BBOP children. 
Genome-Wide Association Studies (GWAS) techniques were then applied to identify frequent 
gene polymorphisms of potential relevance to the vitamin D pathway in JIA. Significant 
variables from linear regressions, genes identified through GWAS, vitamin D pathway genes and 
interactions were selected for further analysis.  
Results. Mean 25(OH)D concentration was significantly higher in JIA patients (79 ± 3.1 nmol/L 
vs. 68 ± 1.8 nmol/L p <0.05) and JIA patients used vitamin D supplements more often (50% vs. 
7% p <0.05). Children with JIA were more likely to be born in the fall and winter compared to 
healthy children. C-reactive protein concentration (CRP) and erythrocyte sedimentation rate 
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(ESR) decreased significantly over the 2 years (p<0.05). Increased 25(OH)D or its associated 
factors predicted lower ESR, CRP and pro-inflammatory cytokine concentrations. Overall, 36% 
of children achieved remission on continuing medications; 25% had sustained remission after 
discontinuing medication. GWAS identified the following genetic components: NOTCH4, 
C6orf10, HLA-DQA1, LEP, IGFBP4, and GPS1. Interactions between frequent gene 
polymorphisms and those in the vitamin D pathway (VDR, GC, CYP24A1, and CYP1R1) 
significantly predicted disease activity-related outcomes.  Genes, when included, modified the 
association between 25(OH)D and indicators of disease activity. With and without genes in the 
model, drinking milk every day predicted a reduction in indicators of disease activity as 
measured by CRP, ESR, and interleukin-6.   
Conclusion. Using 25(OH)D recommendations suggested for healthy children, 25(OH)D was 
adequate in the JIA population. A preponderance of JIA patients born in seasons associated with 
reduced endogenous vitamin D could implicate low vitamin D during gestation and early life as a 
factor influencing JIA pathogenesis. Milk intake, as a source of dietary vitamin D, is associated 
with suppression of inflammation in children with JIA. This is the first time gene and 
environment influences in relation to vitamin D were analyzed together in association with JIA 
disease activity. Environmental, biochemical, and genetic factors, including their interactions, 
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Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases in 
children. The prevalence of JIA is one in 1000 in Canada, with over 7000 children and 
adolescents living with this disease (Bernatsky et al., 2011). Symptoms of JIA, including joint 
pain, morning stiffness, joint swelling, and problems with mobility, it can interfere with daily 
activities and overall quality of life. JIA is a cause of short and long-term disability. It has 
substantial economic impact on patients, their families and the health care system (Bernatsky et 
al., 2007; Rasu et al., 2014; Ravelli & Martini, 2007; Toupin , Cavallo, Feldman, & Ni, 2012). 
Recent studies suggest that vitamin D plays a role in the prevention and pathogenesis of JIA by 
suppressing pro-inflammatory mediators, and immune responses (Von Scheven & Burnham, 
2011). Certain deoxyribonucleic acid (DNA) polymorphisms (genetic variants) are associated 
with susceptibility to some diseases. By determining if a polymorphism occurs more frequently 
in individuals genetically at risk for a disease, there is the potential for preventative care to be  
instituted through the development of pharmacological treatments (Israeli, 2013). Specific 
polymorphisms of VDR genes may be associated with different biologic responses to vitamin D. 
For example, the Cdx2 polymorphism of the VDR gene, specifically the GG genotype and G 
allele, have been suggested to be more represented in patients with JIA (Falcini et al., 2013). The 
environmental role of vitamin D in JIA is impacted by our intake of vitamin D through food and 
supplements as well as our cutaneous synthesis. These factors combined make up our circulating 
vitamin D concentrations in the blood. Investigating the genetic and environmental role that 
vitamin D plays in the prevention and control of JIA over time will help to understand the 
multifaceted role played by vitamin D in this disease. Understanding how genetic variants 
increase the risk of disease development will help guide vitamin D management in individual 
patients and contribute to improving control of disease activity and improve outcomes.  
To date and to our knowledge, no study has investigated the relationship between vitamin 
D status and JIA serially from the time of the first presentation. The ultimate goal of this research 




of vitamin D status with disease activity. I compared the vitamin D status and growth outcomes 
for children and adolescents with JIA to a healthy age-matched population of children and 
adolescents. I explored the relationship of vitamin D status on markers of inflammation and 
measures of disease activity in children and adolescents with JIA and explored a possible genetic 
association between vitamin D levels and VDR gene polymorphisms. Findings from this 
research provide valuable information on the association of vitamin D status with disease activity 
and disease outcomes. 
1.2. Study Objectives 
1.2.1. Study 1: Vitamin D Intake and Growth Patterns of Children with Juvenile Idiopathic 
Arthritis 
Objective: Evaluate vitamin D status and growth parameters in children and adolescents with 
JIA and compare with those of healthy children and adolescents. 
Hypothesis: Children and adolescents with JIA have lower vitamin D status and growth 
parameters (height, weight, waist circumference, body mass index [BMI]) than healthy children 
and adolescents. 
1.2.2 Study 2: Vitamin D and Biochemical Markers of Inflammation in Juvenile Idiopathic 
Arthritis 
Objective: Examine the association between plasma levels of 25(OH)D and disease activity and 
outcomes as determined by clinical and biomarker profiles in JIA. 
Hypothesis: Vitamin D status is negatively associated with markers indicative of inflammation 
and disease activity and outcomes among JIA patients.  
1.2.3 Study 3: Vitamin D Gene Polymorphism in Juvenile Idiopathic Arthritis 
Objective: Evaluate association between vitamin D pathway gene polymorphisms, vitamin D 
levels, and JIA disease activity. 
Hypothesis: There are specific polymorphisms of vitamin D pathway genes associated with JIA. 
The rs11568820 polymorphism of the VDR gene, specifically the GG genotype and G allele, are 







The relationship between vitamin D status and JIA over time in newly diagnosed 
individuals in Canada or abroad has yet to be investigated. Investigating the potential association 
of vitamin D, from both the genetic and environmental (as a nutrient) perspectives, in the same 








Juvenile Idiopathic Arthritis is one of the most common chronic childhood diseases. The 
prevalence of JIA is one in 1000 in Canada, with over 7000 children and adolescents living with 
this disease (Bernatsky et al., 2011). Recent studies suggest that vitamin D plays a role in the 
pathogenesis of JIA by suppressing pro-inflammatory mediators and immune responses (Von 
Scheven & Burnham, 2011). Certain DNA polymorphisms (genetic variants) are associated with 
susceptibility to some diseases. Specific polymorphisms of VDR genes may be associated with 
different biological responses to vitamin D. For example, the rs11568820 polymorphism of the 
VDR gene, specifically the GG genotype, has been suggested to be more represented in patients 
with JIA compared to healthy controls who had the GA genotype more often (Falcini et al., 
2013). The role of vitamin D in JIA is influenced by vitamin D intake through food and 
supplements as well as cutaneous synthesis. Together these factors determine our circulating 
vitamin D concentrations in blood. Investigating genetic, nutritional and environmental factors 
that influence vitamin D in JIA could help inform ways in which vitamin D status influences the 
occurrence and activity of JIA. Understanding if genetic variants increase the risk of disease 
development will help guide vitamin D management in individual patients, contribute to 
improving control of disease activity, and improve outcomes.  
To date and to our knowledge, no study has investigated the relationship between vitamin D 
status and JIA serially from the time of the first presentation. The purpose of this review is to 
describe the current knowledge about vitamin D in JIA, then to summarize the evidence of the 
potential association of vitamin D with the development and disease activity of JIA 
2.2. Juvenile Idiopathic Arthritis 
JIA is a term that encompasses all forms of continuous inflammation from unknown 
causes of one or more joints, beginning in children younger than age 16 years that lasts for at 
least six weeks (Petty, Southwood, & Manners, 2004). JIA is characterized by persistent joint 
swelling that is due to an accumulation of synovial fluid and thickening of the synovial lining 




and decreased joint mobility; these symptoms interfere with daily activities and overall quality of 
life (Ravelli & Martini, 2007). The pathogenesis and influences on outcomes of JIA are still 
poorly understood and may include both genetic and environmental components (Ravelli & 
Martini, 2007). 
2.2.1. Classification Systems and Clinical Characteristics  
 
Two previous classification systems to describe chronic childhood arthritis were 
proposed in the 1970’s. The American College of Rheumatology (ACR) (Brewer et al., 1977) 
classification criteria referred to chronic childhood arthritis as Juvenile Rheumatoid Arthritis 
(JRA). The second classification system adhered to by the European League Against 
Rheumatism (EULAR) applied the term Juvenile Chronic Arthritis (JCA) (Woods, 1978). Key 
differences between the two classifications systems prevented interchangeable use and hindered 
comparison of research among users of the two systems (Borchers et al., 2006). To reconcile 
differences between ACR and EULAR criteria, the International League Against Rheumatism 
(ILAR) criteria were created and the term JIA was adopted. The criteria were further revised in 
2001 (Petty et al., 2004). The three classification systems are summarized in Table 2.1. When 
quoting the literature, the terminology for chronic childhood arthritis that was used at the time of 
publication of the respective referenced citations will be used in this review.  
Juvenile idiopathic Arthritis can be further classified into seven categories based on 
inclusion and exclusion criteria according to features present within the first six months of 
disease (Table 2.2). These categories are systemic, oligoarticular, polyarticular with positive 
rheumatoid factor (RF positive), polyarticular without rheumatoid factor (RF negative), psoriatic 
arthritis, and enthesitis-related arthritis. A seventh category of patients who do not fit into one 
category, meet criteria for more than one category, or have exclusion criteria that preclude 
assigning a category are classified as undifferentiated. Most subtypes of JIA occur more 
frequently in females; oligoarticular JIA, which constitutes 27-56% of all JIA, is approximately 







Table 2.1. Comparison of classification systems of chronic childhood arthritis 
 American College of 
Rheumatology 1977  
European League Against 
Rheumatism 1978  
International League Against 
Rheumatism 1994 and 2001 
Symptom duration Minimum 6 week  Minimum 3 month  Minimum 6 week  
Classification Title Juvenile Rheumatoid Arthritis Juvenile Chronic Arthritis Juvenile Idiopathic Arthritis 
Subtypes Systemic Systemic Systemic 
 Polyarticular Polyarticular Polyarticular RF negative  
  JRA (RF positive Polyarticular) Polyarticular RF positive  
 Pauciarticular Pauciarticular Oligoarthritis 
          Persistent 
          Extended  
  Juvenile psoriatic Psoriatic arthritis  
  Juvenile ankylosing spondylitis Enthesitis-related arthritis  
  Arthritis associated with 
inflammatory bowel disease 
 
   Undifferentiated arthritis 






Table 2.2. Summary of JIA types 
Type Sex Ratio 
M:F 
% of Total 
JIA cases 







peak at 2-4 years 
Definition: Arthritis is affecting one to 4 joints during the first 
six months of disease. Two subcategories are recognized:  
1. Persistent oligoarthritis: Affecting not more than 4 
joints throughout the disease course 
2. Extended oligoarthritis: Affecting a total of more than four 
joints after the first six months of disease 







Late childhood or 
adolescents 
Definition: Arthritis affecting 5 or more joints during the first six 
months of disease; 2 or more tests for RF at least three months 
apart during the first six months of disease are positive. 









peak at 2-4 years and 
later at 6-12 years 
 
Definition: Arthritis affecting 5 or more joints during the first six 
months of disease; a test for RF is negative. 






Late childhood and 
adolescents 
Definition: Arthritis and enthesitis, or arthritis or enthesitis with 






1. The presence of or a history of sacroiliac joint tenderness 
and/or inflammatory lumbosacral pain 
2. The presence of HLA-B27 antigen 
3. Onset of arthritis in a male over six years of age 
4. Acute (symptomatic) anterior uveitis 
5. History of ankylosing spondylitis, enthesitis-related 
arthritis, sacroiliitis with inflammatory bowel disease, 
Reiter’s syndrome, or acute anterior uveitis in a first-degree 
relative 











peak at 2-4 years and 
later peak at 9-11 
years 
Definition: Arthritis and psoriasis, or arthritis and at least 2 of the 
following: 
1. Dactylitis 
2. Nail pitting or onycholysis 
3. Psoriasis in a first-degree relative 





…. Definition: Arthritis that fulfills criteria in no category, or in 2 or 







a. Psoriasis or a history of psoriasis in the patient or first-degree relative. 
b. Arthritis in an HLA-B27 positive male beginning after the 6th birthday. 
c. Ankylosing spondylitis, enthesitis-related arthritis, sacroiliitis with inflammatory bowel disease, Reiter’s syndrome, or acute 
anterior uveitis, or a history of one of these disorders in a first-degree relative. 
d. The presence of IgM rheumatoid factor on at least two occasions at least three months apart. 
e. The presence of systemic JIA in the patient. 






2.2.2.1. Global Perspective  
 
Estimates of the incidence and prevalence of JIA have varied. A review of worldwide 
chronic childhood arthritis (JRA, JCA and JIA) prevalence found that prevalence ranged from 
0.07 to 4.01/1000 children, and annual incidence ranged from 0.008 to 0.226/1000 children 
(Manners & Bower, 2002). This review presented results from 34 studies conducted since 1966 
and found a higher prevalence of JIA in studies using a community assessment approach 
(Manners & Bower, 2002). Ellis et al. (2010) hypothesized that the wide variability in incidence 
and prevalence rates is due to the presence of undiagnosed children in the community with mild 
illnesses, who have never presented to clinics. Manners and Bower noted that the studies they 
summarized used a variety of diagnostic criteria, sampling methods (clinic versus community-
based), clinician experience in disease diagnoses, sample sizes and ethnic groupings to estimate 
the incidence and prevalence of chronic childhood arthritis, this contributes to the variability in 
their results (Manners & Bower, 2002).  
2.2.2.1.1. Geographic Location 
 
Differences have been found in the incidence of various JIA subtypes based on 
geographic location or ethnicity. There is evidence that latitude as a marker of vitamin D 
synthesis may potentially influence JIA incidence and sub-type. Latitude and season of 
measurement are important considerations for vitamin D status and have been explored in 
relation to other autoimmune diseases (Ellis, Munro, & Ponsonby, 2010). For Western countries, 
the most common JIA subtype is oligoarthritis; this type is rare in countries such as Costa Rica, 
India, New Zealand and South Africa where the most commonly diagnosed subtype of JIA is 
polyarthritis (Ravelli & Martini, 2007). 
In Europe, JIA incidence follows a north-south gradient, with a lower annual incidence of 
JIA in more southern countries (Gäre, 1999). It was also noted by Gäre (1999) that the incidence 
of JIA in Costa Rica was outside the confidence interval for that of Nordic countries, suggesting 
an environmental and/or genetic influence of disease occurrence and course. The difference in 
JIA incidence between Germany (35/100000 children) and the United States (11.7/100000 





differences in incidences could be due to environmental, genetic or study methodological 
differences. A temporal variation in JIA incidence was observed in Minnesota. The incidence of 
JRA decreased in Minnesota over a 33 year period with the most noticeable reductions in the 
pauciarticular and systemic subtypes (Peterson et al., 1996). The authors suggested that 
environmental factors such as infectious agents may be contributing to this pattern (Peterson et 
al., 1996).  
2.2.2.1.2. Prevalence and Incidence in Canada 
 
The majority of studies reviewed in the systematic review performed by Manners and 
Bower (Manners & Bower, 2002) were conducted in Caucasian populations; however the 
populations studied that were not Caucasian had a lower prevalence of disease. Considering 
ethnicity when comparing incidence and prevalence amongst populations would be useful in 
understanding if the regional differences observed were due to environmental or genetic factors 
or a combination of the two. A multiethnic cohort study of 1082 children at The Hospital for 
Sick Children, Toronto, Ontario was conducted to investigate the influence of ethnicity on the 
risk of developing JIA (Saurenmann et al., 2007). When the diversity of the study population was 
compared to that of the general Toronto region population, there was an overrepresentation of 
patients of European and Indigenous descent and an underrepresentation of patients of Black, 
Asian, or Indian subcontinent origin in their cohort. European descent was significantly 
associated with an increased risk of developing JIA, including all subtypes except RF positive 
polyarticular JIA.  
A higher prevalence of rheumatic diseases is reported in Indigenous children (Jarvis & 
Cleland, 2003). Hence, large Indigenous populations in Saskatchewan may explain why 
Saskatchewan and Manitoba have a higher prevalence of childhood chronic arthritis than other 
provinces where the prevalence of JIA has been reported (Shiff et al., 2014). Children of 
Indigenous ancestry were more likely to develop polyarticular RF-positive JIA (Saurenmann et 
al., 2007).  
In 1982 the prevalence of JRA among Western Canadian Indigenous children was 
reported by Rosenberg et al (Rosenberg et al, 1982). Using data from two pediatric rheumatic 
disease clinics, one in Winnipeg, Manitoba and one in Vancouver, British Columbia the 





Caucasian children (Rosenberg et al, 1982). Like Saurenmann et al., (Saurenmann et al., 2007) 
JRA, polyarticular RF positive subtype was significantly more common in the Indigenous 
population. A 3-5 year cyclical pattern was also found in Manitoba by Oen et al. (Oen, Fast & 
Postl, 1995). Peaks in JRA in 1979, 1982, 1986, and 1990-91 corresponded with increases in 
confirmed Mycoplasma pneumonia infection at those time points (Oen, Fast & Postl, 1995). 
Using a prospective disease registry, data on 3269 consecutive cases of JRA were collected from 
the Pediatric Rheumatology Clinic at the University of Saskatchewan in Saskatoon, 
Saskatchewan. The clinical point prevalence and clinical referral incidence were reported as 
35.0/100,000 children and 4.7/100,000 children respectively (Rosenberg, 2005).  
Both vitamin D status and JIA have genetic and environmental components, including the 
impact of latitude. Determining if the differences in JIA prevalence in varying ethnicities is due 
to genetic or environmental differences in vitamin D status and metabolism will help to focus 
research on the appropriate risk factors.  
2.2.3. Extra-articular manifestations of JIA 
 
Certain subtypes of JIA are more likely to present with specific extra-articular 
manifestations and some extra-articular manifestations (such as fever with systemic JIA) are 
included as criteria for JIA category assignment.. Extra-articular manifestations of systemic JIA 
include a high spiking fever, rash, serositis, lymphadenopathy, hepatosplenomegaly, pericarditis, 
and growth disterbances (both whole body or localized) (Boros, 2010; Hahn & Kim, 2010). Like 
systemic JIA, an extra-articular manifestation of psoratic JIA is included in the subtype diagnosis 
of the disease. The definition of psoratic arthritis includes the extra-articular manifestation of 
either psoriasis or two of the following: dactylitis, nail pitting, onycholysis, or psoriasis in a first 
degree relative (Petty et al., 2004). In patients with RF positive polyarthritis, the most common 
extra-articular manifestation is the development of subcutanious nodules with approximatly 30% 
of RF positive patients developing nodules within the first year (Cassidy, Petty, Laxer & 
Lindsley, 2011) . 
Three examples of serious extra-articular manifestations that can be associated with 
certain JIA subtypes are chronic asymptomatic uveitis, macrophage activation syndrome (MAS) 
and secondary amyloidosis. Chronic asymptomatic uveitis can be present in up to 30% of 





2006). Uveitis associated with JIA is a potential cause of childhood blindness (Bou et al., 2015). 
Chronic, asymptomatic anterior uveitis can also occur in children with RF- polyarthritis and 
psoriatic JIA. Acute, symptomatic uveitis can occur in enthesis-related arthritis (Angeles-Han & 
Prahalad, 2010; Borchers et al., 2006). Risk factors for chronic, asymptomatic uveitis include 
young onset age, female sex, oligoarthritis, and a positive antinuclear antibody (ANA) test  
(Angeles-Han & Prahalad, 2010; A Consolaro et al., 2014). As uveitis associated with JIA is 
usually asymptomatic, regular screening and monitoring by an ophthalmologist are 
recommended. Guideliness for follow-up frequency based on the risk of uveitis have been 
suggested by an interdisciplinary panel of experts with a special interest in uveitis associated 
with JIA (Bou et al., 2015). 
MAS is a potentially fatal complication of systemic JIA (Borchers et al., 2006). MAS is 
associated with excessive activation and proliferation of T cells and macrophages which lead to a 
massive systemic inflammatory reaction (Grom, 2004; Yokota et al., 2015). The clinical 
manifestation of MAS include persistent fever, mental status changes, lymphadenopathy, 
hepatosplenomegaly, liver dysfunction, and thrombocytopenia (Grom, 2004).  
The third condition is secondary amyloidosis (Woo, 2006). Amyloidosis is characterized 
as abnormal accumulation of amyloid protein deposits in tissues and organs. Secondary 
amyloidosis frequently affects the kidneys and the gastrointestinal tract (Okuda & Takasugi, 
2006). There has been a decline in the incidence of amyloidosis within the past two decades 
(Immonen et al., 2011). The prevalence of amyloidosis secondary to JIA is reported to be 1.8% 
in the United States of America (Immonen, Savolainen, & Hakala, 2016). The surveillance of, 
prevention and management of these complications are crucial for the long-term quality of life of 
the child (Gowdie & Tse, 2012). To our knowledge, no study has linked these complications to 
vitamin D status. They are, however, important in describing the severity of the disease and may 
be important covariates in describing inflammatory status. 
2.2.4. Etiology and Pathogenesis 
 
The etiology of JIA is unknown and the pathogenesis of JIA not well understood. Given 
the clinical heterogeneity of the disease there are most likely different etiologies and pathogenic 





believed to be involved resulting in the dysregulation of the immune system (Moncrieffe, 
Prahalad, & Thompson, 2014; Ravelli & Martini, 2007). 
 Genetic 
Ethnic differences in epidemiologic studies and an increased risk of JIA in patients’ 
relatives form evidence for the contribution of genetic factors influencing the risk of developing 
JIA (Manners & Bower, 2002; Saurenmann et al., 2007). The prevalence of JIA in twins and 
siblings of JIA patients is 15-30 times higher than that of the general population. There is also 
concordance in the age of onset, and disease course for diagnosed pairs (Ellis, Munro, & 
Ponsonby, 2010; Prahalad & Glass, 2008). While a heritable risk component is thought to be 
present, JIA is believed to be determined by both genetic and environmental factors. JIA does 
not exhibit classic Mendelian inheritance patterns meaning the cause of JIA cannot be attributed 
only to variations in a single gene locus (Ellis et al., 2010; Oliver & Silman, 2009; Prahalad & 
Glass, 2008).  
Variants at the human leukocyte antigen (HLA), protein tyrosine phosphatase (PTP2) and 
lymphoid tyrosine phosphatase (PTPN22) loci are associated with JIA (Angeles-Han & Yeh, 
2012; Ellis et al., 2015). Both HLA and PTPN22 play a role in the development of other 
autoimmune diseases (Ellis et al., 2010). HLA is estimated to account for 17% of the 
concordance of JIA occurrence in siblings (Prahalad & Glass, 2008). Other genes currently being 
explored include VTCN1, IL-2RA/ CD25 (encoding IL-2 receptor a), TRAF1-C5 locus 
(encoding TNF receptor-associated factor 1 and complement component 5), TNFA MIF 
(polymorphisms in the migration inhibitory factor). The NRAMP1 gene may also play a role in a 
predisposition to JIA (Ellis et al., 2010; Oliver & Silman, 2009; Prahalad & Glass, 2008). These 
loci, however, still need to be confirmed. It is important to note that the concurrence rate for JIA 
development in twins is only 25% (Prahalad, 2006). Therefore, while genetics is likely to have 
some influence on the occurrence of JIA, additional factors are involved in the pathogenesis of 
JIA. Exploring genetic interactions between multiple genes involved in the inflammatory 
pathway in conjunction with the study of potential environmental influences will be required to 









  Multiple environmental factors have been suggested to impact the development and 
progression of JIA in children with a susceptible genetic predisposition (Table 2.3). The 
environmental exposure (or exposures) have yet to be fully explored with very few studies 
conducted in this area. Therefore, these factors have yet to be proven as causal events in the 
disease pathway (Burke et al., 2005; Ellis et al., 2010).  
 
Table 2.3. Environmental factors explored for association in the development of JIA 
Short duration of breastfeeding  
Stress and psychological factors  
Infectious agents and microbe exposure 
Maternal smoking 
Season of birth 
Vitamin D status 
Adapted from (Berkun et al., 2015; Berkun & Padeh, 2010; Ellis et al., 2010; Neufeld, 
Karunanayake, Maenz & Rosenberg 2013; Rigante et al., 2014) 
 
Duration of breastfeeding 
A JIA biobank study from Melbourne, Australia called CLARITY - ChiLdhood Arthritis 
Risk factor Identification sTudY, has the broad aim of identifying genomic and environmental 
disease risk factors associated with JIA ( Ellis et al., 2012). This study follows children ≤18 
years of age with a diagnosis of JIA by 16 years of age (cases) and healthy children ≤18 years of 
age, born in the state of Victoria, undergoing a minor elective surgical procedure (controls) (Ellis 
et al., 2012). In the most recent publication, the CLARITY study reports no significant difference 
in the commencement of breastfeeding among cases or controls. Additionally, for those who 
were breastfed no significant difference in duration of breastfeeding has been found. A 
significant difference in the introduction of cow’s milk has been found amongst cases and 
controls with cases starting cow’s milk at a younger age. However, the association was not 
present after adjustment for covariates (Ellis et al., 2012). Mason et al. (1995) reported a case-
control study of 54 mothers of children with JRA and 79 playmates from North Carolina, that 





breastfed (Mason et al. 1995). They also noted a lower odds ratio for increased duration of 
breastfeeding in children with JRA and concluded that breastfeeding might have a protective 
effect on the development of JRA. A larger longitudinal case-controlled population survey of 
children in Saskatchewan, Canada found no statistically significant difference in breastfeeding 
rates amongst 137 JRA cases and 331 controls (Rosenberg, 1996). Additionally, no difference in 
breastfeeding history and duration was found between the cases and controls. 
 
Stress and psychological factors 
Neufeld et al. (2013) investigated patients presenting for their first visit to a pediatric 
rheumatology clinic in Saskatoon, Canada between 1981 and 2010 for JRA symptoms. Patients 
were more likely than controls (unrelated child of the same age and sex, living in the same 
geograhical region at approximately the same time) to have experienced a stressful life event 
such as a serious upset, a currently ill family member, separated parents, or difficulties with 
interpersonal relationships (Neufeld et al., 2013). The suggested mechanism for the relationship 
between experiencing a stressful life event and the expression of juvenile arthritis relates to how 
certain pro-inflammatory cytokine single nucleotide polymorphisms (SNPs) are associated with 
heightened cytokine production in response to stress and that some individuals through genetic 
predisposition may experience an exaggerated stress-induced inflammatory response (Neufeld et 
al., 2013). 
 
Infectious agents and microbe exposure 
It has been suggested that exposure to infectious agents or exposure to certain microbial 
agents may lead to the development of JIA in genetically susceptible individuals (Carlens et al., 
2009; Ellis et al., 2010; Ellis et al., 2012; Rigante et al., 2014). Also, a lack of exposure to 
microbial agents has been suggested to be associated with immune disorders (hygiene 
hypothesis). Caesarean delivery has been associated with an increased risk of childhood immune 
disorders; this may be related to a lack of exposure to vaginal and intestinal flora during birth 
(Ellis et al., 2010; Neu & Rushing, 2011). A case-control study conducted in Sweden by Carlens 
et al. (2009) investigating perinatal characteristics, early life infections, and later risk of 
rheumatoid arthritis and JIA, discovered that being hospitalised for any infection during the first 





statistically significant increase in  the risk of JIA development was also observed for individuals 
born after more than 42 gestational weeks and for those delivered by Caesarean section (Odds 
Ratio 1.1:1, 95% confidence interval 1.0 to 1.3) (Carlens et al., 2009). The CLARITY study, 
however, found no risk associated with caesarean delivery and JIA development (Ellis et al., 
2012). 
A review by Rigante et al. (2014) investigated how different external antigens could 
stimulate multiple antigen-specific pathways such as  cytotoxic T cell responses, to produce 
proinflammatory cytokines (Rigante et al., 2014). They reviewed the possible role of parvovirus 
B19, Epstein-Barr virus, Salmonella, Shigella, Campylobacter, Mycoplasma pneumoniae, 
Chlamydophila pneumonia, Bartonella henselae, and Streptococcus pyogenes for the 
development of immune-mediated JIA. The review found no clear evidence for any of the viral 
or bacterial agents investigated (Rigante et al., 2014). 
 
Maternal smoking 
Symmons et al. (2005) surmised that smoking might play a role in the development of 
JIA through a number of mechanisms (Symmons, 2005). Smoking may directly cause 
immunological abnormality in children. This is hypothesized to increase susceptibility to 
childhood infections and might trigger arthritis. Maternal smoking, while the child is in utero, 
may be a marker for exposure to second-hand smoke during the early years of life, (the mother 
may continue to smoke after pregnancy) and that may trigger the autoimmune response.  
Smokers have been reported to have abnormalities in T-lymphocyte function, a reduction 
in the number of natural killer cells, and abnormalities in humoral and cellular immunity. This 
phenomenon may occur in children exposed to second-hand smoke (Symmons, 2005).  Symons 
also discusses the correlation between maternal smoking and reduced likelihood of breastfeeding 
which could potentially be the link between maternal smoking and JIA. This controversy will 
require further investigation. A case-control study of 1196 JIA patients and randomly selected 
healthy controls from Washington State conducted from 1997-2010 did not observe an increased 
risk of JIA, overall or in relation to JIA subtypes, with maternal prenatal smoking. They found 
smoking to occur less often in mothers of JIA cases (Shenoi S, Bell S, & Wallace CA, 2015). 
The study by Carlens et al. (2009) was conducted using a nationwide registry-based case-control 





significantly alter the risk of developing JIA (Carlens et al., 2009). In the CLARITY study, fewer 
mothers and fathers of cases reported any smoking at the time of the interview (Ellis et al., 
2012). There is still uncertainty as to what role if any maternal smoking plays in the pathogenesis 
of JIA. 
As a link between the above environmental factors is currently being investigated for 
their role in the development of JIA, they are important covariates to include in the analysis of 
the impact of other environmental measurements on JIA. 
 
Season of birth 
Season of birth has been suggested to have an impact on the risk of developing a number 
of autoimmune diseases such as multiple sclerosis, type 1 diabetes and celiac disease (Berkun et 
al., 2015). A recent study investigating month of birth and risk of JIA found a difference in the 
pattern of the birth month for children with JIA compared to that of the general population 
(Berkun et al., 2015). Children with JIA were more likely to be born between November to 
March with the birth month for the general population peaking in the summer months. The study 
by Carlens et al. (2009) also investigated the relationship between season of birth and the risk of 
developing JIA and found no increased risk (Carlens et al., 2009). Season of birth may be a 
marker for vitamin D status in utero with children born in the non-vitamin D synthesizing 
periods being exposed to less vitamin D during the third trimester than those who are born during 
the vitamin D synthesizing seasons. 
 
 Vitamin D status 
Recent studies suggest that vitamin D plays a role in the pathogenesis of JIA because 
vitamin D might be immunosuppressive (Cutolo, Pizzorni, & Sulli, 2011). Therefore, low levels 
would be associated with inflammation (Cutolo et al., 2011). The role of vitamin D in other 
autoimmune disorders has been established but  has not been fully explored in relation to JIA 
(Holick, 2005). The CLARITY study explored the use of nutritional supplements during 
pregnancy and the risk of developing JIA. The use of vitamin D and fish oil during pregnancy 
was lower in case mothers than controls but the association was not statistically significant 
following covariate adjustments (Ellis et al., 2012). A case-cohort investigation from Denmark, 





JIA using dried blood spot samples that were collected at birth,  did not find any association 
between 25(OH)D status at birth and JIA risk development risk (Thorsen et al., 2016). 
Concentrations of 25(OH)D fluctuated statistically significantly by season of birth and year. 
There was no follow up as to if there was an impact of 25(OH)D status or season during the first 
year of life impacted risk of JIA or whether other subtypes of JIA were impacted by season of 
birth of 25(OH)D status at birth 
 
Pathogenesis of JIA 
The pathogenesis of JIA is thought to involve both the innate and adaptive immune 
system (Prahalad & Glass, 2008). In genetically susceptible individuals exposed to an 
environmental trigger, the synovial tissue comprises various auto-antigens and is infiltrated by 
inflammatory cells including neutrophils, plasma cells, dendritic cells and activated T-cells. The 
trigger activates both the innate and adaptive immune system to up-regulate local inflammation 
(Borchers et al., 2006; Prahalad & Glass, 2008; Prakken, Albani, & Martini, 2011; Reinards et 
al., 2014). 
 Activated T-cells have been found in high levels in the synovium of patients with JIA 
(Borchers et al., 2006).  It is believed that autoreactive T-cells (mainly Th1 cells are the initiator 
of insult that lead to the cascade of inflammation (Prakken & Albani, 2009). Monocytes, 
macrophages, fibroblasts and T cells within the inflamed synovial fluid in response then secrete 
mediators that interact directly with the surrounding tissue and have a pro-inflammatory effect 
(de Jager et al., 2008).  T-cells produce pro-inflammatory cytokines including interleukin (IL)-2,  
IL-6, interferon-γ, and  tumour necrosis factor (TNF)-β and-α (Prahalad & Glass, 2008). IL-1 
and TNF-α stimulate the release of tissue-destroying matrix metalloproteinases  and inhibit the 
production of  the enzymes that inhibit metalloproteinases (Hahn & Kim, 2010).  This is what 
causes joint damage (Hahn & Kim, 2010). Interleukin-1 also stimulates the production of IL-6  
which is associated with clinical and laboratory measures of disease activity in children with JIA 
(Hahn & Kim, 2010; Świdrowska-jaros, Orczyk, & Smolewska, 2016). IL-12 p40 levels also 
showed a significant positive correlation with CRP and ESR and a negative correlation with 






2.2.5. Diagnosis and Assessment 
 
There are no definitive diagnostic tests for JIA; a diagnosis is made clinically and 
requires excluding other diagnostic possibilities.  The ILAR criteria are then applied to 
categorize the JIA subtype. (Petty et al., 2004). 
 
  2.2.5.1. Biochemical Tests for Diagnosis and Follow-up  
 
There are no specific diagnostic laboratory tests for JIA.  Laboratory tests are performed 
to monitor inflammation status or secondary complications of the disease. Table 2.4 presents the 
commonly performed laboratory tests.  The erythrocyte sedimentation rate (ESR) and C-reactive 
protein (CRP) are non-specific markers of inflammation (Tugal-Tutkun & Quartier, 2014). The 
Antinuclear Antibody (ANA) test is performed in children with JIA as a positive test indicates a 
higher risk of developing iridocyclitis (Breda et al., 2012). ANA positive children tend to be 
female, have asymmetric arthritis, and an early disease onset (Breda et al., 2012). ANA’s are 
detected in approximately 30-50% of JIA patients (Borchers et al., 2006).  Testing positive for 
Rheumatoid Factor  is associated with more aggressive joint disease in children and adults 
(Breda et al., 2012). In children, it can also impact the growing skeleton either by impeding 
overall growth or by accelerating growth in the affected joint (Prakken et al., 2011). RF positive 
polyarthritis impacts approximately 5% of JIA patients (Prakken et al., 2011).  
 
Table 2.4. Commonly performed biochemical measurements 
Erythrocyte sedimentation rate Antinuclear Antibodies 
C-reactive protein Rheumatoid Factor 





While there is no cure for the disease, treatments and therapies are used to manage the 
disease and improve the quality of life. Treatment of JIA is based on pharmacotherapy, 





the  ACR published recommendations for the treatment of JIA which provided guidance for the 
use of therapeutic agents (medications) (Beukelman et al., 2011). The ACR did not use the ILAR 
sub-types in providing their recommendations. Instead, they grouped children into five distinct 
“treatment groups”. These groups are 1) History of arthritis of 4 or fewer joints, 2) History of 
arthritis of 5 or more joints, 3) Active sacroiliac arthritis, 4) Systemic arthritis with active 
systemic features (and without active arthritis) and 5) Systemic arthritis with active arthritis (and 
without active systemic features). For each treatment group there is a therapeutic treatment 
pathway recommended, a description of the features of poor prognosis and methods to classify 
disease activity level (Beukelman et al., 2011). In 2013 updated recommendations were 
published by the ACR for the treatment of systemic JIA and for screening children receiving 
biologics for tuberculosis (Ringold et al., 2013).  
Most patients are first treated with non-steroidal anti-Inflammatory drugs (NSAIDs).  
However, early treatment with disease-modifying anti-rheumatic drugs (DMARDS) for certain 
JIA subsets is required to improve long-term outcomes. (Borchers et al., 2006). Another 
treatment option occasionally used is corticosteroids, either oral or provided by intra-articular 
injection (Gowdie & Tse, 2012). DMARDs help prevent irreversible damage and reduce long-
term exposure to medications with harmful side effects such as corticosteroids. (Gowdie & Tse, 
2012). Biologic agents are a group of medications that blocks the body’s inflammation response. 
They are used mostly in treating systemic and polyarticular JIA. They are occasionally used in 
the treatment of enthesitis-related arthritis and chronic uveitis.  While biologic therapies are 
effective in treating JIA in patients who do not respond to standard therapies use can be limited 
in some jurisdictions because of their high costs (Gowdie & Tse, 2012). Each medication has its 
own side effect profile that can impact quality of life and nutritional status such as gastro-
esophageal reflux, nausea, stomach ulcers, elevated blood glucose, increased appetite and risk of 
infection as shown in Table 2.5. These factors can lead to an imbalance of energy and nutrients 










Table 2.5. Summary of side effects of JIA medication classes 
Medication Side effects 
NSAIDs Edema (feet), gastro-esophageal reflux, nausea, stomach ulcers 
and possibly increased the risk of blood clots, heart attack, and 
stroke. 
Corticosteroids Cataracts, elevated lipids and blood glucose, increased appetite, 
weight gain and bone loss. 
DMARDs Nausea and increased susceptibility to infection. (Other side 
effects vary by drug) 
Biologic agents Injection or infusion site reactions, including redness, swelling 
and increased risk of serious infections. Other side effects vary 
by drug. 
Adapted from (Borchers et al., 2006; Gowdie & Tse, 2012; Ringold & Wallace, 2007) 
2.2.7. Outcome Measures of Disease Activity 
 
Various survey tools have been developed to measure the success of a treatment or define 
improvement of a patient with JIA. The three terms that are most often used to describe changes 
in disease activity are disease improvement, disease flare and disease remission (Ringold et al., 
2013). As no individual measure is an accurate indicator of disease activity,  composite scores 
that combine a number of indices, have been developed to reflect the multifaceted nature of the 
disease (Duffy, 2007). These indices can be used to follow changes in response to treatment of 
individuals or differences in treatment response between groups in clinical trials (Ringold & 
Wallace, 2007).  
The ACR has outlined a core set of outcomes for use when defining clinically important 
patient improvement in pediatric patients. This is called the ACR Pediatric 30 (Giannini et al., 
1997). This set of criteria was initially for use in clinical trials as opposed to monitoring 
improvement in individuals in a clinic setting The ACR30 outlines six components 1) Physician 
global assessment  (PGA) of overall disease activity (measured on a 10 cm visual analog scale), 
2) parent or patient global assessment of overall well-being (measured on a 10 cm visual analog 
scale), 3) functional ability (Childhood Health Assessment Questionnaire (CHAQ)), 4) number 





(Table 2.6). Disease improvement is defined as a minimum improvement of 30% from the 
baseline measure in any three of the six components, with a worsening of no more than one of 
the components (Giannini et al., 1997). A disease flare was defined by Brunner et al. for patients 
with polyarticular JRA as a less than 40% worsening of a minimum of two of the six ACR 
Pediatric 30 components, with no more than one component improving by more than 30% 
(Brunner, Lovell, Finck, & Giannini, 2002). Inactive disease is defined by Wallace et al. as when 
all six of the criteria in Table 2.7 are met (Wallace, Ruperto, Giannini, & Arthritis, 2004). There 
are two types of clinical remission, clinical remission on medication and clinical remission off 
medication, which are also described in Table 2.7. 
A limitation of the ACR Pediatric 30 Criteria is that it does not quantify disease activity of 
an individual in a way that allows for comparison between individuals. The Juvenile Arthritis 
Disease Activity Score (JADAS) is a composite score that combines four components and was 
developed for this purpose. It combines four indices, 1) physician global assessment of disease 
activity which is measured on a 10 cm visual analog scale, 2) parent or patient global assessment 
of well-being which is also measured using a 10 cm visual analog scale, 3) active joint count in 
10, 27 or 71 specified joints, 4) ESR, which has been normalized to a scale of 0-10 (Consolaro et 
al., 2012). The JADAS score has not been established as a measure for clinical practice by the 
ACR; there are however suggested numerical cut-off values for inactive, mild, moderate and 
highly active disease. The values available are for all types of JIA and specific cut-offs for 
oligoarthritis and polyarthritis are not defined. Given that the number of joints with active 
arthritis is a part of the definition of the subtypes as well as a measurement of disease activity, 
the cut-offs are not appropriate for comparison between subtypes.  
 
Table 2.6. Core set of outcome variables for the ACR 30 
1. Physician global assessment of overall disease activity 
2. Parent or patient global assessment of overall well-being 
3. Functional ability 
4. Number of joints with active arthritis 
5. Number of joints with limited range of motion 
6. ESR 





Table 2.7. Criteria for the clinical remission of JIA 
1. No joints with active arthritis 
2. No fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA  
3. No active uveitis  
4. Normal ESR and/or CRP  
5. Physician’s global assessment of disease activity indicates no disease activity  
Key Definitions 
Inactive disease: all five criteria must be met  
Clinical remission on medication: The criteria for inactive disease must be met for a minimum 
of 6 continuous months while the patient is on medication in order for the patient to be 
considered to be in a state of clinical remission on medication.  
Clinical remission off medication: The criteria for inactive disease must be met for a minimum 
of 12 continuous months while off all anti-arthritis and anti-uveitis medications in order for the 
patient to be considered to be in a state of clinical remission off medication.  
Adapted from (Wallace et al., 2004) 
2.3. Nutrition and Juvenile Idiopathic Arthritis 
Nutritional impairment in JIA has been assessed using a number of anthropometric and 
biochemical methods. However, there is no consensus on the optimal nutritional assessment 
method for this population (Cleary, Lancaster, Annan, Sills, & Davidson, 2004). Children with 
JIA often experience nutrition-related concerns such as protein energy malnutrition, 
micronutrient deficiencies and growth abnormalities (Dinardo et al., 1991). Inadequate intake 
due to mechanical feeding problems, reduced physical activity, joint pain and inflammation, drug 
side effects, fatigue, and disease activity status may influence nutrient requirements (Dinardo et 
al., 1991). Growth can be impacted by a number of interrelated facets including medication side 
effects, inflammation, poor nutrition, lack of exercise, genetic background, disease severity and 







Figure 2.1. Factors impacting growth in children with JIA 
 (adapted from (Marcovecchio et al., 2012) 
 
Nutritional impairment, while not the sole cause, can contribute to reduced growth, 
osteoporosis, anemia and suboptimal body composition in children with JIA (Cleary et al., 
2004). Delayed or retarded growth in children with JIA has been established and is hypothesized 
to be related to disease activity (Liem & Rosenberg, 2003). In 1990, when Bacon et al. 
investigated the relationship between growth and dietary intake in children with JRA, it was 
found that one-third of the children studied were at or below the tenth percentile in height for age 
(Bacon et al., 1990). Overall, meal caloric and nutrient intakes were found to be adequate when 
compared to the Recommend Daily Allowance (RDA) of the National Academy of Science. No 
correlation was found linking dietary intake to growth percentiles. Biochemical measurements of 
dietary intake showed abnormalities amongst the subtypes of JRA and discrepancies between 
dietary intake and blood values (low plasma levels of vitamins A and C, albumin, prealbumin, 
retinol binding protein and zinc; and increased concentrations of copper and glutathione 
peroxidase activity). It was hypothesized that this was due to altered absorption, requirement or 
that there was increased utilization due to chronic inflammation (Bacon et al., 1990).  Mixed 
results on the impact of JIA on body weight have been reported with both evidence of under and 





& Sachdev, 2014; Markula-Patjas et al., 2014). These mixed results are most likely due to an 
individual’s response to the disease activity through either reduced intake, increased requirement 
and/or physical activity.  
Growth failure has been estimated to occur in 11-41% of patients with JIA (Gaspari, 
Marcovecchio, Breda, & Chiarelli, 2011). Growth failure occurs most often  in children with 
systemic and polyarticular JIA and although less severe, it also presents in children with 
oligoarticular JIA (Marcovecchio et al., 2012). A study by Liem et al. in which the height for age 
z-score of 67 children with JRA had been followed for at least five years (most until their 18th 
year), found a delay in height in some  children (Liem & Rosenberg, 2003). Additionally, 
children with RF-positive polyarticular and systemic JRA had more significant growth 
retardation than children with other subtypes of JRA, and in some cases, they did not recover the 
lost height. Rooney et al. reported that the degree of growth retardation is associated with the 
duration of the disease activity (longer duration of disease activity reduces growth potential) and 
that disease remission can improve growth (Rooney, Davies, Reeve, Preece, & Ansell, 2000). It 
was concluded that normal height can be achieved through catch-up growth after 2-3 years of 
disease remission unless the epiphyseal growth nuclei had already fused. 
The relationship between disease activity and growth failure is described by Gaspari et al. 
(Gaspari et al., 2011). Pro-inflammatory cytokines such as IL-6, IL-1β and TNFα may act locally 
or systemically through altering growth hormone secretion (IL-6) or by directly affecting the 
grow plate chondrocytes of long bones (IL-1β and TNFα). Okumus et al. compared height 
standard deviation scores, bone mineral density and biochemical measures in children with JIA 
to healthy age and gender matched controls (Okumus, Erguven, Deveci, Yilmaz, & Okumus, 
2008). Children with JIA were found to be shorter than controls and have lower bone mineral 
density. Steroid use was shown to have a negative effect on growth and children with JIA had 
significantly lower IGF1 than controls.  
As new medications and treatments become available, growth outcomes may improve. 
While there is currently no standard nutrition therapy or specific diet for children with JIA 
nutrition does play a role in disease management. Some issues that may arise include the 
management of energy intake, increased requirements of key nutrients due to pro-inflammatory 
cytokines, secondary deficiencies caused by pharmacological treatments, food texture 





recommendations are the same as they are for all children and specific recommendations are 
made based on individual outcomes and requirements (Dinardo et al., 1991). This has not 
stopped parents of children with JIA from using unconventional nutritional therapies with one 
study finding that 70% of children were receiving some form of alternative nutritional therapy 
(Southwood, Malleson, Roberts-thomson, & Mahy, 1990). These therapies include mega doses 
of vitamins, fish oil supplementation, dietary restrictions and herbal remedies.  
2.4. Vitamin D  
Vitamin D is a pro-hormone that can be considered a “conditional dietary essential 
vitamin”.  To maintain adequate vitamin D levels humans require adequate UVB radiation 
exposure for cutaneous synthesis and/or  adequate dietary intake. (Chung et al., 2009; Holick, 
2007). Vitamin D status is impacted by both environmental and genetic factors and plays a role 
in inflammation (Cutolo et al., 2011). It has multiple roles including those in pathways related to 
the pathogenesis and progression of JIA. However further studies that explore vitamin D status 
and JIA development and activity are required to confirm a direct relationship between vitamin 
D and JIA 
2.4.1. Physiology of Vitamin D 
 
The most well-known function of vitamin D is regulating calcium and 
phosphorous concentrations in the blood by promoting their absorption from foods and 
supplements in the small intestine and by promoting re-absorption of calcium from the 
kidneys (Lips, 2006). Without vitamin D, humans would only be able to absorb 10-15% 
of dietary calcium and approximately 60% of phosphorous through passive transport 
(Institute of Medicine, 2011).  In the presence of vitamin D, the efficiency of calcium and 
phosphorous absorption is increased to about 30-40% and 80%, respectively, through 
active transport processes (Holick, 2007). This supports bone formation and 
mineralization and is required to develop and maintain optimal peak bone mass. The role 
that vitamin D plays is not limited to the regulation of calcium. Vitamin D is involved in 
maintaining immune function, regulating cell growth and differentiation, neuromuscular 
function and suppressing inflammation (Hayes, Nashold, Spach, & Pedersen, 2003; 





and cell types throughout the body including bone, kidneys, lungs pancreas, brain, and 
muscle highlighting that vitamin D has a role outside of calcemic regulation (Yongji 
Wang, Zhu, & DeLuca, 2012). 
2.4.1.1. Vitamin D Acquisition 
 
Vitamin D can be acquired from limited sources in the Canadian diet, typically 
from fortified milk and margarine (see Table 2.8 for selected dietary sources of vitamin 
D) or through endogenous synthesis, which is triggered by ultraviolet beta (UVB) 
radiation from the sun (Holick, 1995; Holick, 2002; Holick, 2007).  
 
Table 2.8. Selected foods containing vitamin D 
Food µg per serving* IU per serving* 
Cod liver oil, 1 Tablespoon 32.0 1,280 
Salmon Atlantic, baked, 100 g 6.8 272 
Salmon Sockeye, canned/bone, 100g 18.6 744 
Mackerel, cooked, 100 g 2.6 104 
Tuna fish, canned in oil, 171 g 2.1 84 
Milk, non-fat, reduced fat, and 
whole, vitamin D fortified, 250 mL 
2.6 104 
Margarine, fortified, 15 mL 1.9 76 
Orange juice, fortified, 250 mL 2.5 100 
Egg, 1  large whole (vitamin D is 
found in egg yolk) 
1.0 40 
Liver, beef, cooked, 75 g 0.9 36 
 
*  Health Canada, Canadian Nutrient File, 2015 
 
There are two dietary sterols that can form precursors for vitamin D. One form is 
found in fungi and protozoa and is called ergosterol. It can be activated through 
irradiation by UVB to form ergocalciferol (also known as vitamin D2) (Institute of 





sources such as fish or liver. Both forms, when ingested, are incorporated into the 
chylomicron fraction and transported to the liver. Endogenous synthesis of vitamin D is 
possible through 7-dehydroxycholesterol, which is found throughout both the dermis and 
epidermis; when it is exposed to a specific wavelength of UVB light (290-315 nm) it 
forms previtamin D3 (precalciferol) (Lips, 2006).  Within one day, precalciferol is 
thermalised to cholecalciferol (vitamin D3). It diffuses from the skin to the blood stream 
where is it transported to the target tissue (usually the liver) by α-2globulin vitamin D-
binding protein (Holick, 2007).  A dose response study by Heaney et al. providing 
vitamin D3 or vitamin D2 found vitamin D3 to be 13% more potent in raising and 
maintaining serum 25(OH)D concentrations and that it produced a 2- to 3-fold greater 
storage of vitamin D than an equimolar dose of vitamin D2 (Heaney, Recker, Grote, 
Horst, & Armas, 2011).  
Fortification of fluid milk and margarine is mandatory in Canada; regulations are 
administered through the Canadian Food and Drug Regulations. Fluid milk “shall contain added 
vitamin D in such an amount that a reasonable daily intake of the milk contains not less than 300 
IU and not more than 400 IU of vitamin D” (35–45 IU vitamin D per 100 mL) and margarine, 
530 IU/100g, respectively (Calvo & Whiting, 2013). Fortified plant-based beverages must 
contain vitamin D (either vitamin D2 or D3) in an amount equivalent to fluid milk. Foods such as 
yogurt, orange juice, and some meal replacement items are fortified in Canada; the amount of 
fortification permitted depends on the intended use of the product (Calvo, Whiting, & Barton, 
2004; Calvo & Whiting, 2013).   
Most people meet at least some of their vitamin D requirements through sunlight. 
However, there are a number of factors that can affect the endogenous synthesis of vitamin D 
from UVB radiation. Skin pigmentation is one of the factors influencing UVB absorption.  The 
more melanin there is in the skin  to compete for UVB photons,  the fewer UVB photons 
available for endogenous synthesis of vitamin D (Kimlin et al., 2007). Wearing a sunscreen with 
an SPF greater than 8 eliminates endogenous synthesis by absorbing, reflecting or scattering UV 
radiation (Holick, 1995). The solar zenith angle which is a combination of the time of day, time 
of year and latitude impacts the strength of UV radiation as it forces the UV radiation to travel 
through a greater portion of the earth’s atmosphere to reach its destination (Tsiaras & Weinstock, 





synthesis of vitamin D all year long (Wacker & Holick, 2013). In populated Canada (latitude of 
42 to 53o North) between October to March/ April UVB radiation is not strong enough to elicit 
endogenous synthesis of vitamin D (Webb, Kline, & Holick, 1988). Thus, during this time of the 
year there is increased risk for vitamin D deficiency. This is in part due to reduced UVB and is 
attributed to the zenith angle, which is in turn related to the shortening of days during the winter 
months (Webb et al., 1988).  Vitamin D synthesis cannot occur if the sunlight passes through 
clothing or windows (Holick, 1995). Complete cloud cover including that caused by severe 
pollution can reduce UVB strength (Agarwal et al., 2002; Parisi, Turnbull, & Downs, 2012). 
These factors are important to consider since vitamin D deficiencies have been detected 
worldwide due to cultural or religious clothing habits (Holick, 1995), skin pigmentation (Kimlin 
et al., 2007), an increase in sedentary lifestyles that is associated with less exposure to UVB, and 
pollution (Holick, 1994; Holick, 2002). Body composition may also impact vitamin D status as 
vitamin D is readily taken up by adipose tissue. Obese individuals have lower serum 25(OH)D 
concentrations than normal weight individuals (Tsiaras & Weinstock, 2011).  A study with the 
goal of characterizing the dose-response relationship of vitamin D supplementation and serum 
25-Hydroxyvitamin D (25(OH)D) concentration in a large sample of healthy volunteers, and to 
quantify the dose-response relationship for different BMIs and for absolute body weight found 
that BMI was a better determinant of 25(OH)D concentrations than absolute weight. When 
compared to normal weight subjects, obese and overweight adult subjects have serum 25(OH)D 
concentrations that are on average 19.8 nmol/L and 8.0 nmol/L lower, respectively (p<0.001) 
(Ekwaru, Zwicker, Holick, Giovannucci, & Veugelers, 2014). The correlation between body 
fatness and vitamin D status has also been found in children (Wakayo, Belachew, Vatanparast, & 
Whiting, 2015). Overweight children were found to have lower 25(OH)D concentrations than 
non-overweight children, based on classification of both BMI-for-age and triceps skinfold-for-
age percentile (Wakayo et al., 2015).  
Regardless of the source of vitamin D, both dietary and endogenously acquired 
forms are only biologically active following further metabolism through hydroxylation in 
the liver at the 25th carbon to produce 25(OH)D which is the major circulating form of 
vitamin D.  Subsequent hydroxylation is performed  in the kidney at the first carbon 
yielding the metabolically active form 1,25-dihydroxyvitamin D (1,25(OH)2D) (van den 





other tissues (bone, placenta, macrophages, T-lymphocytes, dendric cells, several cancer 
cells, prostate, keratinocytes and the parathyroid gland) are capable of performing a small 
amount of this hydroxylation (Gröber, Spitz, Reichrath, Kisters, & Holick, 2013). The 
circulating serum concentration of 25(OH)D is commonly used to indicate vitamin D 
status as it reflects both dietary and endogenous sources. Since the half-life of 25(OH)D 
is 2-3 weeks, it is considered to be the most reliable measure of a person’s cumulative 
vitamin D status (Holick, 2003). The half-life of the active form of vitamin D, 
1,25(OH)2D3, is only 4-6 hours making it a difficult and unrealistic measure of vitamin D 
status (Holick, 2003).  
2.4.1.2. Functions of Vitamin D at the Cellular Level 
 
Vitamin D status continues to be a public health concern due to its role in the 
prevention of rickets, osteomalacia, and osteoporosis. Vitamin D regulates a number of 
noncalcemic functions as well. Vitamin D is involved in the regulation of cell 
differentiation and proliferation, hormone secretion, stimulation of insulin secretion, 
modulation of immune function and inhibition of renin production (Hayes et al., 2003; 
Wacker & Holick, 2013). The VDR is involved in the majority of vitamin D’s biological 
actions (Uitterlinden, 2004). These actions are mediated with 1,25(OH)2D acting as a 
ligand, through the binding of VDR-RXR (Retinoid X Receptor) to the vitamin D 
response element of target genes (Kato, 2000).  
 The main function of vitamin D is to maintain adequate blood calcium levels. 
This is done through interacting with receptors in the small intestine. 1,25-
dihydroxyvitamin D enhances absorption of intestinal calcium and dietary phosphorous 
through increasing the efficiency of their absorption (American Society for Bone and 
Mineral Research [ASBMR], 2005). If there is inadequate dietary calcium available to 
meet requirements, 1,25(OH)2D and parathyroid hormone mobilizes monocytic stem 
cells in the bone marrow to become mature osteoclasts. Interaction with the VDR-RXR in 
osteoclasts ultimately leads to the dissolving of the bone mineral matrix in order to 
restore blood calcium, signal transduction and neuromuscular activity (ASBMR, 2005). 
When calcium status is adequate, vitamin D also stimulates bone formation by enhancing 





Cells in the immune system have the potential to synthesize 1,25(OH)2D and elicit an 
autocrine or paracrine response from immune cells that express VDRs (Hewison, 2012). Cells 
involved in innate and adaptive immune responses such as macrophages, dendritic cells, T cells 
and B cells express the VDR, and CYP27B1 and, therefore, can both produce and respond to 
1,25(OH)2D (Adorini & Penna, 2008). Similar to the role of  vitamin D in calcium homeostasis, 
1,25(OH)2D binding to the VDR results in a heterodimerization of VDR with the RXR in the 
nucleus of the cell (Holick, 2012). Then the complex binds to the VDRE. Depending on the 
target gene, either co-activators or co-repressors are attracted to the complex to induce or repress 
gene transcription (Baeke, Takiishi, Korf, Gysemans, & Mathieu, 2010). In most cells in the 
immune system vitamin D works to suppress the immune response (Cutolo et al., 2011). 
2.4.1.3. Interpreting Vitamin D Status  
 
While there is no cure for the disease, treatments and therapies are used to manage the 
disease and improve the quality of life. Treatment of JIA is based on pharmacotherapy, 
physiotherapy, occupational therapy, and psychosocial support (Prakken et al., 2011). In 2011 
the  American College of Rheumatology  (ACR) published recommendations for the treatment of 
JIA which provided guidance for the use of therapeutic agents (medications) (Beukelman et al., 
2011). The ACR did not use the ILAR sub-types in providing their recommendations. Instead, 
they grouped children into five distinct “treatment groups”. These groups are 1) History of 
arthritis of 4 or fewer joints, 2) History of arthritis of 5 or more joints, 3) Active sacroiliac 
arthritis, 4) Systemic arthritis with active systemic features (and without active arthritis) and 5) 
Systemic arthritis with active arthritis (and without active systemic features). For each treatment 
group there is a therapeutic treatment pathway recommended, a description of the features of 
poor prognosis and methods to classify disease activity level (Beukelman et al., 2011). In 2013 
updated recommendations were published by the ACR for the treatment of systemic JIA and for 
screening children receiving biologics for tuberculosis (Ringold et al., 2013).  
Most patients are first treated with bon-steroidal anti-Inflammatory drugs (NSAIDs).  However, 
early treatment with disease-modifying anti-rheumatic drugs (DMARDS) for certain JIA subsets 
is required to improve long-term outcomes. (Borchers et al., 2006). Another treatment option 
occasionally used is corticosteroids, either oral or provided by intra-articular injection (Gowdie 





medications with harmful side effects such as corticosteroids. (Gowdie & Tse, 2012). Biologic 
agents are a group of medications that blocks the body’s inflammation response. They are used 
mostly in treating systemic and polyarticular JIA. They are occasionally used in the treatment of 
enthesitis-related arthritis and chronic uveitis.  While biologic therapies are effective in treating 
JIA patients who do not respond to standard therapies use can be limited in some jurisdictions 
because of their high costs (Gowdie & Tse, 2012). Each medication has its own side effect 
profile that can impact quality of life and nutritional status such as gastro-esophageal reflux, 
nausea, stomach ulcers, elevated blood glucose, increased appetite and risk of infection as shown 
in Table 2.5. These factors can lead to an imbalance of energy and nutrients and subsequently 
affect growth and development in children with JIA.   
 
Table 2.9. Serum 25-hydroxyvitamin D (25(OH) D) concentrations and health 
Adapted from (Institute of Medicine, 2011) 
 
Vitamin D status 
Range Units                    
(nmol/L)             (ng/mL) 
Health Implications 
Vitamin D deficient <30 nmol/L <12 ng/mL 
Associated with vitamin D 
deficiency, leading to rickets in 
infants and children and 
osteomalacia in adults 
Subclinical deficiency 30–50 nmol/L 12–20 ng/mL 
Generally considered inadequate 
for bone and overall health in 
healthy individuals 
Adequate >50 nmol/L 20 ng/mL 
Generally considered adequate 
for bone and overall health in 
healthy individuals 
Toxicity >125 nmol/L >50 ng/mL 
Emerging evidence links 
potential adverse effects, related 
to hypercalcemia, to such high 






The Endocrine Society has published clinical practice guideline as well for 
patients at risk of vitamin D deficiency (Holick et al., 2011). They have included 
recommendations for a number of at-risk populations including: “obese children and 
adults and children and adults on anticonvulsant medications, glucocorticoids, antifungals 
such as ketoconazole, and medications for Acquired Immune Deficiency Syndrome be 
given at least two to three times more vitamin D for their age group to satisfy their body's 
vitamin D requirement” (Holick et al., 2011) (see Table 2.10). They suggest a daily 
intake value and tolerable upper limit levels, based on age and clinical circumstances 
(Holick et al., 2011). They also have daily intake values that are 2-3 times higher for 
obese patients (Holick et al., 2011). The Canadian Paediatric Society published vitamin D 
supplementation recommendations for Canadian mothers and infants in 2007; these were 
reaffirmed in 2013 (Godel & Society, 2013). They recommend, “Total vitamin D intake 
from all sources for the premature infant should be 200 IU/kg/day to a maximum of 400 
IU/day. Subsequent vitamin D dosage should be 400 IU/day for all infants during the first 
year, with an increase to 800 IU/day from all sources between October and April north of 
the 55th parallel (approximate latitude of Edmonton) and between the 40th and 55th 
parallel in individuals with risk factors for vitamin D deficiency other than latitude alone 
(Godel & Society, 2007).” The Canadian Paediatric Society  also has different definitions 
of  25(OH)D status than the IOM with 25(OH)D <25 nmol/L defined as deficient status, 
25-75 nmol/L insufficient, optimal vitamin D status as between 75-225 nmol/L, 
pharmacological as > 255 nmol/L and potentially toxic as >500 nmol/L 25(OH)D (Godel 
& Society, 2013).  The Canadian Cancer Society and Osteoporosis Canada (Hanley, 
Cranney, Jones, Whiting, & Leslie, 2010) have also published guidelines for vitamin D 
intake their guidelines were published for adults but  not for children and adolescents. For 
the duration of this review all 25(OH)D concentrations and dietary intake values will be 








Table 2.10. Dietary Reference Intakes (DRIs) values and daily allowance for vitamin D 
 
* Adequate intake per day 
Adapted from (Holick et al., 2011; Institute of Medicine, 2011)




(EAR) IU per day  
Recommended 
Dietary Allowance 
(RDA) IU per day 
Tolerable Upper 
Intake Level (UL) 




Intake Level (UL) 
per day (IU/day) 
0-6 
months 
400 (10 μg) * - 1000 (25 μg) 
400-1000 (10-25 μg) 2000 (50 μg) 
7-12 
months 
400 (10 μg) * - 1500 (38 μg) 
400-1000 (10-25 μg) 2000 (50 μg) 
1-3 years 400 (10 μg) 600 (15 μg) 2500 (63 μg) 600-1000 (15-25 μg) 4000 (100 μg) 
4-8 years 400 (10 μg) 600 (15 μg) 3000 (75 μg) 600-1000 (15-25 μg) 4000 (100 μg) 
9-13 years 400 IU (10 μg) 600 IU (15 μg) 4000 IU (100 μg) 1500-2000 (38-50 μg) 4000(100 μg) 
14-18 
years 




Serum 25OHD levels increase in response to increased vitamin D intake in a non-linear 
manner (Institute of Medicine, 2011). A randomized, double-blind placebo-controlled trial by 
Cashman et al. (2008) was conducted in 238 men and women aged 20–40 years old who 
received supplemental doses of 0, 200, 400, or 600 IU/d of vitamin D3 throughout the winter. It 
was found that, vitamin D intakes (combination of food and prescribed supplement) required to 
maintain serum 25(OH)D concentrations of 37.5, 50, and 80 nmol/L in 97.5% of the sample 
were 796, 1120, and 1644 IU, respectively (Cashman et al., 2008). A meta-regression conducted 
by Chung et al. (2009), showed that serum concentrations are increased by an average of 1.95 
nmol/L for each 40IU per day supplementation. Supplementation with ergocalciferol instead of 
cholecalciferol resulted in smaller increases. A relationship between increasing doses of vitamin 
D3  and increasing 25(OH)D concentrations was present in both adults and children and the dose-
response relationships differed depending on study participants’ serum 25(OH)D status at 
baseline with a difference in effect found among participants who had a vitamin D status ≤40 vs. 
>40 nmol/L, and duration of supplementation ≤3 vs. >3 months  (Chung et al., 2009). The 
analysis contained four  studies in children and adolescents and they summarised that the impact 
of supplementation in this group was increased 25(OH)D concentrations in a dose-dependent 
manner, ranging from 8 nmol/L (200 IU D3/day), 16.5 (with 600 IU D3/day) to 60 nmol/L (2000 
IU of vitamin D3/day) (Chung et al., 2009). 
Vitamin D deficiency is a concern throughout the lifespan. In infants, it can lead to 
rickets which is characterized by abnormal growth of bones resulting in bowed legs, outward-
bowed chest, and rachitic rosary on the ribs (Wharton, 2003). In adults, it manifests as 
osteomalacia where the symptoms include bending of the spine and bowing of the legs. It can 
also lead to muscle weakness and bone pain, which can go unnoticed during the initial stages of 
the deficiency. Long-term vitamin D deficiency, even that which does not lead to rickets or 
osteomalacia, can over time play a role in adult bone loss (Heaney, 2003). This reduction in bone 
mass in older persons is known as osteoporosis and is characterized as bones becoming porous 
and fragile (Heaney, 2003).   
Vitamin D toxicity is rare and is most likely linked to high intakes of supplements 
or cod liver oil. It is unlikely to occur from intake of food or sun exposure. The 
symptoms of vitamin D toxicity include nausea, vomiting, poor appetite, constipation, 




mental confusion (ASBMR, 2005). High blood concentrations of calcium also can cause 
heart rhythm abnormalities and eventually calcification of soft tissues such as the renal 
tubules of kidney (Institute of Medicine, 2011). 
 
2.5. Vitamin D Status in Children and Adolescents 
 2.5.1. Vitamin D Status of Children and Adolescents World Wide 
 
Vitamin D deficiency is not only an issue in Canada but worldwide. It has been estimated 
that one billion people worldwide have vitamin D deficiency or insufficiency  (Holick, 2007). A 
systematic review of vitamin D status of populations worldwide found that 88% of 25(OH)D 
values had a mean value below 75 nmol/l, 37% had mean values below 50 nmol/l and 7% had 
mean values below 25 nmol/l (Hilger et al., 2014).  Vitamin D status was significantly higher in 
North America than in Europe or the Middle East and Africa. While no age-related differences 
were found in Europe and North America, in the Asia/Pacific region, children and adolescents 
were found to have significantly lower 25(OH)D values than adults and elderly. Children and 
adolescents from the Middle East/Africa have significantly higher 25(OH)D values than adult 
and the elderly populations (Hilger et al., 2014). Higler et al. speculate that the contrast between 
the two regions could be due to the amount of time spent outdoors by the varying age groups of 
both cultures. This systematic review found no sex-related differences for any of the populations 
studied. In the United Kingdom, sub-groups of the population have been found to be at increased 
risk of vitamin D deficiency, particularly South Asian ethnic minority (Prentice, 2013).  
Traditional diet and clothing customs of South Asia have impacted vitamin D status. 
Rickets cases has been reported particularly among children from families of South Asian, 
African, Afro-Caribbean or Middle-Eastern origin children commonly affected are reported to be 
dark-skinned, to have had limited opportunities for skin UVB exposure, born to mothers who had 
poor vitamin D status during pregnancy, and were exclusively breastfed for an extended period 
and weaned onto poor diets (Prentice, 2013). This trend has also been found in Canada, where a 
national survey found that newcomer immigrant and refugee children particularly girls were 
more likely to be vitamin D deficient or insufficient compared to non-immigrant children 
(Vatanparast, Nisbet, & Gushulak, 2013). Countries closer to the equator also report vitamin D 




as well as the religious or cultural requirement to remain fully covered (Balasubramanian et al., 
2003; Challa et al., 2005; Goswami et al., 2000; Shaikh & Alpert, 2004).  In Qatar, a country 
located in Southwest Asia at a latitude of approximately 25°, 25(OH)D status was measured in 
healthy children under 16 years of age (Bener, Al-Ali, & Hoffmann, 2009). The study revealed 
that vitamin D deficiency was most prevalent among children ages 11-16 (61.6%).  Vitamin D 
deficiency increased with age, reduced intake of vitamin D and family history of vitamin D 
deficiency. Vitamin D deficiency was more prevalent in children with lower body mass indexes, 
lack of sunlight exposure, and children with reduced physical and outdoor activity (Bener et al., 
2009).  
2.5.2. Vitamin D Status of Canadian Children and Adolescents 
 
To highlight vitamin D status in Canadians, the Canadian Health Measures Survey Cycle 
1 (CHMS) measured 25(OH)D status and vitamin D intake of a representative sample of 
Canadians aged 6-79 years of age (Whiting, Langlois, Vatanparast, & Greene-Finestone, 2011). 
One quarter of Canadians did not meet the RDA for vitamin D intake and had 25(OH)D 
concentrations below the optimal level. Specifically, for children ages 6-11 years and 12-19 
years, 14.1% and 26.3% of children had a vitamin D status below optimal concentrations (75 
nmol/L). In both age groups a statistically significant (p <0.05) percentage of males had lower 
vitamin D status than females. Overall vitamin D supplement users were found to have higher 
vitamin D concentrations than non-supplement users and non-white Canadians were at greater 
risk of not meeting the DRI’s for vitamin D intake. A cross-sectional study investigating 
thevitamin D status of preschoolers attending licenced daycares in Montreal found that 88% of 
children ages 2-5 years had 25(OH)D concentrations above 50 nmol/L even though the 95% of 
children were not meeting the EAR for vitamin D (Hayek et al., 2013).  Additionally, a cross-
sectional study of preschoolers recruited from pediatric and family medicine primary care 
practices in Toronto (called TARGet Kids!) found, only 7% of children ages 1-6 had vitamin D 
concentrations below 50 nmol/l (Lee et al., 2014). Another cross-sectional study investigating 
vitamin D status of children in Newfoundland 35.5% of children 0-14 years of age were found to 
have a 25(OH)D value below 50 nmol/L.  The effect of season on 25(OH)D status was also 
noticed with vitamin D insufficiency being more common in winter (Newhook et al., 2009). A 




years) which included 24 studies of cross-sectional design 6 of which investigated vitamin D 
intake concluded that vitamin D intake (along with a number of other key nutrients) was 
inadequate in this population (Gates, Skinner, & Gates, 2014). Ward et al. highlights that vitamin 
D deficient rickets is still present amongst Canadian children (2007). An annual incidence rate of 
2.9 cases of rickets per 100, 000 children per year was documented between July 1, 2002, and 
June 30, 2004. The mean age of the children diagnosed with rickets was 1.4 years of age (Ward, 
Gaboury, Ladhani, & Zlotkin, 2007). Many of these infants were of First Nations ethnicity and 
were not receiving vitamin D supplements. Among newly arrived refugee children to Calgary, 
Canada aged 0-19 years  42% had 25(OH)D concentrations below 50 nmol/L (Aucoin, Weaver, 
& Thomas, 2013). The highest 25(OH)D mean concentrations were in children aged 0 to 5 years.   
Mean 25(OH)D values for male and female refugee children were statistically similar in all age 
groups with the exception of those aged 12- to 19-years, in which female refugees had lower 
mean values (p = .01). The TARGet Kids! Study found an association between non-Western 
immigration compared to immigration from western countries and lower serum 25(OH)D status 
in early childhood. The study suggested that the difference was due to reduced vitamin D 
supplementation practices in this group and suggested that supplementation was an opportunity 
for intervention (Omand et al., 2013).  
2.6. Vitamin D in Immune and Inflammatory Pathways 
Recently, the roles of vitamin D metabolism and signaling for both innate 
immune (antimicrobial activity and antigen presentation) and adaptive immune (T and B 
lymphocyte function) responses have been investigated (Christakos et al., 2013). The 
mechanism by which vitamin D impacts the immune system and inflammatory pathways 
is through the active form 1,25(OH)D (Cutolo et al., 2011). 1,25(OH)D can then induce a 
response in VDR to bind to the promoter region in a number of immune cells and 
promote transcriptional regulation (Christakos et al., 2013). Activated T- and B-
lymphocytes, monocytes, and macrophages, as well as dendric cells, have VDRs the 
vitamin D-activating enzyme CYP27B1 and the enzymes capable of hydroxylating 
25(OH)D to 1,25(OH)2D (Gröber et al., 2013).   
In relation to the innate immune system 1,25(OH)2D either locally or 




macrophage differentiation (Gröber et al., 2013; Pludowski et al., 2013). 1,25(OH)2D  
can modulate production of Th1 and Th2 cells and reduce the secretion of a 
proinflammatory cytokine such as TNFα (Gröber et al., 2013; Wöbke, Sorg, & 
Steinhilber, 2014).  In general,  vitamin D’s role in immune function is to regulate 
inflammation when activate and up-regulate the production of cells that reduce 
inflammatory reactions (Cutolo et al., 2011). Reich et al. assessed the anti-inflammatory 
effects of 25(OH)D3 doses on blood cells. When the cells were pre-incubated with ≥30 
ng/ml 25(OH)D3 (75 nmol/L), a significant inhibition of lipopolysaccharide-induced IL-6 
mRNA expression was observed (Reich, Fedorak, Madsen, & Kroeker, 2014). This was 
not observed when cells were cultured with a 25(OH)D dose of 15 ng/ml (37.5 nmol/L). 
Providing >75 nmol/L 25(OH)D achieved a similar degree of suppression as providing 
0.1 nmol/L of active 1,25(OH)D.  When > 75 nmol/L of 25(OH)D was incubated with 
blood cells and lipopolysaccaride-induced TNF-α mRNA expression measured a similar 
effect as with IL-6 expression was observed (Reich et al., 2014). 
2.7. Vitamin D and relationship to Juvenile Idiopathic Arthritis 
 
A number of studies have demonstrated that patients with a autoimmune disease have 
lower levels of vitamin D (Nisar, Masood, Cookson, Sansome, & Ostör, 2013).  The mechanism 
by which this occurs is believed to be through vitamin D non-calciotropic functions in the 
immune system and inflammation pathways (Nisar et al., 2013). Vitamin D may play a role in 
the prevention and pathogenesis of JIA by enhancing macrophage production of antimicrobial 
peptides, and suppressing proinflammatory properties of dendritic cells, and antigen presenting 
cells that stimulate immune responses, prevent autoimmunity and link adaptive immune response 
(Von Scheven & Burnham, 2011). 
In adult patients with rheumatoid arthritis, low serum 25(OH)D concentrations are 
associated with increased disease activity (Sabbagh, Markland, & Vatanparast, 2013); however, 
little is known about children with juvenile arthritis. A meta-analysis, which included only three 
studies of the currently available data on JIA and vitamin D, reported the prevalence of vitamin 
D insufficiency in this population to be 82% (Nisar et al., 2013). There was, however, no 




effect, or increased utilization due to the disease status. Additionally, details as to the disease 
outcome and date of diagnosis were not reported (Nisar et al., 2013).  A study comparing JIA 
patients and healthy controls in Brazil found no statistically significant difference between the 
two groups. However, both controls and JIA patients had a high frequency of vitamin D 
insufficiency and deficiency (Munekata, Terreri, Peracchi, & Len, 2013). A number of studies 
conducted in the 1990’s where vitamin D status in JRA patients was measured with the purpose 
of studying the relationship of vitamin D to bone mineralization, found no difference in 
25(OH)D concentrations between JIA patients and controls (Falcini, Ermini, & Bagnoli, 1998; 
Hillman, Cassidy, Johnson, Lee, & Allen, 1994; Pepmueller, Cassidy, Allen, & Hillman, 1996). 
In these studies, however, many children were being actively treated for their JRA and the 
season of measurement was not reported, therefore, the relationship and impact of vitamin D on 
JRA could not be established. 
The optimal level of vitamin D for patients with JIA has yet to be determined. A study 
designed to investigate the relationship of vitamin D status to JIA by Pelajo et al. (2012) found 
that children with JIA were more likely to be vitamin D deficient than healthy controls (n=154) 
(Pelajo et al., 2012). This study was conducted in children with established ongoing JIA, and a 
portion of the participants were taking medication that could potentially modify the disease 
outcome. This study found that when the entire sample was considered (n=154), there was no 
relation between serum 25(OH)D concentrations and disease activity. A cross-sectional study 
conducted which included 152 patients with JIA at the University of Florence found significantly 
reduced 25(OH)D status in JIA patients compared with  188 age-and-sex-matched controls (Stagi 
et al., 2014). Active disease or frequent disease relapse significantly reduced vitamin D status 
compared with patients with no active disease or frequent disease flare-ups. The authors 
questioned whether JIA patients with more severe disease require higher supplementation of 
vitamin D to maintain normal 25(OH) D concentrations. Vitamin D status was also found to be 
worse in winter (Stagi et al., 2014). Another cross-sectional study exploring the association 
between 25(OH)D and disease activity in children with JIA was conducted in Turkey (Çomak, 
Doğan, Uslu-gökçeoğlu, Akbaş, & Özdem, 2014). Most patients (72.3%) had 25(OH)D < 50 
nmol/L, and a significant negative association between serum 25(OH)D concentrations and 
disease activity (p=0.01, r=-0,37). Disease activity was measured using the JADAS-27; mean 




patients with 25(OH)D levels >37.5 nmol/L (p = 0.003). This was not found in a study by Wang 
et al. who used the ACR Pediatric 30, CRP and ERS as measures of disease activity (Wang et al. 
2015). There was a significant difference between JIA and control 25(OH)D concentrations with 
JIA patients having lower 25(OH)D status, but no statistically significant correlation between 
25(OH)D and JIA subtypes.  The relationship between vitamin D status and disease activity in 
children with JIA is still unclear. Studying newly diagnosed patients who are treatment naive 
will help discover this relationship as there will be fewer confounders that are associated with 
patients who have had the disease for varying degrees of time (medication, lifestyle 
modifications, and disease duration).  
Thus far, all studies that have been conducted have included patients who were being 
treated for JIA many of whom were receiving corticosteroids as shown in Table 2.11. Many of 
the articles published before 2013 were described by Nissar et.al (2013) and the studies were 
conducted with the purpose of investigating the relationship between juvenile arthritis (JIA, JCA 
or JRA) and bone health. Of the 30 studies summarized as a scoping review in Chapter 3, six 
studies had mean 25(OH)D status above 75 nmol/L, the majority (15 studies) had mean 
25(OH)D concentrations between 50-75 nmol/L and 9 had mean values below 50 nmol/L. Of the 
11 studies that published mean 25(OH)D statuses of healthy control groups, 6 had mean values 
statistically significantly greater than the population with juvenile arthritis, 3 had concentrations 
that were statistically similar, and two studies had mean 25(OH)D values that were statistically 
significantly below. Mean 25(OH)D status of most of the studies was below optimal for children 
with juvenile arthritis and required further investigation into the dietary intake of vitamin D, 
lifestyle factors, disease activity and genetic polymorphisms to tease out the relationship between 




2.7.1. Vitamin D Receptors and Juvenile Idiopathic Arthritis 
 
While the VDR is principally involved in calcium regulation, the receptor also regulates a 
variety of other metabolic pathways, including a number of pathways involved in both innate and 
adaptive immunity, suggesting that vitamin D plays a role in the pathogenesis of autoimmune 
diseases (Falcini et al., 2013; Ramagopalan et al., 2010). Specific polymorphisms in the VDR 
gene may be associated with different biologic responses to vitamin D. Certain polymorphisms 
(genetic variants) are associated with susceptibility to some diseases. By determining if a 
polymorphism occurs more frequently in those with JIA, we will be able to target preventative 
care towards those individuals. It has been suggested that the rs11568820 polymorphism of the 
VDR gene may impact transcriptional activity (Falcini et al., 2013). Specifically, the GG 
genotype and G allele were found to be more represented in Italian patients with JIA and were 
hypothesized to lead to a reduction in VRD activity and subsequent decrease in response to 
vitamin D. No study has investigated this relationship in a Canadian population. Recently the 
idea of investigating epistasis (gene-gene interactions) amongst genes in the inflammatory and 
vitamin D pathway and how their interactions contribute to JIA risk was explored by Ellis et al. 
(2015). This is the first study to explore this interaction, and the authors suspect that through 
exploring these interactions there is the opportunity to account for the missing heritability that 
has been observed with complex diseases with genetic components (Ellis et al., 2015). Their 
work found evidence of epistasis amongst PTPN2 and genes of the vitamin D pathway, including 




Thus far, we know that there is a role for vitamin D in the inflammatory pathways, a high 
prevalence of 25(OH)D insufficiency among children with JIA, and an established link of 
vitamin D with other autoimmune diseases.  We do not, however, know the optimal vitamin D 
status for children with JIA, whether reduced vitamin D is caused by increased utilization or 
reduced vitamin D status in children with JIA, the impact of vitamin D in disease activity or the 




to explore the association. The relationship between vitamin D status and JIA over time in newly 
diagnosed individuals in Canada or abroad has yet to be investigated. Investigating the genetic 
and environmental role that vitamin D plays in the prevention and control of JIA in the same 
children will help to tease out the multifaceted role played by vitamin D in this disease. Being 
able to suggest specific targets for vitamin D status as a potential adjunct therapy in the treatment 
of JIA and understanding how genetic variants increase the risk of disease development will 







Following the general literature review (Chapter 2), as indicated in page 43, the state of 
knowledge and gaps in research on the role of vitamin D in JIA were comprehensively 
evaluated in this scoping review.  
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3.1. Introduction 
Arthritis is among the most common chronic diseases in children. JIA is the current 
nomenclature applied to denote a group of clinically distinguishable subsets that share chronic, 
childhood-onset arthritis of unknown cause as a unifying feature.  The etiologies of JIA are 
unknown and the pathogeneses unclear but are likely multifactorial.  Among epidemiologic 
studies there is substantial variability in the frequencies with which JIA and its respective 
subtypes are reported to occur; chronic arthritis prevalence rates range from 0.07 to 4.01/1000 
children and annual incidences from 0.008 to 0.226/1000 children (Manners & Bower, 2002).  
Putative explanations for the disparities in reported juvenile arthritis prevalence rates include, as 
examples, differences in diagnostic criteria applied (specifically, JIA or the earlier JRA (Brewer, 
Bass, Baum, Cassidy, Fink, Jacobs, Hanson, Levinson, Schaller, 1977) or JCA (Woods, 1978) 
classification systems) and in case ascertainment methods.    
While methodologic inconsistencies among JIA epidemiologic studies might account for 
perceived prevalence differences, actual differences might occur as a consequence of genetic, 
ethnic, environmental, and lifestyle influences.  Vitamin D status is potentially governed by these 
same factors; VDR genotype, ethnically-related skin tone and clothing, environmental variations 
in exposure to ultraviolet B radiation relating to the latitude of residence and season, and vitamin 




As an immune and inflammatory mediator, vitamin D is implicated in the pathogenesis of 
autoimmune diseases including, as examples, multiple sclerosis, type 1 diabetes, rheumatoid 
arthritis, Crohn's disease, and chronic childhood arthritis (Agmon-Levin, Theodor, Segal, & 
Shoenfeld, 2013; Cutolo et al., 2011; Von Scheven & Burnham, 2011). Cells involved in innate 
and adaptive immune responses such as macrophages, dendritic cells, T cells, and B cells express 
enzymes required to activate and respond to vitamin D (Adorini & Penna, 2008; Hewison, 2012; 
Holick, 2012). Cytochrome p450 27B1 (CYP27B1) is the enzyme required to synthesize 1,25-
dihydroxyvitamin D (1,25(OH)2D), the active form of vitamin D, from circulating 25(OH)D. 
The actions of 1,25(OH)2D are mediated by its binding to the VDR, a nuclear transcription 
factor. VDR then binds to the Vitamin D Response Element (VDRE),  a genetic sequence 
located in the promotor region of genes regulated by vitamin D. (Adorini & Penna, 2008; 
Hewison, 2012; Holick, 2012). Vitamin D tends to suppress the immune response (Cutolo et al., 
2011). Consequently, low vitamin D concentrations are associated with an increase in pro-
inflammatory mediators and more active disease (Baeke et al., 2010; Cutolo et al., 2011) 
consistent, for example, with the observation that low serum 25(OH)D is associated with 
increased disease activity in rheumatoid arthritis (Sabbagh et al., 2013).  
Reports of relationships between vitamin D and chronic childhood arthritis are derived 
from studies having different methodologic approaches, originating from multiple geographic 
regions, and comprising demographically disparate populations.  Since the last analysis of these 
reports in  2013 (Nisar et al., 2013) the number of studies reporting 25(OH)D concentrations in 
children with chronic arthritis have increased from 14 to 38.  An updated, systematic analysis of 
pertinent literature should help to further refine understanding of the relationships between 
vitamin D and juvenile arthritis, contribute to optimizing management of vitamin D status in 
children with arthritis, and clarify vitamin D’s potential role in mediating disease pathogenesis. 
Scoping reviews are methodologic approaches for thoroughly distilling and synthesizing 
information derived from different studies having varied designs.  The purposes of scoping 
reviews are to not only capture key concepts that can guide care but also to recognize knowledge 
gaps that can inspire future research priorities (Daudt, van Mossel, & Scott, 2013) 
Although nomenclature applied to chronic childhood arthritis classification systems has 
changed over the years, JIA is the current terminology.  For clarity, this review will hereafter use 




JRA classification systems. However, in this review, when quoting the literature, we use the 
terminology for chronic childhood arthritis (JCA, JRA, or JIA) that was applicable at the time 
the cited reference was published (Arksey & Malley, 2005).  
Here we report the results of a vitamin D- JIA  scoping review that summarizes, 
synthesizes, evaluates, and interprets pertinent evidence from the literature to address the 
following research questions: 1) What is the relationship between vitamin D status and the 
occurrence of JIA?  2) What is the relationship between vitamin D status and childhood arthritis 
activity? 3) What is the relationship between vitamin D status in JIA and medication use?   4) 
What is the relationship between vitamin D status and geographic and demographic 
characteristics in children with JIA?  
3.2. Methodology 
To ensure a comprehensive literature scan, this scoping review applied the iterative 
methodological framework described by Arksey and O’Malley, with refinements by Levac et al. 
and Colquhoun et al. (Arksey & Malley, 2005; Colquhoun et al., 2014; Levac, Colquhoun, & 
O’Brien, 2010). Five biomedical literature search engines were accessed, in the following 
sequence: Medline (using Ovid), Embase (using Ovid), Cumulative Index to Nursing and Allied 
Health Literature (CINHAL), Web of Science, and Scopus. Reference lists within each of the 
publications retrieved from the web-based searches were scanned to ensure that no relevant 
citations were missed. Medical Subject Heading (MeSH) terms used for retrieval were “vitamin 
D” and “juvenile arthritis”.  The search term “juvenile arthritis” was general enough to capture 
citations that referred to JCA, JRA and JIA classification terms (Table 3.1).    Search results, 
which included published articles, letters, and abstracts from conference proceedings, were 
collated and duplicates of articles removed.  Publication titles and abstracts were then screened 
for relevance to the subject of vitamin D in children with idiopathic chronic arthritis as defined 
by JIA, JCA, or JRA classification criteria (Brewer, Bass, Baum, Cassidy, Fink, Jacobs, Hanson, 
Levinson, Schaller, 1977; Petty et al., 2004; Woods, 1978).  The full texts of relevant articles 
were then reviewed.   
Inclusion criteria for the review were 1) study conducted in humans, 2) 25(OH)D 
concentrations reported, 3) participants having a diagnosis of JCA, JRA, or JIA, and 4) JCA, 




were 1) study conducted in animals, 2) the presence of an associated autoimmune disease 3) 
pregnant or lactating subjects, 4) 25(OH)D concentrations not reported), and 5) review articles. 
The process applied to identify eligible articles for the review is shown in Figure 3.1 (Moher, 
Liberati, Tetzlaff, & Altman, 2009).  Articles in any language were eligible; however, no non-
English language articles without at least an English abstract were found.  From all relevant 
articles retrieved the following information was extracted: juvenile arthritis classification system 
( JCA, JRA, or JIA); sample size; sex ratio; patient age (at baseline or time of study if the study 
was  cross-sectional); geographic location (country, city, and latitude and longitude), year of 
study; 25(OH)D concentration; study conclusion;  and,  if applicable,  control group sample size, 
characteristics, and 25(OH)D concentration. The latitudes and longitudes reported were that of 
the city where the study was conducted; if unavailable, the province, state or region’s center 
latitude was used and, as a last resort, the country’s central latitude was used. 25(OH)D status by 
season of measurement was not reported in any of the articles found and therefore could not be 
considered.  
Geographic Information Systems (GIS) mapping was performed using ArcGIS version 
10.4 to visualize studies by juvenile arthritis classification, 25(OH)D status, location, and 
latitude. For all reported studies, an additional map comparing the difference in 25(OH)D 
concentration between those reporting active versus inactive disease was made.  
Defining Vitamin D Status. 
Vitamin D deficiency is defined as a serum 25(OH)D concentration less than 30 nmol/L,  
a 25(OH)D concentration between 30-50 nmol/L is considered insufficient, greater than 50 
nmol/L is considered sufficient and a 25(OH)D status  greater than 125 nmol/L is considered at 
risk of adverse effects (Institute of Medicine, 2010). These values are based on the IOM review 
of published research focused on determining the optimal vitamin D concentration for maximal 
calcium absorption, prevention of rickets, reduction of fracture risk and prevention of 
osteomalacia in healthy populations (Institute of Medicine, 2010). In the most recent review of 
vitamin D requirements,  the IOM concluded that there was inadequate information to make 
intake recommendations in relation to other biologic roles of vitamin D (Institute of Medicine, 
2010). The current RDA of vitamin D  are 400 IU from 0 to 12 months of age and 600 IU per 




The Endocrine Society has published clinical practice guidelines for patients at risk of 
vitamin D deficiency (Holick et al., 2011). The Society recommends that at-risk populations, 
including “obese children and adults and children and adults on anticonvulsant medications, 
glucocorticoids, antifungals such as ketoconazole, and medications for acquired immune 
deficiency syndrome be given at least two to three times more vitamin D for their age group to 
satisfy their body's vitamin D requirement” (Holick et al., 2011).   The optimal 25(OH)D 
concentration suggested by the Endocrine Society is 75nmol/L. To meet this concentration it is 
recommended that 400-1000 IU be given between 0 to 12 months of age,  600 - 1000 IU per day 
from 1 to 8 years of age,  and 1500-2000 IU for children between ages 9-18 years (Holick et al., 
2011).  These recommendations, however, are not specific for children with chronic arthritis. 
3.3. Results of Scoping Review and Discussion 
Considerations when evaluating the role of vitamin D in JIA include vitamin D 
requirements for this population and the role that vitamin D plays in disease activity. Using the 
specified MeSH search terms (vitamin D and childhood arthritis), 386 reports (full-text articles, 
conference abstracts, and letters to the editor) were identified.  Thirty-eight studies met the 
inclusion criteria and are the subject of this review (Table 3.2).  One meta-analysis reported 
cumulative  25(OH)D concentrations from fourteen studies comprising children with  JIA, JCA, 
and JRA and other rheumatic conditions; this meta-analysis was not included in our scoping 
review but is referenced in the discussion (Nisar et al., 2013). This present review summarizes 
accumulated evidence on vitamin D and chronic childhood arthritis by disease activity and 
latitude. Additionally, this study provides new information about differences in 25(OH)D status 
between healthy controls and children with JIA. 
3.3.1. Vitamin D Status in Relation to Chronic Childhood Arthritis Classification    
 
Twenty-one of the 38 studies (55.3%) reported 25(OH)D status for patients with JIA 
(Alhomaidah, Alsagheir, & Al-mayouf, 2016; Bouaddi et al., 2014; Çomak et al., 2014; 
Dağdeviren-çakır, Arvas, Barut, Gür, & Kasapçopur, 2016; de Sousa Studart et al., 2015; Dey et 
al., 2014; Goralczyk, Konstantynowicz, Abramowicz, Dobrenko, & Babinska-Malec, 2015; Lien 
et al., 2005; Markula-patjas et al., 2012; Miettinen, Kinnunen, Harjutsalo, Reinert-Hartwall, 




Sansome, 2013; Peixoto, Teixeira, Lucas, Costa, Costa, 2013; Pelajo et al., 2012; Rosiles, 
Salazar, Velazquez, Ruiz, 2015; Siamopoulou et al., 2001; Stagi et al., 2014; Szymanska-Kaluza, 
Biernacka-Zielinska, Stanczyk, 2013; Tang, 2016; Valta, Lahdenne, Jalanko, & Aalto, 2007a), 
eight (21.1%) for patients with JRA (Bianchi et al., 1990; Falcini et al., 1998; Henderson et al., 
1997; Hillman et al., 1994; Pepmueller et al., 1996; Reed, Haugen, Pachman, & Langman, 1991; 
Reed, Haugen, Pachman, & Langman, 1993; Stark, Davis, Janicke, Mackner, Hommel, Bean, 
Lovell, Heubi, 2006) and five (13.2%)  for JCA patients (Elsasser et al., 1982; Johansson; 
Portinsson; Akesson; Svantesson; Ockerman; Akesson, 1986; Reeve et al., 1993; Rooney, 
Davies, Reeve, Preece, Ansell, 2000; Tzoufi, Siamopoulou-Mavridou, Challa, & Lapatsanis, 
1994).  Additionally, there were four studies that included patients with juvenile arthritis and 
other rheumatic diseases (Hillman et al., 2008; McNally et al., 2012; Reed, Haugen, Pachman, & 
Langman, 1990; Warady, Lindsley, Robinson, 1994). As the JRA classification system tended to 
be applied in North America and the JCA classification in Europe, there was a corresponding 
hemispheric-specific   division in the geographic region from which  JRA and  JCA articles 
originated.  Studies originated from 17 countries at latitudes ranging from 3°S to 61°N (Table 
3.2). There were no eligible studies found that reported data below a latitude of 39°N prior to the 
introduction of the ILAR JIA disease classification systemic and no eligible JRA studies above 
42°N. 
The 2013, systematic literature review of 19 childhood arthritis  studies reported vitamin 
D status (14 reporting 25(OH)D and 11 reporting 1,25(OH)D) suggested that at that time there 
was no clear link between vitamin D status and children with chronic arthritis (Nisar et al., 
2013). The review also contained a meta-analysis comprising three studies that reported the 
prevalence of vitamin D insufficiency to be 82% in JIA (Nisar et al., 2013). Only three studies 
reported in the meta-analysis were conducted using  ILAR JIA criteria (Nisar et al., 2013).  
3.3.2. Comparison of Study Design 
 
Seventeen studies used a cross-sectional design (n=17; 44.7%) (Alhomaidah et al., 2016; 
Bouaddi et al., 2014; Çomak et al., 2014; Elsasser et al., 1982; Goralczyk et al., 2015; Henderson 
et al., 1997; Markula-patjas et al., 2012; McNally, Matheson, & Rosenberg, 2009; Miettinen, 
Kinnunen, Harjutsalo, Reinert-Hartwall, Lamberg-Allardt, Toumilehto, Saila, 2013; Nisar, 




Benitez, & Miller, 2012;  Reed et al., 1993; Reed et al., 1990; Reeve et al., 1993; Tang, 2016; 
Valta, Lahdenne, Jalanko, & Aalto, 2007b) , 16 (42.1%) a case-control design  (Bianchi et al., 
1990; Dağdeviren-çakır et al., 2016; de Sousa Studart et al., 2015; Dey et al., 2014; Falcini et al., 
1998; Hillman et al., 1994; Lien et al., 2005; Munekata et al., 2013; Pepmueller et al., 1996; 
Rooney, Davies, Reeve, Preece, Ansell, 2000; Rosiles, Salazar, Velazquez, Ruiz, 2015; Stagi et 
al., 2014; Szymanska-Kaluza, Biernacka-Zielinska, Stanczyk, 2013; Tzoufi et al., 1994; Ying 
Wang et al., 2015) and the remainder (5; 13.2%) were randomized controlled trials  (Hillman et 
al., 2008;  Reed et al., 1991; Siamopoulou et al., 2001; Stark, Davis, Janicke, Mackner, Hommel, 
Bean, Lovell, Heubi, 2006; Warady, Lindsley, Robinson, 1994). The primary objective of the 
majority of studies was to investigate the relationship between juvenile arthritis and bone health 
(n=20; 52.6%). In all studies where sex distribution was reported, there were significantly more 
female participants than males, an observation consistent with the overall preponderance of 
females in JIA (Borchers et al., 2006). With the exception of one study (Nisar, Cookson, 
Masood, Sansome, 2013), the age range of the participants was 0-21 years. 
3.3.3. 25(OH)D status 
 
Of the 38 studies  reviewed, six (15.8%) had mean 25(OH)D concentrations above 75 
nmol/L (Alhomaidah et al., 2016; Henderson et al., 1997; Hillman et al., 2008; Reed et al., 1993; 
Reeve et al., 1993; Stark, Davis, Janicke, Mackner, Hommel, Bean, Lovell, Heubi, 2006).   
Seventeen studies (44.7%)  had mean 25(OH)D concentrations between 50-75 nmol/L (Bouaddi 
et al., 2014; de Sousa Studart et al., 2015; Falcini et al., 1998; Hillman et al., 1994; Markula-
patjas et al., 2012; McNally et al., 2009; Miettinen, Kinnunen, Harjutsalo, Reinert-Hartwall, 
Lamberg-Allardt. Toumilehto, Saila, 2013; Munekata et al., 2013; Peixoto, Teixeira, Lucas, 
Costa, Costa, 2013; Pelajo et al., 2012;  Reed et al., 1991; Rosiles, Salazar, Velazquez, Ruiz, 
2015; Siamopoulou et al., 2001; Stagi et al., 2014; Tang, 2016; Warady, Lindsley, Robinson, 
1994) and 15  (39.5%) had values below 50 nmol/L (Bianchi et al., 1990; Çomak et al., 2014; 
Dağdeviren-çakır et al., 2016; Dey et al., 2014; Elsasser et al., 1982; Goralczyk et al., 2015; Lien 
et al., 2005; Nisar, Cookson, Masood, Sansome, 2013; Pepmueller et al., 1996; Reed et al., 1990; 
Rooney, Davies, Reeve, Preece, Ansell, 2000; Szymanska-Kaluza, Biernacka-Zielinska, 
Stanczyk, 2013; Tzoufi et al., 1994; Valta et al., 2007a; Ying Wang et al., 2015). Of those 15 




range or cutoff was provided for four studies). Of the 14 studies (36.8%) that published mean 
25(OH)D status of healthy control groups, nine (64.3%)  had mean control values significantly 
greater than the population with childhood arthritis (Bianchi et al., 1990; Dağdeviren-çakır et al., 
2016; de Sousa Studart et al., 2015; Dey et al., 2014; Pepmueller et al., 1996; Rooney, Davies, 
Reeve, Preece, Ansell, 2000; Stagi et al., 2014; Tzoufi et al., 1994), three  (21.4%) had 
concentrations that were statistically similar (Munekata et al., 2013; Rosiles, Salazar, Velazquez, 
Ruiz , 2015; Ying Wang et al., 2015), and two studies (14.3%)   had mean 25(OH)D values 
significantly below the juvenile arthritis comparison groups (Falcini et al., 1998; Hillman et al., 
1994). One study compared 25(OH)D concentrations in children with JIA to hospitalized 
children and found no statistically significant difference between the two groups  (Szymanska-
Kaluza, Biernacka-Zielinska , Stanczyk, 2013). Mean 25(OH)D status of most studies (32 of the 
38; 84.2%) was below the optimal concentration of 75 nmol/L in children with arthritis (Holick 
et al., 2011).  
3.3.4. Geography in Relation to 25(OH)D Status in Chronic Childhood Arthritis 
 
Vitamin D status in children with JIA appears to follow a north-south gradient (Figure 
3.2). While this could be due to the diagnostic resources of the countries reporting values, the 
gradient does appear to be present in Europe where access to care and diagnostic resources are 
similar. Interestingly, the relationship between reduced vitamin D status and increased disease 
activity also appears to be present and follow a north-south gradient (Figure 3). More studies are 
required to confirm this relationship worldwide, especially in locations around the equator as 
well as in the southern hemisphere where thus far only two studies have taken place (de Sousa 
Studart et al., 2015; Munekata et al., 2013).  
The major source of vitamin D for most people is endogenous vitamin D synthesis 
induced by sunlight exposure (Holick, 2016).   Above 33 latitude UVB radiation is not intense 
enough for the cutaneous synthesis of vitamin D all year long (Tsiaras & Weinstock, 2011; 
Wacker & Holick, 2013). At latitudes 42 and 53o North, between October to April, UVB 
radiation is not intense enough to elicit endogenous vitamin D synthesis (Webb et al., 1988) thus 
potentiating the risk of vitamin D deficiency, (Tsiaras & Weinstock, 2011). 
The prevalence of JIA, as well as the dominating subtype, varies with latitude (Manners 




populations residing at latitudes at or below 33°(Alhomaidah et al., 2016; de Sousa Studart et al., 
2015; Dey et al., 2014; Munekata et al., 2013; Rosiles, Salazar, Velazquez, Ruiz, 2015; Tang, 
2016; Ying Wang et al., 2015), 19 studies  (50.0%) were conducted between 33-50° (Bianchi et 
al., 1990; Bouaddi et al., 2014; Çomak et al., 2014; Dağdeviren-çakır et al., 2016; Falcini et al., 
1998; Henderson et al., 1997; Hillman et al., 1994; Hillman et al., 2008; Peixoto, Teixeira, 
Lucas, Costa, Costa, 2013; Pelajo et al., 2012; Pepmueller et al., 1996; Reed et al., 1991;  Reed 
et al., 1993; Reed et al., 1990; Siamopoulou et al., 2001; Stagi et al., 2014; Stark, Davis, Janicke,  
Mackner, Hommel, Bean, Lovell, Heubi, 2006; Tzoufi et al., 1994; Warady, Lindsley, Robinson, 
1994), and 12 at a latitude above 50° (Elsasser et al., 1982; Goralczyk et al., 2015; Lien et al., 
2005; Markula-patjas et al., 2012; McNally et al., 2009; Miettinen, Kinnunen, Harjutsalo, 
Reinert-Hartwall, Lamberg-Allardt, Toumilehto, Saila, 2013; Nisar, Cookson, Masood, 
Sansome, 2013; Reeve et al., 1993; Rooney, Davies, Reeve, Preece, Ansell, 2000; Szymanska-
Kaluza, Biernacka-Zielinska, Stanczyk, 2013; Valta et al., 2007a). For those below 33°, 1 study 
(14.3%) reported a mean 25(OH)D concentration >75 nmol/L, 4 (57%) reported a concentration 
between 50-75 nmol/L, and two (29%) reported values less than 50 nmol/L. For the studies that 
took place between 33-45° latitude, four studies (21.1%) reported a 25(OH)D concentration >75 
nmol/L (21%), nine (47.4%) reported a concentration between 50-75 nmol/L(47%) and six 
(31.6%) reported values less than 50 nmol/L. From the studies that took place above 45° latitude, 
one study (8.3%) reported a 25(OH)D concentration >75 nmol/L, four (21.1%) reported a 
concentration between 50-75 nmol/L (33%) and seven (36.8%) reported values less than 50 
nmol/L (39%).  
3.3.5. Current Chronic Childhood Arthritis Diagnostic Criteria 
 
Of the 21 studies that applied the current chronic childhood arthritis criteria used by  
ILAR to diagnose children with JIA, only one study reported mean 25(OH)D concentrations 
above 75 nmol/L (15%) (Alhomaidah et al., 2016). The majority of the studies (n=11; 52.4%) 
reported mean concentrations between 50-75 (52%) nmol/L (Bouaddi et al., 2014; de Sousa 
Studart et al., 2015; Hernández Rosiles, Duarte Salazar, Maldonado Velazquez, Rivas Ruiz, & 
Clark, 2017; Markula-patjas et al., 2012; Miettinen, Kinnunen, Harjutsalo, Reinert-Hartwall, 
Lamberg-Allardt, Toumilehto, Saila, 2013; Munekata et al., 2013; Peixoto, Teixeira, Lucas, 




and the remaining studies (n=9; 42.9%) reported a mean concentration below 50 nmol/L (43%) 
(Çomak et al., 2014; Dağdeviren-çakır et al., 2016; Dey et al., 2014; Goralczyk et al., 2015; Lien 
et al., 2005; Nisar, Cookson, Masood, Sansome, 2013; Szymanska-Kaluza, Biernacka-Zielinska, 
Stanczyk, 2013; Valta et al., 2007a; Ying Wang et al., 2015). As latitude increased, the 




Figure 3.1. PRISMA flow diagram. Articles identified from the retrieved publications reference 
lists are identified as “other” in the flow diagram. 
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3.3.6. Vitamin D and Disease Activity 
 
No single measure has been established as an accurate indicator of childhood arthritis 
disease activity. While C-reactive protein and Erythrocyte Sedimentation Rate are indicators of 
inflammation, they alone do not fully reflect overall disease activity. In the studies reviewed, a 
variety of validated composite scores were used to measure function or disease activity, 
including the CHAQ, JADAS-27 and ACR Peds 30)  (Duffy, 2007; Ringold & Wallace, 2007; 
Ringold et al., 2013).  
Fifteen of the 38 studies comprising this present review (39.5%) evaluated the relationship 
between vitamin D and disease activity (Figure 3.3). Seven studies (18.4%) reported that patients 
with active disease or those with elevated inflammatory biomarkers had lower 25(OH)D 
concentrations than those patients who were in remission or who had less disease activity 
(Bianchi et al., 1990; Çomak et al., 2014; Nisar, Cookson, Masood, Sansome, 2013; Peixoto, 
Teixeira, Lucas, Costa, Costa, 2013; Stagi et al., 2014; Tang, 2016; Tzoufi et al., 1994). One 
study (26.3%) showed the opposite relationship; those with active disease had higher vitamin D  
concentrations than those with inactive disease (Miettinen, Kinnunen, Harjutsalo, Reinert-
Hartwall, Lamberg-Allardt, Toumilehto, Saila, 2013). Of the seven studies (18.5%)  that reported 
no relationship between 25(OH)D and disease activity (Bouaddi et al., 2014; Dağdeviren-çakır et 
al., 2016; de Sousa Studart et al., 2015; Munekata et al., 2013; Pelajo et al., 2012;  Reed et al., 
1993; Reed et al., 1990)  one found a relationship between 25(OH)D concentrations and disease 
activity in the univariate but not the multivariate analysis (Bouaddi et al., 2014). Except for one 
study conducted in Turkey (Dağdeviren-çakır et al., 2016), all other studies conducted in Europe 
that explored disease activity reported a negative association between vitamin D and disease 
activity.  
 Long-term cohort studies can further clarify the relationship between vitamin D 
concentration and disease duration or frequency of relapse. Such an association was explored in 
a cross-sectional study which found significantly reduced 25(OH)D status in JIA patients 
(n=152)  compared with  188 age-and-sex-matched controls (Stagi et al., 2014). Active disease 
or frequent relapse was associated with reduced vitamin D status compared to patients with no 
active disease or frequent flare-ups. The authors questioned whether JIA patients with more 
severe disease require higher supplementation of vitamin D to maintain normal 25(OH) D 




between patients with active versus inactive disease, in comparison to lower latitudes as 
illustrated in Figure 3.3. 
To date, the evidence to support a relationship between vitamin D and disease activity 
with autoimmune diseases in humans is correlative and not causative (Dankers, Colin, van 
Hamburg, & Lubberts, 2017). Long-term, adequately powered randomized studies, which 
control for confounding variables (sun exposure, season, and vitamin D intake), are required to 
confirm a causative relationship between vitamin D and disease activity. 
3.3.7. Potential Requirements of Vitamin D Intake  
 
Vitamin D intake was only measured in seven studies (Dey et al., 2014; Henderson et al., 
1997; Lien et al., 2005; Markula-patjas et al., 2012; Pepmueller et al., 1996; Stagi et al., 2014; 
Valta et al., 2007a). All of these studies reported a mean or median vitamin D intake that was 
less than the EAR of  400 IU per day set by the IOM (Institute of Medicine, 2010). This is the 
amount of vitamin D that is expected to be sufficient for 50% of the population (Institute of 
Medicine, 2010).  This indicator is used to evaluate the prevalence of inadequacy at the 
population level. The recommendation at the individual level is the RDA that ranges from 400-
600 IU based on age groups. Two studies reported intake of vitamin D supplements by study 
participants but neither had a mean 25(OH)D that reached the optimal concentration (Henderson 
et al., 1997; Valta et al., 2007a). Three studies reported intake of both children with JIA and 
healthy controls (Dey et al., 2014; Lien et al., 2005; Stagi et al., 2014).  Vitamin D intake and 
status was similar for two JIA patient groups (Lien et al., 2005; Stagi et al., 2014), and lower 
intake resulted in lower vitamin D status in the third group (Dey et al., 2014).  In comparison to 
the control groups, Lien et al. found similar intake and 25(OH)D status between those with JIA 
and controls (Lien et al., 2005). Stagi et al. reported similar intake of vitamin D and higher 
25(OH)D in controls, and in the study reported by Dey et al. the intake of control participants 
was two times higher than the participants with JIA and the control group had higher 25(OH)D 
concentrations (Dey et al., 2014; Stagi et al., 2014).   
It has been theorized that there may be an increased utilization of vitamin D during active 
inflammation, possibly caused by \the presence of  vitamin D receptor polymorphisms in patients 
with autoimmune diseases (Cutolo, Otsa, Uprus, Paolino, & Seriolo, 2007; Cutolo et al., 2011). 




are required to determine if children with chronic arthritis require additional vitamin D to 
maintain serum concentrations in comparison to healthy children. Understanding this 
relationship will be important in the use of vitamin D as a potential adjunct therapy. 
Additionally, improved understanding of vitamin D needs in children with chronic arthritis will 
help to clarify the role of vitamin D in the underlying disease processes so that therapies that 
target specific vitamin D responsive immune pathways can be developed.  By exploring the 
factors that influence vitamin D status (genetics, environment, and nutrition), we will be better 
able to discern an association between vitamin D and JIA.  
Two articles have discussed vitamin D requirements for children with rheumatic 
conditions not in the context of corticosteroids.  In 2011, von Scheven and Burnham suggested 
that in the absence of specific guidelines for children with rheumatic conditions that the 
American Academy of Pediatrics guidelines of 400 IU per day be used as a suggested minimum 
dosing regimen  (Von Scheven & Burnham, 2011). The authors cautioned that providing large 
doses of vitamin D can result in providing “too much of a good thing” and that studies 
comparing children with rheumatic diseases to healthy children are required.  The second article 
was published by Vojinovic and Cimaz and recommends that the guidelines set out by the 
Endocrinology Society for patients receiving corticosteroids be followed for all children with 
rheumatic diseases (Vojinovic & Cimaz, 2015). This would result in a dose of 2-3 times the 
current recommendation and would be approximately 2000 IU/day. This dose is still below the 
IOM’s tolerable upper limit for all children over the age of one (2500 IU ) (Institute of Medicine, 
2010).  
3.3.8. Vitamin D and Medication Interactions in JIA Patients 
 
All but one study (Szymanska-Kaluza, Biernacka-Zielinska, Stanczyk, 2013), have been 
conducted with children already being treated for arthritis, many receiving corticosteroids, which 
could impact 25(OH)D concentration and inflammatory status. Corticosteroids promote the 
breakdown of both 25(OH)D and 1,25(OH)D and also counteract effects of vitamin D on bone 
formation (Gröber & Kisters, 2012; Gröber et al., 2013). These patients also had varying disease 
duration. A study of newly diagnosed individuals, however, did not compare patients with JIA to 




2013) . Comparing children with JIA to healthy controls allows for discerning biologic 
differences that could inform treatment targets.  
The lowest mean 25(OH)D concentration, 22 nmol/L (n=35) was  reported from  India.  
These patients were found to be consuming significantly less vitamin D and had less sun 
exposure compared to healthy controls (Dey et al., 2014).  The highest 25(OH)D, 140.8 nmol/L  
(n=17),  concentrations were reported in Finland,  in a population receiving Prednisone (Reeve et 
al., 1993). The authors hypothesized that the reason their patients’ 25(OH)D concentrations were 
so high was that their previous research had found low concentrations of 25(OH)D and they were 
encouraging their patients to consume vitamin D fortified foods and to spend time in the sun 
(Reeve et al., 1993). A survey of steroid-related osteoporosis, prevention and treatment practices 
of pediatric rheumatologists in North America was conducted by Soybilgic et al. in 2014 
(Soybilgic, Tesher, Wagner-Weiner, & Onel, 2014).  They found that the majority of pediatric 
rheumatologists are recommending vitamin D for patients who were on long-term corticosteroids 
(Soybilgic et al., 2014). The role of vitamin D in mediating bone health, especially in relation to 
corticosteroids, has been established (Gröber & Kisters, 2012). Both short and long-term 
corticosteroid intake even at small doses impact bone health in patients with autoimmune 
diseases (Gröber et al., 2013). The role and an appropriate amount of vitamin D intake or 
25(OH)D target for inflammation or disease activity have yet to be established.  
3.3.9. Additional Research Directions 
 
Considering ethnicity when comparing incidence and prevalence amongst populations 
would be useful in understanding if the regional differences observed are due to environmental 
or genetic factors or a combination of the two. Evidence from a multiethnic cohort study of 1082 
children at The Hospital for Sick Children,  Toronto, Canada investigated the influence of 
ethnicity on the risk of developing JIA  (Saurenmann et al., 2007). When the diversity of the 
study population was compared to that of the general Toronto region population, there was an 
overrepresentation of patients of European and Indigenous descent and an underrepresentation of 
patients of Black, Asian, or Indian subcontinent ethnicity in their cohort. European descent was 
significantly associated with an increased risk of developing JIA, including all subtypes except 
RF-positive polyarthritis JIA. Exploring the environmental and genetic factors that may 




While this review focused on vitamin D status in children with JIA, vitamin D may be 
involved in both disease development and subsequent disease activity status. Exploring elements 
of vitamin D status that may have a role in disease development such as early life and gestational 
vitamin D status as well as genes in the vitamin D pathway will help to clarify the role of vitamin 
D.  
Season of birth has been suggested to have an impact on the risk of developing a number 
of autoimmune diseases such as multiple sclerosis, type 1 diabetes and celiac disease (Y Berkun 
et al., 2015). A recent study investigating month of birth and risk of JIA found a difference in the 
pattern of the birth month for children with JIA compared to that of the general population (Y 
Berkun et al., 2015). Children with JIA were more likely to be born between November to 
March, with the birth month for the general population peaking in the summer months. The study 
by Carlens et al. also investigated the relationship between season of birth and the risk of 
developing JIA and found no increased risk (Carlens et al., 2009). Season of birth may be a 
marker for vitamin D status in utero with children born in the non-vitamin D synthesizing 
periods being exposed to less vitamin D during their time in utero than those who are born 
during the vitamin D synthesizing seasons. 
  The CLARITY explored the use of nutritional supplements during pregnancy and the risk 
of developing JIA (Ellis et al., 2012). The use of vitamin D and fish oil during pregnancy in case 
mothers was not significantly different from controls following covariate adjustments (Ellis et 
al., 2012). A case-cohort investigation from Denmark, comparing 25(OH)D status in children 
diagnosed with either oligoarticular or polyarticular JIA using dried blood spot samples that were 
collected at birth  did not find any association between 25(OH)D status at birth and risk of 
developing JIA (Thorsen et al., 2016). Concentrations of 25(OH)D fluctuated significantly by 
season of birth and year of birth (calendar year). There was no follow up to determine if 
25(OH)D status or season during the first few months of life impacted risk of JIA or whether 
other subtypes of JIA were impacted by season of birth of 25(OH)D status at birth.  
Certain VDR gene polymorphisms may be associated with different biologic response to 
vitamin D. The rs11568820 polymorphism of the VDR gene specifically the GG genotype, have 
been suggested to be more represented in patients with JIA compared to healthy controls who 
more often have the GA genotype (Falcini et al., 2013). Recently the idea of investigating 




how their interactions contribute to JIA risk was explored by Ellis et al. (Ellis et al., 2015). This 
is the first study to explore this interaction, and the authors suspect that through exploring these 
interactions there is the opportunity to account for the missing heritability that has been observed 
with complex diseases with genetic components (Ellis et al., 2015). Their work found evidence 
of epistasis amongst tyrosine-protein phosphatase non-receptor type 2 (PTPN2) gene and the 
vitamin D binding protein gene in contributing to the risk of JIA (Ellis et al., 2015). The role of 
genes in the vitamin D pathway on both disease development and disease activity are still in the 
early stages of investigation. Also how they impact the biological response involving vitamin D 
and inflammation remains unclear. Investigating genetic, nutritional and environmental factors 
that influence vitamin D in JIA could help inform ways in which vitamin D status influences the 
occurrence and activity of JIA. Understanding if genetic variants increase the risk of disease 
development will help tailor vitamin D management in individual patients, contribute to 
improving control of disease activity, and improve outcomes.  
A north-south gradient of incidence and a mechanism for the suppression of inflammation in 
relation to 25(OH)D status has been suggested. However, no study has summarized the current 
evidence of chronic childhood arthritis diagnosis by 25(OH)D status in relation to latitude and 
disease activity. This first step is important for the development of future studies leading to the 
exploration of potential optimal target concentrations of vitamin D for the reduction of 
inflammation in children with chronic arthritis. 
3.3.10. Limitations 
 
This scoping review has limitations due to the limited amount of comparative data.  
Season of measurement and JIA subtype could not be considered due to a lack of reporting in 
most reviewed articles. With the exception of one study, all studies reviewed used various 
unreported types of medication in patients who had had JIA for varying durations. These 
variables can make it difficult to interpret the relationship between vitamin D and disease activity 
in relation to both inflammation status and risk of relapse.  Of the studies that investigated the 
relationship between vitamin D and function or disease activity, various measures were used. 
The most common included the CHAQ, JADAS-27 and ARC Peds 30. The JADAS-27 and 
ACRS Peds 30 both include active joint counts in their scoring which confounds comparisons of 




involved. subtypes (Alessandro Consolaro et al., 2012; Giannini et al., 1997; Petty et al., 2004). 
Many studies included multiple subtypes of JIA measured by the same disease activity score that 
included an active joint count. This review was unable to explore the relationship between 
vitamin D status and ethnicity, vitamin D receptor genes or other genes that influence vitamin D 
metabolism.  
3.4. Conclusion 
This is the first scoping review to summarize research relating to vitamin D and JIA in 
the context of vitamin D status, latitude, disease activity. It is also the first to map the results 
according to geography. Thirty-two studies (84.2%) reported a mean 25(OH)D concentration 
below 75nmol/L or the optimal value. This suggests that whether due to inadequate intake or 
increased utilization the majority of children with juvenile arthritis do not have optimal 25(OH)D 
status as defined by the Endocrine Society (Holick et al., 2011).  The optimal concentration of 
25(OH)D and the corresponding dietary requirements for patients with chronic childhood 
arthritis has yet to be determined. Further, the relationship between vitamin D status and disease 
activity in children with JIA is still unclear. Studying newly diagnosed patients who are 
treatment naive for longer periods of time would help characterize this relationship as there 
would be fewer confounders associated with patients who have had the disease for varying 
durations (medication, lifestyle modifications, and disease duration). Thus far, we know that 
there is a role for vitamin D in the inflammatory pathways, a high prevalence of 25(OH)D 
insufficiency among children with JIA, and an established link of vitamin D with other 
autoimmune diseases.  We do not, however, know the optimal vitamin D status for children with 
JIA, whether reduced vitamin D is caused by increased utilization or reduced vitamin D status in 
children with JIA, the impact of vitamin D in disease activity or the role of VDR polymorphisms 
with JIA. Larger, long-term studies of new-onset JIA are required to explore the association. The 
relationship between vitamin D status and JIA over time in newly diagnosed individuals has yet 
to be investigated. Investigating the genetic and environmental role that vitamin D plays in the 
prevention and control of JIA in the same children will help to tease out the multifaceted role 
played by vitamin D in this disease. Being able to suggest specific targets for vitamin D status as 




increase the risk of disease development will enhance the quality of life of patients and their 
families.  
After reviewing the literature and conducting the scoping review, regarding the association of 
vitamin D and JIA, we aimed at focusing on the above-identified gap and addressing the 
aforementioned objectives for the Canadians population in Objectives 1-3. In the next chapter, we 
demonstrate the general methodology that was used for Studies 1-3 of this thesis. 
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Table 3.1. Comparison of classification systems of chronic childhood arthritis* 
 American College of 
Rheumatology 1977 (Brewer, 
Bass, Baum, Cassidy, Fink, 
Jacobs, Hanson, Levinson, 
Schaller, 1977) 
European League Against 
Rheumatism 1978 (Woods, 1978) 
International League Against 
Rheumatism 1994 and 2001(Petty 
et al., 2004) 
Classification Title Juvenile Rheumatoid Arthritis Juvenile Chronic Arthritis Juvenile Idiopathic Arthritis 
Symptom duration Minimum 6 weeks  Minimum 3 month  Minimum 6 weeks 
Subtypes Systemic Systemic Systemic 
 Polyarticular Polyarticular Polyarthritis RF negative  
  JRA (RF positive Polyarticular) Polyarthritis RF positive  
 Pauciarticular Pauciarticular Oligoarthritis 
          Persistent 
          Extended  
  Juvenile psoriatic Psoriatic arthritis  
  Juvenile ankylosing spondylitis Enthesitis-related arthritis  
  Arthritis associated with 
inflammatory bowel disease 
 
   Undifferentiated arthritis 
*Prior to 1997, two chronic childhood arthritis classification systems were used.  The American College of Rheumatology (ACR) 
(Brewer, Bass, Baum, Cassidy, Fink, Jacobs, Hanson, Levinson, Schaller, 1977) classification criteria referred to chronic childhood 






Chronic Arthritis (JCA) (Woods, 1978). Differences between the two classification systems hindered exchange and comparison of 
data between the two systems (Borchers et al., 2006). To reconcile differences between ACR and EULAR criteria, the International 
League Against Rheumatism (ILAR) JIA criteria were introduced. This table provides a  comparison of diagnostic criteria (Petty et al., 
2004). The ILAR classification system defines JIA as all forms of inflammation of one or more joints  beginning in children younger 
than age16 years (Petty et al., 2004). JIA is further classified into seven categories based on inclusion and exclusion criteria according 
to features present within the first six months of disease.  The seventh category includes those who do not fit into one category, meet 
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et al. 2001 
JIA n=10 (6F) 13.1 ± 2.5 53.9 ± 8.5  All patients were 
vitamin D replete 
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 Reed et al. 
1991 
40°N 
(Reed et al., 
1991) 
JRA n=13 (12F) 5-18 70.0 ± 40  Vitamin D may 
help  prevent bone 
loss in children 
with active disease.  
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n= 37 (27) 12.5 ± 3.1 55.0 ± 13.9 No difference 
between children 
with JIA and 
controls. 
Healthy controls 
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n=30 (23F) 14 (4-20) 64.1 ± 21.6  High frequency of 
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groups; no 
difference between 
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Lien et al. 
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59°N 
(Lien et al., 
2005) 
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8.1 nmol/L D  
Intake JIA 164 
± 84 IU control 
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et al. 1997 
40°N 
(Henderson 
et al., 1997) 
JRA n=48 (37 )  8.1 ± 1.9 89.4 ± 28.7  Serum 1,25-
dihydroxyvitamin 
D concentrations 
were able to 
accurately 
segregate 79.6% of 
the JRA subjects 
into either the low 
or normal BMD 
groups. 




 Reed et al. 
1993 
40°N 
(Reed et al., 
1993) 
JRA n=27 (23) 2.9-16 84.9 ± 11.0  No difference in 
vitamin D status 
between active and 
inactive groups. 
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In this chapter, the methodology related to the studies included in this thesis is 
demonstrated. Specific details to each study’s methodology are available in the corresponding 
Study’s chapter. 
The overarching goal of this research was to understand how vitamin D affects disease 
activity in children who are suffering from JIA. The specific objectives of this research were to: 
(1) Evaluate and compare vitamin D status and anthropometric characteristics between healthy 
children/adolescents and patients with JIA. (2) Determine vitamin D status and its association 
with disease activity and outcomes in children with JIA.  (3) Identify potential association of the 
vitamin D pathway gene polymorphisms and JIA. It was hypothesized that vitamin D has an 
impact on disease activity in children who are suffering from JIA. The study tested the following 
specific hypotheses: (1) Children and adolescents with JIA have lower vitamin D status and 
growth parameters (height, weight, waist circumference, BMI) than healthy children and 
adolescents. (2) Vitamin D status is negatively associated with inflammatory markers and 
disease activity among JIA cases. (3) There are specific polymorphisms of vitamin D pathway 
genes associated with JIA.  
4.1. Research Plan 
 
To address the aforementioned objectives, I used data from the Biologically Based 
Outcome Predictors (BBOP) in Juvenile Idiopathic Arthritis study. 
Biologically Based Outcome Predictors (BBOP) in Juvenile Idiopathic Arthritis  
The Biologically-based Outcome Predictors (BBOP) in JIA study is a multi-centre cross-
Canada cohort study with the goal of identifying clinical and biological factors that help predict 
disease outcomes in JIA to help guide disease management and improve outcomes earlier. 
Additionally, BBOP aspired to demonstrate how environmental and modifiable risk factors 
interact with genetic and inflammatory processes to impact disease outcomes. 
BBOP is a prospective cohort study with data collected between December 2007 and 




were recruited from multiple centres across Canada (British Columbia Children’s Hospital, 
University of British Columbia, Vancouver, BC; Alberta Children’s Hospital, Calgary, 
University of Alberta, AB; Stollery Children’s Hospital, Edmonton, University of Alberta, AB; 
Royal University Hospital, Saskatoon, University of Saskatchewan, SK; Children’s Hospital, 
Winnipeg, University of Manitoba, MB; The Hospital for Sick Children, University of Toronto, 
Toronto, ON; The Montreal Children’s Hospital, McGill University, Montreal, QC; Centre 
Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC; Centre Hospitalier de l’universite 
Laval, Laval, QC; IWK Health Centre, Dalhousie University, Halifax, NS; Janeway Children’s 
Health and Rehabilitation Centre, Memorial University, St. John’s, NL).  
Enrollment criteria included meeting the International League of Associations for 
Rheumatology (ILAR) classification criteria (Petty et al., 2004),  as determined by a pediatric 
rheumatologist BBOP team member, being within six months of disease onset and having 
received no medications with the exception of nonsteroidal anti-inflammatories or methotrexate 
as a treatment for their condition. Informed consent was received from participant’s parents as 
well as consent or assent from participants where appropriate. Additional consent forms allowing 
for storage of blood samples and DNA for future studies were also collected. Recruitment was 
from participants in each of seven JIA subtypes (systemic, oligoarthritis, rheumatoid-factor-
positive polyarthritis, rheumatoid-factor-negative polyarthritis, enthesitis-related arthritis, 
psoriatic arthritis, undifferentiated arthritis). The aim was to recruit a representative sample for 
each subtype. To achieve this, only participants with polyarthritis or systemic JIA (the least 
prevalent subtypes) were eligible during the first six months of enrollment after which any JIA 
subtype was eligible.  The study was approved by the research ethics boards at each participating 
site. 
 
Overview of Data Collection and Methodologies 
Environmental and clinical data were collected and blood samples were obtained. 
Follow-up took place every 6 months for 2 years.  Surveys, physical examination, and 
anthropometric measurements occurred every 6 months for 2 years. Blood samples were 
collected at baseline and 6 months and a saliva sample for DNA extraction took place at 6 
months. See Table 4.1 for BBOP data collected of relevance to this thesis and Table 4.2 for 




in this thesis included plasma for 25(OH)D, inflammatory markers and cytokine analysis as well 
as saliva for DNA analysis.  
 
Demographic Data 
 At enrollment, a patient identification number and a diagnostic category were assigned 
(following RF test results determined by the respective centres’ service laboratories) and the 
following enrollment information documented: Birth date, sex, ethnic groups, date of JIA 
symptom onset, and primary household income.  
 
Anthropometric Assessments 
  Standing and sitting heights and weight were recorded at enrollment and semi-annually 
thereafter to 24 months. Height was measured using a wall stadiometer and recorded to the 
nearest 0.1 centimeter. Weight was measured twice on an electronic scale and recorded to the 
nearest 0.1 kg. Duplicate measures were averaged. Z-scores for height, weight and BMI were 
calculated. We defined underweight as BMI <5 percentile, overweight risk as >85 to <95 
percentile, and overweight as > 95 percentile.  
 
Indicators of Disease Activity and Outcome Measures:  
Cytokine Selection 
Forty-six cytokines were analyzed for the BBOP study. We chose to focus on the cytokines listed 
below because they are most commonly listed in the literature as having been explored in 
participants with JIA or other autoimmune diseases and are associated with vitamin D (Cutolo et 
al., 2011; Dankers et al., 2017; Hayes et al., 2015). 
Pro-Inflammatory Cytokines 
From blood  samples collected at baseline and at six months, inflammatory mediators IL-2, IL-
17, IL-1α,IL-1rα, IL-1β, IFNɤ, IL-1β, IL-6, IL-8,  and TNFα were  measured  
Anti-Inflammatory Cytokines 
Anti-Inflammatory cytokines IL-4 and IL-10 were measured. 
 Measures of Inflammation  






Objective and self-reported measures of disease outcomes  
Physician global assessment of disease activity, and the CHAQ-JIA, were measured as 
indicators of function at all time points. Pain was assessed using the CHAQ question how much 
pain do you think your child has had because of his/her illness in the past week? .The patient or 
parent-completed Juvenile Quality of Life Questionnaire (JAQQ) was used to assess quality of 
life at all time points and the Hassle score was measured at baseline 12 months and 24 months. 
 
Clinical disease remission 
Clinical disease remission was defined using the criteria proposed by Wallace et al. 
(Wallace et al., 2004) defined as inactive disease, meaning no active joints, absence of fever, 
rash, serositis, splenomegaly or generalized lymphadenopathy attributable to JIA, normal ESR 
and CRP concentration, and physician global assessment of no disease activity, either for at least 
6 months if on medication or for 12 months if off medications (Wallace et al., 2004). Patients 
were classified as having active disease (not meeting all of the criteria and designated lowest 
level for statistical analysis) remission on medication (designated intermediate level in statistical 
coding) and remission off medication (designated highest level in statistical coding). 
 
Vitamin D status 
In order to assess vitamin D intake over the last month, the frequency of milk intake 
(always, never/sometimes) and vitamin D containing supplement use (always/sometimes, never) 
were collected for analysis.  Medications prescribed were assessed at every time-point and 
categorized by medication class (NSAID, steroid, DMARD or biologic) as certain medications 
9steroids) can impact vitamin D concentrations. Season of measurement was also noted as it 
reflects the potential for vitamin D synthesis through UVB radiation. 
A method to standardize, compare and combine inflammatory biomarkers developed by 
Tabung et al.  was used (Tabung et al., 2015). Z-scores of the log-transformed CRP, IL-6, and 
TNFα concentrations were then added together to create the overall pro-inflammatory biomarker 
score. The same method was applied to create an anti-inflammatory score where the anti-




defining remission, we used these scores to include other measures of inflammation that are not 
included in the definition of remission.  
 
Laboratory-Based Assays 
Sample Collections and Handling:  
At enrollment and at 6 months, blood was collected in P100 Blood Collection and 
Preservation vacutainer tubes (BD Biosciences, San Jose, CA). Immediately after collection the 
sample was shipped to the Medical and Related Sciences Centre (MaRS, Toronto, ON) and 
plasma recovered and stored at -80oC in accord with previously described protocols (Matheson, 
Duong, Rosenberg, & Yeung, 2008). At the 6-month visit a saliva sample was collectedusing the 
OrageneTM collection systems (DNAgenotek). Saliva samples were courier shipped 
unrefrigerated to The Centre for Applied Genomics (TCAG), Hospital for Sick Children, DNA 
extracted and used for SNP genotyping according to standard protocols.   
 
All visits 
Total white blood cell, neutrophil, lymphocyte, and platelet counts; hemoglobin concentrations; 
ESR and CRP concentrations were measured in clinical service laboratories affiliated with each 
of the participating sites.    
 
Cytokine Protein Expression 
 Certain soluble inflammatory mediators (cytokines) were assessed in plasma by multiplex bead-
based assays (Fluorokine® Multi Analyte Profiling, Multiplex human cytokine panel A {R&D 
Systems} using a Luminex analyzer(Luminex Corp.)  
 
Vitamin D Assay 
Vitamin D assays were undertaken as previously described (McNally, et al. 2009).  Blood 
samples were collected from a peripheral vein into P100 tubes (BD Biosciences, San Jose, CA)  
and lasma separated by centrifugation and then stored at -800C. Samples were batch assayed at 
the end the study using   a   competitive   binding   enzyme-linked immunoassay  (EIA;  
Immunodiagnostic  Systems Ltd, Montreal, Quebec, Canada) (Wilkinson, Llewelyn, Toossi, 
Patel et al., 2000) in accord with manufacturers instructions. Information available from DEQAS 




is  one  of  two most  commonly used  methods  to  measure  25  25(OH)D (Carter, Carter, 
Gunter, Jones et al., 2004). Our quality assurance studies confirmed that plasma  25(OH)D  
concentrations  obtained from  EIA  showed    positive  correlation with  25(OH)D  measured  by  
high  performance  liquid chromatography (HPLC) (slope=1.17, intercept= -8.8, r2=0.92).   
These   results   are   consistent   with   other reports comparing EIA and radioimmunoassay to 
HPLC (Carter, Carter, Jones & Berry, 2004; Roth, Schmidt-Gayk, Weber & Niederau, 2008). 
EIA measures both vitamin D2 (75%) and  vitamin  D3  (100%)  and  has  intra-assay  and  inter-
assay   coefficients   of   variation   of <8%   and <10% respectively. Three quality control 
samples were included in each assay plate  and   samples and controls (from DEQAS) were 
assayed in duplicate. The absorbance was read at 450 nm using an ELx800 micro-plate reader 
(Bio-Tek Instruments, Winooski, VT). 25(OH)D   levels   were   categorized   as deficient  (<50 
nmol/L),  insufficient  (> 50 nmol/L <75 nmol/L),  and sufficient   (>75 nmol/L) in accord with 
guidelines (Canadian Paediatric Society, 2007).  
 
Genotyping 
Single nucleotide polymorphism (SNP) gene testing was done using Human 12-sample 
Immuno BeadChip 11419691 B (Illumina®). The data were analyzed using Genome Studio 
2011.1. Testing was done at the Genetic Analysis Facility, The Centre for Applied Genomics, 





















Table 4.1. Data collection of relevance to the proposed study 
Category Variables to be used in Data 
Analysis 
Method of Collection 
Demographic Sex, age, ethnicity, season of birth Baseline Questionnaire 
Socioeconomic 
Status 
Family income, parent’s education Socioeconomic Status Questionnaire 
Anthropometry Height, weight, waist 
circumference 
Direct measurements at the clinic  
Indicators of 
Disease Status 
Biochemical markers of 
inflammation, CHAQ, JAQQ, 
Hassles Scale 
Markers of inflammation were 
measured in serum. CHAQ, JAQQ, 




Milk intake, vitamin D supplement 
use, serum 25(OH)D, Season, VDR 
polymorphism 
Food Frequency Questionnaire, serum 
25(OH)D status measured through 
enzyme immunosorbent assay, and 
VDR obtained through saliva sample 
using GoldenGate® 96-sample 
Sentrix® Array Matrices and a 




Disease subtype, medication, 
family history of disease, physical 
activity, 











Table 4.2. BBOP timeline of relevant data collection 
 
0 mo. 6 mo. 12 mo. 18 mo. 24 mo. 
Sociodemographic questionnaire X     
Saliva for DNA analysis  X    
25(OH)D and cytokines X X    
Establish remission or active disease X X X X X 
Measures of inflammation X X X X X 
Season of measurement X X X X X 
Medication use X X X X X 
Milk intake and supplement use (FFQ) X X X X X 
25(OH)D 25-hydroxyvitamin D, DNA deoxyribonucleic acid, FFQ Food Frequency 
Questionnaire, Mo. Month  
4.1.1. Methodology for Objective 1 
 
Objective 1: Evaluate vitamin D status and growth parameters in children and adolescents with 
JIA and compare with those of healthy children and adolescents. 
 
To address Objective 1, we analyzed vitamin D status and anthropometric measurements 
in JIA patients enrolled in BBOP and compared them with a nationally representative age-
matched sample of Canadian healthy children using CHMS data (Cycles 1, 2007-09, 2009-11).   
 
Canadian Health Measures Survey  
CHMS is a Canadian cross-sectional nationally representative health survey that runs in 
bi-yearly cycles. Healthy children who participated in this survey will serve as a control group. 
We will be comparing the baseline data collected in the BBOP study to healthy age-matched 
children from the CHMS Cycles 1 and 2 based on 25(OH)D status, anthropometric measures 
(weight, height and waist circumference, BMI), intake of vitamin D and calcium, socioeconomic 




2 (2009-2011) were combined. There are approximately 4,500 children between the ages of 3-19 
sampled for the 2 cycles of CHMS which ran at the same time as data collection for the BBOP 
study. In BBOP study the distribution of JIA patients has the approximate rate of 3:1 F to M, 
while in CHMS this rate is 1:1.  To be able to properly consider this distribution at the 
population level we performed additional age- and sex-specific analyses. Further, considering the 
complex survey design in CHMS, we used weight variables and the combined bootstrap files as 
instructed by Statistics Canada to obtain estimates and their variation at the population level.  
 
Data cleaning and management 
 Data manipulation, cleaning, grouping and creating the variables of interest was done in 
SPSS Version 22 (IBM, 2014). Existing variables of interest that are included in both CHMS and 
BBOP are as follows: age; sex; ethnicity; socioeconomic status; physical activity; weight; height; 
waist circumference; vitamin D intake, and 25(OH)D status. See Chapter 7 for age, sex and 
ethnicity of BBOP participants. We used 25(OH)D concentrations to estimate the prevalence of 
vitamin D deficiency, insufficiency, and sufficiency in both BBOP and CHMS data. After 
excluding children with chronic conditions in CHMS combined data, we created an age group 
equivalent to the BBOP children’s age group.  
 
Data analysis 
 The prevalence of vitamin D deficiency, vitamin D intake, and growth parameters 
respectively, were determined across demographic and socioeconomic factors via frequencies 
and cross-tabulation. The difference in estimates of children between BBOP and CHMS is 
considered significant at an alpha of 0.05 if the point estimates do not lie within the estimated 
confidence intervals for parameters from the other populations. This approach allows us to 
compare variables of interest at population levels.  Analyses at this section addressed the 
hypothesis whether children and adolescents with JIA have lower vitamin D status and growth 
parameters (height, weight, waist circumference, BMI) than healthy children and adolescents.  
4.1.2. Methodology for Objective 2 
 
Objective: Examine the association between plasma levels of 25(OH)D and disease activity and 





Using the BBOP data collected every 6 months for 2 years characterized the relationships 
between both vitamin D intake and vitamin D status with disease outcome over time in children 
with JIA. In order to assess vitamin D intake over the last month, food frequency questionnaires 
focusing on the intake of vitamin D and calcium-containing foods have been collected for 
analysis.  Medication and supplement use were assessed at every time-point. Indicators of 
disease activity data are available as assessed by ACR core set of disease activity variables 
which include the following: number of joints with active arthritis, number of joints with limited 
movement, physician global assessment of disease activity, acute phase reactants (ESR and 
CRP), and the Child Health Assessment Questionnaire – JIA (CHAQ-JIA) (Giannini et al., 
1997). Measures of inflammatory mediators (cytokines), and 25-hydroxyvitamin D are available 
at enrollment and 6 months post-enrollment. See Table 4.3 for biochemical measurements 
conducted. The biochemical markers of inflammation as well as the surveys to measure disease 
activity were investigated to determine if there is a relationship between vitamin D status and 
markers of inflammation, and disease activity.  
Descriptive statistics (means and standard deviations for continuous variables and 
percentages for categorical variables) were summarized the data at five time points. The 
descriptive analysis done using SPSS Version 22 (IBM 2014). For inference, Multi-Level 
Mixed-Effects (MLM) Modeling  with manuel backwards selection with patients set as a random 
effect factor (individual patient change by time/visit number), was utilized. The repeated 
measures across time points had unstructured covariance structure. Criteria for variable 
elimination was any variables that were statistically insignificant (p-value > 0.05), the one 
making the smallest contribution as determined by p-value was dropped. After each variable was 
removed, the likelihood ratio test was performed to ensure that removing the parameter/ 
predicting variable from the model does not significantly reduce the fit of the model. If removing 
the statistcally non-significant variable from the model reduced the fit then it was left in the 
model.   Missing data was assumed to be missing at random and initial exploration of missing 
variables by time point showed no pattern of dropout by  age, sex, disease subtype, ethnicity or 
income. The goal was, to determine if there is association between factors associated with 
vitamin D status and markers of inflammation /disease outcomes in the presence of potential 




was used for analysis. Analyses of this section will address whether vitamin D status is 
negatively associated with inflammatory markers and disease activity among JIA cases. 
 
Table 4.3. Biochemical markers 
Marker Abbreviation 
Interferon gamma IFNƴ 














Tumor necrosis factor  TNFa 
Hemoglobin HGB 
Total neutrophil count ANC 
Total lymphocyte count TLC 
Platelet count PLT 
White blood cell count WBC 
Erythrocyte sedimentation rate ESR 
C‐reactive protein rate CRP 






4.1.3. Methodology for Objective 3 
 
Objective 3: Evaluate association between vitamin D pathway gene polymorphisms, vitamin D 
levels, and JIA disease activity. 
 
At the second visit, a saliva sample was collected for genotyping. DNA was extracted to 
analyze VDR polymorphisms and the genotype data were analyzed to determine if there is a 
higher proportion of certain polymorphisms of VDR’s in children with JIA.  
Genotyping was performed using GoldenGate® 96-sample Sentrix® Array Matrices and 
a customized 1536-SNP panel (Illumina Inc.) at the Centre for Applied Genomics, Toronto, 
Canada.    
 
4.1.3.1. Genetic Analysis 
 
Step 1: Genome-Wide Association Studies (GWAS) 
For the BBOP study single nucleotide polymorphism (SNP) gene testing was done using: 
Human 12-sample Immuno BeadChip 11419691 B (Illumina®). Genome information (.bed, 
.fam, .bam files (https://www.ensembl.org/info/website/upload/bed.html)) was provided by the 
Genetic Analysis Facility, The Centre for Applied Genomics, The Hospital for Sick Children, 
Toronto. 
In addition to BBOP, two other genetic datasets were used. 1) The “Better Outcomes for 
Children: GWAS from Cincinnati Children's Hospital Medical Center (CCHMC) - eMERGE 
Phase II” dataset (dbGaP Study Accession: phs000494.v1.p1).  This dataset includes genotyping 
data from six cohorts. Cohort D of the dataset comprises  Caucasian patients with JIA. The 
dataset includes 814 JIA cases and 658 controls of self-reported non-Hispanic European 
American (EA) ancestry (Thompson et al., 2012). 2) The National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK) healthy control genetic dataset were merged to build a 
case/control dataset, where BBOP samples were used as cases and the NIDDK Dataset used as 
controls. GWAS analysis was performed using PLINK version 1.9 
(http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell, Neale, Todd-Brown, Thomas et al., 2007) 
according to the protocol specified by Anderson et al. (Anderson et al., 2011).  This approach 




control for these two datasets by following the procedure suggested by Anderson et al. 
(Anderson et al., 2011), there was a small overlap between SNPs in these datasets. This was 
mainly because NIDDK and BBOP used two different platforms with a small overlap between 
their results; therefore, we avoided extracting control samples from NIDDK dataset and 
conducting a case-control study.  
A subset of markers was assembled based on the following criteria: 
 Markers suspected to be involved in JIA extracted from the literature  
 Markers associated with the vitamin D pathway 
Markers extracted from the analysis of the Cincinnati  cohort D The genotype data were 
extracted for the candidate SNPs for all samples, in the BBOP dataset, that passed the quality 
control procedure (Anderson et al., 2011). These SNPs later were used for regression analysis. 
 
GWAS results are presented in Table 4.4.  
4.1.3.2. Statistical Analysis  
 
Step 2: Descriptive statistics  
Descriptive statistics (means and standard deviations for continuous variables and 
percentages for categorical variables) were used to summarize the data at five time points of 
measurements (CHAPTER 7 Table 7.2).  
 
Step 3: Genetic predictors of disease activity 
Bivariate analysis was performed to explore what individual genes identified through 
GWAS as well as genes known to be in the vitamin D pathway (Table 4.4) may predict disease 
activity. Any genes that were identified to have a p<0.05 were included in the full MLM 
Modeling building process. A linear as opposed to a non-linear model was chosen because the 
parameters to be estimated were either linear or could be log-transformed to become linear. 
Specifically, MLM was chosen because it provided individual-specific effects (as opposed to the 
population average effect). The repeated measures across time points had unstructured 
covariance structure. Given that the goal was to describe the potential impact of vitamin D on 
patient disease activity this method was considered  appropriate. 




Next, multivariate analysis of epistasis of genes identified through GWAS and those in 
the vitamin D pathway was performed. Those with a p-value <0.01 were included in the full 
model building process. Variables that were significant in the previous steps were included in the 
full MLM building process. 
 
Step 5: Environmental, genetic and interactions that predict disease activity 
Analysis of environmental, treatment and lifestyle-related factors as well as detailed 
methodology for that objective are presented in Chapter 7.  Linear regressions were performed to 
identify gene-environment interactions that significantly (p-value <0.05) impacted disease 
activity measures to be included in the final MLM. Significant variables from linear regressions 
performed in Chapter 7, as well as those genes identified through GWAS, vitamin D pathway 
genes, gene-gene interactions were included in the final analysis to identify what environmental 
and genetic factors impact disease activity.  
Step 6: Multi-Level Mixed-Effects (MLM) Modeling   
MLM Modeling  and manuel backwards methodology with patients set as random 
variable (individual patient change by time/visit number), was utilized. The repeated measures 
across the time points had unstructured covariance structure.  Criteria for variable elimination 
was any variables that were statistically not significant, the one making the smallest contribution 
as determined by p-value was dropped. After each variable was removed the likelihood ratio test 
was performed to ensure that removing the parameter/ predicting variable from the model does 
not signifigantly reduce the fit of the model. If removing the statistcally non-significant variable 
from the model reduced the fit then it was left in the model.  Missing data was assumed to be 
missing at random and initial exploration of missing variables by time point showed no pattern 
of dropout by  age, sex, disease subtype, ethnicity or income. Intreactions with a p-value > 0.01 
were not selected for the final model to adjust for the increased false discovery rate of multiple 
comparisons. The goal was to determine if there is association between genes potentially related 
to the vitamin D pathway and markers of inflammation /disease outcomes in the presence of 
potential covariates, such as socioeconomic status, sex, age, and ethnicity. STATA 15 (StataCorp 












Through GWAS*  
Single Nucleotide 
Polymorphism  
VDR  NOTCH4  
 rs4516035  rs2071286 
 rs11568820  rs415929 
 rs1544410 C6orf10 rs6907322 
 rs1540339 HLA-DQA1 rs9272219 
 rs3890733 LEP rs2071045 
 rs4760648 IGFBP4  
 rs731236  rs584438 
 rs7975232  rs584828 
 rs2248098 GPS1 rs9916764 
 rs10783219   
 rs2238136   
GC rs7041/rs4588   
CYP24A1    
 rs4809959   
 rs2248359   
CYP1R1    
 rs17116978   
 rs1035798   
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Abstract 
Objective. The objective of this study was to compare vitamin D levels in children with Juvenile 
Idiopathic Arthritis (JIA) to healthy children. 
Methods. Data from a Canadian cohort of children with new onset JIA were compared to 
Canadian Health Measures Survey (CHMS) data. Comparisons were made with respect to data 
from healthy children comparing 25-hydroxy vitamin D (25(OH)D) concentrations, measures of 
inflammation, vitamin D supplement use, milk intake, and season of birth.   
Results. The mean 25(OH)D blood level was significantly higher in JIA patients (79 ± 3.1 
nmol/L) than in healthy controls (68 ± 1.8 nmol/L p <0.05) and JIA patients more often used 




nmol/L) was 6% for both groups. Children with JIA with 25(OH)D deficiency or insufficiency 
(<50 nmol/L) had higher CRP levels.  Children with JIA were more likely to be born in the fall 
and winter compared to healthy children.  
Conclusion.  Contrary to the expectations, we found that vitamin D levels in Canadian children 
with JIA were not lower than  healthy children; an observation that might relate to the frequent 
use of vitamin D supplements in the JIA population.  A preponderance of JIA patients born in 
seasons with reduced endogenous vitamin D production could implicate low vitamin D during 
gestation and early life as a factor influencing JIA pathogenesis.  Among children with JIA, a 
low CRP concentrations, indicating less inflammatory disease activity, are associated with a 
25(OH)D concentration above 50 nmol/L. 
5.1. Introduction 
 
Juvenile Idiopathic Arthritis is one of the most frequent chronic childhood diseases.  
Reported JIA prevalence rates range from 0.07 to 4.01/1000 children and annual incidence rates 
from 0.008 to 0.226/1000 (Manners & Bower, 2002). The occurrence and outcomes of JIA are 
likely influenced by multiple factors including genetic (Cobb, Hinks, & Thomson, 2014; Ellis et 
al., 2015), sociodemographic (Chiaroni-Clarke, Munro, & Ellis, 2016), lifestyle (Carlens et al., 
2009) and environment (Ellis et al., 2010). However, the precise cause and pathogenesis of JIA 
are unknown.   
Low vitamin D has been reported in a number of autoimmune diseases including multiple 
sclerosis, type 1 diabetes,  Crohn’s disease and JIA (Berkun et al., 2015; Cutolo et al., 2011; 
Nisar M., Cookson P., Masood F., Sansome A., 2013; Nisar et al., 2013; Shapira, Agmon-Levin, 
& Shoenfeld, 2010; Von Scheven & Burnham, 2011). In adults with rheumatoid arthritis, low 
25(OH)D is associated with increased disease activity (Sabbagh et al., 2013). Vitamin D is 
known to exert an immunosuppressive effect by suppressing the synthesis of pro-inflammatory 
cytokines and preventing prolonged inflammatory responses (Cutolo et al., 2011).  
Although a meta-analysis reported the prevalence of vitamin D insufficiency in JIA as 
82% (Nisar et al., 2013), it is unclear if this was a consequence of reduced dietary intake, season 
of measurement, a medication effect, or increased utilization and/or decreased absorption in the 




with more active arthritis in certain JIA categories when patients are receiving vitamin D 
supplementation while receiving glucocorticoids to treat active disease (Miettinen, Kinnunen, 
Harjutsalo, Reinert-Hartwall, Lamberg-Allardt, Toumilehto, Saila, 2013).  
Vitamin D status  is categorized by the IOM based on serum 25(OH)D concentrations  
and classified as : (i) deficient <30 nmol/L; (ii) insufficient >30 and <50 nmol/L; or (iii) 
sufficient ≥50 nmol/L (Institute of Medicine, 2010). In contrast, the Endocrine Society (ES) 
proposed that the  optimal serum 25(OH)D concentration is > 75 nmol/L and recommended 
vitamin D supplementation dose for at-risk populations that is twice as high as the IOM 
recommendations (Holick et al., 2011). The discrepancies in IOM and ES recommendations, 
both of which are made in the context of bone health, reflect current uncertainty as to the optimal 
25(OH)D concentration; no targets specific for children with JIA are available.  
The aim of the present study was to further investigate the associations of vitamin D 
status in JIA patients compared to healthy children.   We hypothesized that Vitamin D levels 
would be decreased in children with JIA and that children with higher levels of inflammation 
would have further reduced vitamin D levels.   
5.2. Subjects and Methods 
5.2.1. Data Sources 
Participants from  the Biologically Based Outcome Predictors  (BBOP) Study were 
compared with a sample of overall healthy Canadian children and matched by age and sex, taken 
from CHMS Cycles 1 (2007–09) and 2 (2009–11) in a case-control study design To be able to 
keep the integrity of the population-based data in CHMS and avoid selection bias, we used the 
same 1:1 ratio of female to male as exist based on the complex survey design in CHMS. JIA 
impacts more females than males (Ravelli, 2007) although the reason for sex disparity in JIA is 
not well-understood.   We analyzed the data in both sexes together and separately to explore if 
the relationship of disease development and sex was associated with vitamin D status.  
BBOP is a prospective inception cohort study that enrolled 186 new-onset JIA patients 
aged 1–16 years from 11 Canadian pediatric rheumatology centers. Enrolment criteria included 
consenting participants who:  (i) met  ILAR JIA classification criteria (Petty et al., 2004); (ii) 
were diagnosed within six months of disease onset; and (iii) had not been treated with DMARDs 




each of the seven JIA categories. The study aimed to recruit a representative sample from each 
category. To achieve this, only participants with polyarthritis or systemic JIA (the least prevalent 
categories) were eligible during the first six months of enrollment after which any JIA category 
was eligible. Patients and/or legal patients legal guardians provided written informed consent for 
study participation and publication of summarized results. The study was approved by the 
research ethics boards at each participating site (Research Ethics Board approval #07-86). 
CHMS is a Canadian cross-sectional health survey that runs in bi-yearly cycles (Giroux, 
2007). Data from CHMS Cycles 1 and 2 were combined for children aged 6–16 years. For 3 to 5 
year olds data were taken from Cycle 2 (Statistics Canada, 2014). Healthy children who were 
reported as having no chronic disease served as the comparison group (Tremblay & Connor 
Gorber, 2007).  
For participants in the BBOP study, plasma 25(OH)D was measured from a blood sample 
obtained at enrollment using a competitive binding enzyme-linked immunoassay (EIA 
Immunodiagnostic Systems ) as previously described (McNally et al., 2008). Total white blood 
cell, neutrophil, lymphocyte, and platelet counts; hemoglobin; and CRP were measured in 
clinical service laboratories affiliated with each of the participating sites.   
For participants in the CHMS study plasma 25(OH)D was  measured using the LIAISON 
25(OH)D TOTAL assay (Diasorin, Ltd,) (Sarafin, Durazo-Arvizu, Tian, & Phinney, 2015). 
Further, the original 25(OH)D values in CHMS Cycles 1 and 2 were then standardized to the 
internationally recognized reference measurements as described elsewhere (Sarafin et al., 2015). 
In a study evaluating the accuracy of 25(OH)D assessment methods in comparison with liquid 
chromatography–tandem mass spectrometry, each approach used in BBOP and in CHMS had 
similar concordance with the reference measure (Roth, Schmidt-Gayk, Weber, & Niederau, 
2008). 
 
Comparison of groups.  
We compared baseline BBOP data from children aged 3–16 years with healthy children 
from CHMS Cycles 1 and 2 assessed at the same time as the BBOP study. In BBOP, distribution 
of JIA patients had the approximate ratio of 2:1 female to male, while in CHMS sex distribution 





Data analysis.  
We performed age group and sex-specific analyses by weighting variables and the 
combined bootstrap files from the two survey cycles to obtain generalizable results at a 
population level (Giroux, 2007). Since children aged 3–5 years were only included in CHMS 
Cycle 2, this age group was analyzed separately.  
Variables of interest included age, sex, ethnicity, household income, date of birth, date of 
blood collection, laboratory measures mentioned above, use of supplements containing vitamin 
D, milk intake, and 25(OH)D status. We used 25(OH)D concentrations to determine the IOM-
defined prevalence of vitamin D deficiency, insufficiency, and sufficiency. Self-identified 
ethnicity categories were White, Non-white and off-reserve Indigenous. Season of birth and 
season of 25(OH)D measurement were based on the seasonal equinoxes. The period between 
April to October, when cutaneous synthesis of vitamin D is most efficient, was designated the 
synthesizing period and November to March was the non-synthesizing period (Wacker et al., 
2013). Milk intake and vitamin D supplement use were assessed using a food frequency 
questionnaire. 
Differences between BBOP and CHMS cohorts were considered significant at alpha= 
0.05 if point estimates (mean values) did not lie within the estimated 95% confidence intervals 
for parameters from the respectively compared population (Dixon et al., 2018). Data 
manipulation, cleaning, grouping and selecting variables of interest were done in SPSS Version 
22 (IBM, 2014). Stat/Transfer Version 10 (Circle Systems, Inc) was then used to transfer data to 
STATA version 14 (StataCorp) for analysis including cross-tabulation, weighting and 
bootstrapping to obtain nationally representative population level estimates. 
5.3. Results 
To be consistent with the CHMS age ranges, BBOP participants comprised 164 children 
with JIA aged 3–16 years (3–5-year olds n=28; 6 to 16-year olds n= 136). Those outside of this  
range were excluded. Characteristics of children with JIA and the CHMS healthy population 







Socio-Demographic Characteristics.   
More females were in the JIA cohort (70 ± 4.0%) than the healthy control group (50 ± 
1%). The proportion of Indigenous children with JIA (10 ± 2.8 %) was greater than the healthy 
population (3.4 ± 7.1 %); (p<0.05). There was no difference between populations in those who 
identified as White and Non-white, or in household income.  
 
Vitamin D. 
 Mean 25(OH)D concentration was significantly higher in children with JIA than in the 
healthy control children (79 ± 3.1 nmol/L vs 68 ± 1.8 nmol/L). Children with JIA used vitamin 
D-containing supplements significantly more than healthy controls (50% vs 7%) (Table 5.2). 
Children with JIA who took supplements had significantly higher 25(OH) D concentrations than 
healthy control children who both did and did not take supplements (Table 5.2). The proportion 
of children with 25(OH)D >100 nmol/L was significantly greater in children with JIA than 
healthy controls (18 ± 3.5% vs. 10 ± 1.2%). The prevalence of 25(OH)D deficiency (<30 
nmol/L) was 6% for both populations. Healthy control children reported “consuming milk 
everyday” significantly more often than children with JIA (Table 5.2). Children with JIA who 
drank milk everyday had a 25(OH)D concentration of 86.28 ± 4.97 nmol/L,  significantly higher 
when compared to those who occasionally or never drank milk who had a 25(OH)D 
concentration of 73 ± 5.2 nmol/L. 
 
Vitamin D and Seasonality.  
Significantly more children with JIA compared to healthy control children were born in 
the fall and winter (Table 5.2). More children with JIA were born in February or December than 
healthy children (Table 5.2). Males with JIA were significantly more likely to be born in the 
winter (males, JIA: 41 ± 8% [27 – 57] vs. healthy: 25 ± 2% [21 – 28]) and females with JIA were 
more likely to be born in the fall (females JIA: 31 ± 5 [22 – 41] vs. healthy: 21 ± 2% [18 – 24]). 
Vitamin D concentrations were highest during the synthesizing period and were significantly 
lower for healthy control children in the non-synthesizing period (Table 2). Children ages 6–8 
years old with JIA were significantly more likely to be born in the non-synthesizing period (JIA: 





Vitamin D and Ethnicity. 
 Children with JIA who identified as White had significantly higher 25(OH)D 
concentrations (83.3 ± 4.1 nmol/L) compared to Non-white (71.5 ± 6.1 nmol/L). Children with 
JIA who identified as White and Non-white had higher 25(OH)D concentrations than their 
healthy peers. Indigenous children with JIA had similar vitamin D concentrations as their healthy 
Indigenous peers (Table 2). Children aged 9-13 years with JIA had the greatest proportion with a 
25(OH)D concentration > 100 nmol/L and the highest 25(OH)D concentration in the non-
synthesizing period. Children aged 9-13 years with JIA who identified as White had the highest 
25(OH)D status (91.9 ± 7.0 nmol/L). Children who identified as Non-white in the 6 to 8-year and 
9 to 13-year age groups with JIA had higher 25(OH)D concentrations (6 to 8 year olds 87.0 ± 8.6 
nmol/L [70.0 – 104.0 ],  9 to 13 year olds 79.0 ± 7.4 [64.3 - 93.7]) than healthy children (6 to 8 
year olds 62.2 ± 3.9 nmol/L [ 54.2 - 70.1 ] 9 to 13 year olds 52.8 ± 4.9 [42.8 - 62.9]). Children 
who identified as Indigenous and had JIA in the 14 to 16 year age group had the lowest 25(OH)D 
concentrations (46.3 nmol/L) but not significantly different from healthy Indigenous children.  
 
Vitamin D and Other Laboratory Tests. 
 There was a significant difference in all laboratory test results including blood cell 
counts and measures reflective of inflammation, between healthy children and those with JIA, 
with the exception of lymphocyte counts (Table 5.3). All markers were higher in children with 
JIA with the exception of hemoglobin concentrations, which were lower. In JIA, those who had a 
25(OH)D concentration < 50 nmol/L had significantly higher CRP concentrations than the other 
groups (Table 3). There were no differences by age or sex. 
 
 
Vitamin D in 3 to 5-year olds.  
Fewer 3 to 5-year old children with JIA were reported to be choosing milk every day and 
a greater proportion were taking a vitamin D containing supplement every day or sometimes 
(50% vs. 32%, p<0.05). Three to five-year old children with JIA who were given supplements 
had higher 25(OH)D than children who were not taking supplements (taking supplements JIA 





Vitamin D and JIA Categories.  
The numbers of patients in each JIA category are  shown in  Table 4. Children with 
psoriatic arthritis had the lowest mean 25(OH)D concentration at 65.3 nmol/L (Table 5.4). This 
was significantly lower than in children diagnosed with enthesitis-related arthritis and 
oligoarthritis who had 25(OH)D concentrations of 95.0 and 85.0 nmol/L respectively. Over 60% 
of children with undifferentiated arthritis were born in the winter. This was significantly different 
from the proportion born in the summer and fall; no children with undifferentiated arthritis were 
born in the spring (Table 5.4). Children diagnosed with systemic arthritis were significantly more 
likely to be born in the winter. Significantly more children with rheumatoid factor negative 
polyarthritis were born in the fall than the winter or spring with no statistical difference in the 
proportion for those born in the summer compared to other seasons.  
5.4. Discussion 
This is the first study, to our knowledge, that compares multiple factors associated with 
vitamin D status in newly diagnosed JIA patients and healthy children at a national level. 
Contrary to our expectation, vitamin D levels   in Canadian children with JIA were not decreased 
when compared to levels in healthy Canadian children.  This might be explained by the high use 
of vitamin D supplements in children with JIA (Institute of Medicine, 2010); approximately half 
of newly diagnosed children were taking a vitamin D supplement which is higher than in the 
healthy population. 25(OH)D status was higher for JIA patients, and 18 nmol/L higher than the 
mean reported in the meta-analysis by Nisar et al. (Nisar, Cookson, Masood, Sansome, 2013).  
25(OH)D levels were significantly different based on self-identified ethnicity and health 
status. In contrast to other studies (Dağdeviren-çakır et al., 2016; de Sousa Studart et al., 2015; 
Nisar et al., 2013; Szymanska-Kaluza, Biernacka-Zielinska, Stanczyk, 2013) BBOP participants 
had significantly higher 25(OH)D levels than healthy children. Those who identified as White in 
both groups had the highest 25(OH)D concentrations. There was a significant negative difference 
in CRP concentrations in children with JIA based on 25(OH)D concentration below or above  the 
IOM defined adequate level of 50 nmol/L (Table 3) (Institute of Medicine, 2010). Additionally, 





In our study the prevalence of 25(OH)D deficiency (<30 nmol/L) was 6% for both 
populations. The higher rate of supplement use in children with JIA might be explained  by a 
higher likelihood of supplement use in sick children (Bailey, Gahche, Thomas, & Dwyer, 2013; 
Dwyer et al., 2013). In a population-based study, the decision to use supplements was the 
caregivers’ and in only 15% of  cases at the physician’s recommendation (Bailey et al., 2013). 
Prior to diagnosis parents may be providing supplements to treat the undiagnosed symptoms as 
was reported in the study by Bailey et al. (Bailey et al., 2013); however, information relating to 
the reasons for administering vitamin D supplements and dosage information were  not collected 
in our study.  
There was a greater proportion of children of Indigenous descent in the BBOP cohort 
compared with the control cohort because the CHMS did not recruit as far north as did the BBOP 
study nor did it collect information from Indigenous reserve communities. Additionally, there 
may be a higher proportion of JIA cases in the Indigenous population than in other populations 
(Jarvis & Cleland, 2003). Contrary to White or Non-White JIA children, children with JIA who 
identified as Indigenous had significantly lower mean 25(OH)D concentrations compared to 
healthy Indigenous children. As having a 25(OH)D level above 50 nmol/L appears to be 
associated with a lower CRP, children with JIA of Indigenous descent may require a targeted 
vitamin D intervention to contribute to modulating inflammation.  
We found children with JIA are more often born in the fall and winter seasons. Season of 
birth has been suggested to have an impact on the risk of developing a number of autoimmune 
diseases (Berkun et al., 2015). In a previous report children with JIA were  more likely to be 
born between November to March compared to birth months for the general population peaking 
in the summer (Berkun et al., 2015). Carlens et al.  also investigated this relationship but found 
no increased risk relating to season (Carlens et al., 2009). Maternal vitamin D status, which can 
be affected by season, may alter fetal vitamin D status or have detrimental consequences in the 
child during the first few months after birth (Çuhacı-Çakır & Demirel, 2015). Investigation into 
maternal vitamin D status and behaviors such as sun exposure, supplement use and intake of 
fortified foods during each gestational trimester could help to understand if, and when maternal 
vitamin D status influences the occurrence of JIA.  
Children with JIA had higher CRP levels and higher white blood cell, neutrophil and 




of active inflammation. Children with JIA who had a 25(OH)D <50 nmol/L had higher CRP 
levels than children with higher 25(OH)D concentrations. Consistent with our finding, an 
association between 25(OH)D concentrations and CRP concentrations was found by Stagi et al. 
(Stagi et al., 2014). Vitamin D has been suggested to play a role in the pathogenesis of JIA 
because vitamin D has immunosuppressive effects (Cutolo et al., 2011). Vitamin D enhances 
macrophage production of antimicrobial peptides, and suppresses proinflammatory properties of 
dendritic cells and antigen presenting cells (Von Scheven & Burnham, 2011). Immune system 
cells that express vitamin D receptors have the potential to synthesize 1,25-
dihydroxycholecalciferol (1,25(OH)2D) and elicit an autocrine or paracrine response (Hewison, 
2012). In most cells in the immune system vitamin D suppresses the immune response (Cutolo et 
al., 2011). Therefore, low vitamin D concentrations would be associated with inflammation 
(Cutolo et al., 2011). The role of vitamin D in other autoimmune disorders has been established 
(Holick, 2005). Our observations might suggest that adequate 25(OH)D reduces inflammation in 
children with JIA. However, further studies are needed to determine if vitamin D status 
influences disease pathogenesis.     
 
Disease Categories.  
The meta-analysis by Nisar et al. summarizes the research into juvenile chronic arthritis 
and juvenile rheumatoid arthritis and 25(OH)D (Nisar et al., 2013). Three studies have explored 
25(OH)D concentrations by JIA category (de Sousa Studart et al., 2015; Stagi et al., 2014; 
Szymańska-Kałuża, Biernacka-Zielińska, Stańczyk, & Smolewska, 2013). The two studies with 
n=50 reported no difference among categories. (de Sousa Studart et al., 2015; Szymańska-Kałuża 
et al., 2013). The study with n= 152 found children with systemic JIA had lower 25(OH)D 
concentrations than children with enthesitis-related arthritis, oligoarticular arthritis, and 
polyarticular arthritis (Stagi et al., 2014). Our results show that although children with systemic 
JIA had the second lowest 25(OH)D concentration it was not significantly lower than in other 
categories. The one other study that has explored season of birth by JIA category found 
rhythmicity (cyclic occurrence) in the enthesitis-related arthritis category with peaks in August 







Data reported here were derived from two separate studies with differences in collection 
methodology including 25(OH)D measurement assays although earlier studies have shown that 
results from these different methodologies yield comparable results (Roth et al. 2008). 
Additionally, the 3-Epi-25-hydroxycholecalciferol epimer of vitamin D was not measured. This 
epimer is less bioactive than other vitamin D metabolites (Aghajafari Field, Rabi, Kaplan, et al. 
2016). Enrolment criteria included being within 6 months of disease onset; therefore, some 
patients may have already changed their behavior because of their disease or the advice of a 
health care practitioner. Additionally, exact time since disease onset was not included in the 
analysis. Skin pigmentation influences baseline 25(OH)D and endogenous synthesis (Mangin, 




Results of this study show that mean vitamin D concentrations were in the optimal range 
JIA population and that higher concentrations of vitamin D in JIA compared to healthy controls 
is associated with more frequent use of vitamin D supplements (Holick et al., 2011). Our results 
show that a preponderance of JIA patients are born in seasons in which endogenous vitamin D 
synthesis is low raising the consideration that low vitamin D during the perinatal period could be 
a factor influencing JIA occurrence.  Having a 25(OH)D level above 50 nmol/L is associated 
with a lower CRP, reflective of less disease activity. However, more research is required to fully 
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Table 5.1. Sociodemographic information of healthy children in comparison to children with JIA  
  Overall 6- to 16-year olds 3- to 5-year olds 
  Healthy JIA Healthy JIA 
  Mean ± SE (95% CI) Mean ± SE (95% CI) Mean ± SE (95% CI) Mean ± SE (95% CI) 
Age (years)   12 ± 0.1 (11–12) 12 ± 0.3 (11–12) 4 ±0.1 (3.8–4.2) 4 ±0.2 (3.6–4.3) 
Sex (%) Male 50 ± 1 (48–53) 30 ± 4 (23–38)* 46 ± 3 (38–53) 39 ± 9 (22 – 59) 
 Female 50 ± 1 (47–52)  70 ± 4 (62–77)*  54 ± 3 (47–62) 61 ± 9 (41–78) 
Annual Household 
Income (%) 
< $49,999 11 ± 1.5 (7.5–14) 9.4 ± 2.9 (5.1–17) 4 ± 1 (2–6) 14 ± 7 (4–37) 
 $50,000 – 74,999 14 ± 1.4 (11–17) 14 ± 3.4 (9–22) 9 ± 2 (5–14) 32 ± 10 (15–55) 
 $75,000 – 99,999 41 ± 1.7 (37–44) 38 ± 4.7 (29–47) 41 ± 3 (34–48) 27 ± 10 (12–51) 
 > $100,000 35 ± 2.4 (30–40) 39 ± 4.8 (30–48) 46 ± 4 (38–55) 27 ± 10 (12–51) 
 Self-Identified 
Ethnicity (%) 
White 74 ± 4.4 (65–83) 71 ± 4.1 (62–78) 77 ± 3 (70–84) 81 ± 8 (60–92) 
 Non-White 23 ± 4.8 (13–33) 19 ± 3.5 (13–26) 20 ± 3 (12–27) 8 ± 5 (2–28) 
 Indigenous 3 ± 0.7 (2–5) 10 ± 3 (6–17)* 3 ± 2 (2–8) 12 ± 6 (3–32)* 
*Bold font represent statistically significant (p<0.05) differences between healthy children and those with JIA. Significance 
established when the point estimates did not lie within the estimated 95% confidence intervals for parameters from the respectively 
compared population 
 
Table 5.2. 25(OH)D concentration and vitamin D-related variables in healthy children and children with JIA 
  6- to 16-year olds 3- to 5-year olds 
  Healthy JIA Healthy JIA 
  Mean ± SE (95% CI) 
 
Mean ± SE (95% CI) 
 
Mean ± SE (95% CI) 
 
Mean ± SE (95% CI) 
 
25(OH)D nmol/L  68 ± 1.8 (65–72) 79 ± 3.1 (73–85) * 78 ± 1.2 (75–80) 101 ± 8.5 (83–118) 
Proportion by Vitamin D Cut-
off Category  
< 30 nmol/L 6 ± 1.6 (2–9) 6 ± 2.1 (3–12) <50 nmol/L  <50 nmol/L 
 30 -  50 nmol/L 17 ± 1.4 (15–20) 10 ± 2.7 (6–17) 8 ± 3 (2–14) 5 ± 5 (1–31) 
 > 50 – 75 nmol/L 42 ± 1.5 (39–45) 37 ± 4.4 (29–46) 39 ± 4 (31–48) 19 ± 9 (7–44) 
 > 75-100 nmol/L 25 ± 1.6 (22–28) 29 ± 4.1 (22–38) 42 ± 3 (35–49) 38 ± 11 (19–62) 
 > 100 nmol/L 10 ± 1.2 (8–12) 18 ± 3.5 (12 –26) * 11 ± 2 (7–14) 38 ± 11 (19–62) * 
Milk Consumption (%) Everyday  81 ± 1.3 (78–83) 68 ± 4.5 (59–76) * 95 ± 2 (90–100) 77 ± 9 (54–91) * 
 Never/sometimes 19 ± 1.3 (17–22) 32 ± 4.5 (24–41) * 5 ± 2 (0–10) 23 ± 9 (9–46) * 
Vitamin D use (%) Never  93 ± 0.9 (91 – 94) 50 ±  5 (40 – 59) * 68 ± 3 (62–74) 50 ± 11 (29–71) 
 Everyday/sometimes  7  ± 0.9 (6 – 9) 50 ±  5 (41 – 60) * 32 ± 3 (26–38) 50 ± 11 (29–71) 
Season of Birth (%) Winter 24 ± 1.2 (21–26) 33 ± 4 (26–41) * 21 ± 4 (13–30) 29 ± 9 (14–49) 
 Spring 27 ± 1.2 (25–30) 19 ± 3.4 (13–27) * 29 ± 4 (20–37) 21 ± 8 (9–42) 







 Fall 22 ± 1.2 (20–25) 29 ± 3.9 (22–37) * 26 ± 3 (19–33) 25 ± 8 (12–45) 
Born in synthesizing vs. non-
synthesizing season (%) 
Non-synthesizing 
period 
48 ± 2 (45–52) 52 ± 4 (44–61) 50 ± 3 (43–57) 57 ± 10 (38–75) 
 Synthesizing 52 ± 2 (48–55) 48 ± 4 (39–56) 50 ± 3 (43–57) 43 ± 10 (25–62) 
25(OH)D by supplement 
containing vitamin D use 
(nmol/L) 
Never Sometimes 68.1 ± 1.8 (64.3 – 71.9) 
 
78.1 ± 6.3 (65.6– 90.5) * 74.6 ± 1.8 (70.7 –  
78.4) 
88.8 ± 12.2 (63.0–114.6) 
 Everyday 71.5 ± 1.8 (67.9 – 75.1)  84.8 ± 4.4 (76.2 – 93.4) * 84.0 ± 2.8 (77.9–90.0) 121.8 ± 14.04 (92.1–151.4) 
* 
      
      
25(OH)D by self-identified 
ethnicity (nmol/L) 
White 73.1 ± 1.2 (70.5–75.7) 83.3 ± 4.1 (75.2–91.3) * 77.7 ± 1.9 (73.6–81.9) 102.6 ± 9.0 (83.9–121.4) 
 Non-white 53.6 ± 3.8 (45.6–61.5) 71.5 ± 6.1 (59.4–83.7) * 76.0 ± 4.0 (67.4–84.7) Inadequate sample size 
 Indigenous 62.5 ± 3.9 (54.5–70.5) 56.2 ± 7.3 (41.6–70.7) 87.4± 13.9 (57.3–
117.5)1  
63.0 ± 10.1 (41.9–84.1) * 
25(OH)D by season (nmol/L) Winter 55.2 ± 3.5 (48.0–62.5) 80.7 ± 6.0 (68.8–92.6)* 67.3 ± 3.1 (60.6–74.0) 100.5 ± 12.1 (75.3–125.7) * 
 Spring  69.8 ± 2.5 (64.7–75.0) 74.6 ± 5.9 (62.9–86.2) 75.1 ± 2.4 (70.0–80.2) 86.0± 13.2(58.6–113.4) 
 Summer 76.2 ± 2.9 (70. 3–82.0) 86.7 ± 7.5 (71.8–101.4) 76.5 ± 3.2 (69.5–83.4) 157.5 ± 22.5 (110.6–204.4) 
*  
 Fall 69.0 ± 1. 5 (66.0–72.0) 74.5 ± 4.7 (65.2–83.9) 81.2 ± 2.1 (76.7–85.7) 90.3 ± 20.1 (48.4–132.1) 




64.2 ± 2.5 (59.1–69.3) 76.2± 3.9 (68.4–83.9)* 77.2 ± 1.6 (73.6–80.7) 90.9 ± 10.6(68.8–112.9) 
 Synthesizing 73.0 ± 1.9 (69.2–76.9) 82.6 ± 5.0 (72.8–92.5) 78.9 ± 1.8 (75.0–82.7) 116.3 ± 13.2 (88.7–143.8) * 
25(OH)D by milk intake 
(nmol/L) 
Always 70.3 ± 1.8 (66.7–74.0) 86.3 ± 5.0 (76.4–96.2)* 78.1 ± 1.1 (75.8–80.4) 115.5 ± 26.1 (60.4–170.6) 
 Never/sometimes 60.0 ± 2.3 (55.2–64.7) 73.9 ± 5.2 (63.7–84.1)* 68.7 ± 4.8 (58.3–79.1) 100.0 ± 10.6 (77.7–122.3) * 
      
1
 includes those who did not report their ethnicity  
* Bold font represent statistically significant (p<0.05) differences between healthy children and those with JIA. Significance 

















 Table 5.3. The comparison of measures of inflammation between healthy children and children 
  6- to 16-years old 3- to 5-years old 
  Healthy JIA Healthy JIA 
  Mean ± SE (95% CI) Mean ± SE (95% CI) Mean ± SE (95% CI) Mean ± SE (95% CI) 
25(OH)D nmol/L  68.1 ± 1.8 (65.3–72.4) 79.2 ± 3.1 (73.4–85.2)* 77.8 ± 1.2 (75.2–80.4 ) 100.5 ± 8.5 ( 83.3 –117.6)* 
White Blood Cell Count 
(109/L) 
 6.7 ± 0.01 (6.5–6.8) 8.7 ± 0.04 (7.9–9.5)* 7.5 ± 0.2 (7.0–7.9) 11.0± 1.1 (8.9–13.1)* 
Platelet Count (109/L)  260.2 ± 2.0 (260.2–270.5) 360.4 ± 10.1 (340.6–
380.8)* 
306.3 ± 2.7 (300.4–312.1) 429.9 ± 30.7 (368.2–491.7)* 
Lymphocytes (109/L)  2.3 ± 0.02 (2.2–2.3) 2.3 ± 0.1 (2.1–2.4) 3.1 ± 0.1 (2.9–3.4) 3.7  ± 0.3 (3.0 –4.4) 
Neutrophils (109/L)  3.6 ± 0.1 (3.5–3.7) 5.6 ± 0.39 (4.8–6.3)* 3.4 ± 0.1(3.2–3.7) 6.1 ± 1.0 (4.0–8.2)* 
Hemoglobin (g/L)  140.2 ± 0.5 (140.0–140.4) 120.1 ± 1.2 (119.8–120.3)* 126.3 ± 0.6 (125.0–127.6) 113.9 ± 2.7 (108.4–119.3) * 
CRP (mg/L)  1.3 ± 0.1 (1.1–1.5) 19.2 ± 2.6 (14.7–24.5)* 1.4 ± 0.47 (0.36–2.4) 18.7± 6.7 (5.1 – 32.2)* 
CRP by 25(OH)D  cutoffs <50 nmol/L 1.4 ± 0.2 (0.9–1.8) 32.2 ±11.8 (8.8–55.6)*a 0.9 ± 0.5 (-0.3–2.1) none 
 <75 nmol/L 1.2 ± 0.1 (0.9–1.4) 19.1 ± 4.7 (9.7–28.5)*b 0.6 ± 0.2 (0.3–0.9) 15.0 ± 14.7 (-16.1–46.1) 
 <100 nmol/L 1.4 ± 0.2 (1.0–1.9) 13.7 ±2.9 (7.8–19.5)*b 1.5 ± 0.5 (0.5–2.6) 36.2 ± 16.8 (0.5–71.9) 
 >100 nmol/L 1.6 ± 0.3 (1.0–2.3) 15.0 ± 5.0 (6.0–25.9)*b 4.0 ± 2.0 (-0.3–8.4) 17.7 ± 12.2 (-8.1–43.5) 
* Bold font represent statistically significant (p<0.05) differences between healthy children and those with JIA. Significance 
established when the point estimates do not lie within the estimated 95% confidence intervals for parameters from the respectively 
compared population. Differing letter superscripts represent statistically significant differences (p<0.05) within group for children with 
JIA by CRP concentrations by 25(OH)D cutoff values. 
 
** Cut-off categories based on the Institute of Medicine categories (Institute of Medicine, 2010) of deficient < 30 nmol/L, insufficient 
30-50 nmol/L, and sufficient >50nmol/L as well as the Endocrinology Society’s definition of optimal >75 nmol/L(Holick et al., 2011). 


















Table 5.4. Vitamin D status of children with JIA in different seasons across JIA categories 







Psoriatic arthritis Undifferentiated 
arthritis 
n= 25 36 15 56 13 11 8 
25(OH)D nmol/L 
Mean ± SE (95% 
CI All seasons 




84.2 ± 16.5 (51.6 - 
116.8)  




65.4 ± 10.0 (45.6 
– 85.2) †§ 
85.0 ± 13.6 (58.1–
92.8) ‡ 
Season of Birth        
       Winter  (%) 
Mean ± SE (95% 
CI 
52.0 ± 10.2 (32.6– 
70.8) ** 
27.8 ± 7.6 (15.4 – 
44.8) 
33.3 ± 12.6 (14.0 – 
60.5) 
19.6 ± 5.4(11.1 – 
32.3) ** 
30.8 ± 13.3  
(11.5 – 60.5 ) 
45.5 ± 15.8 (19.2  
– 74.5) 
62.5 ± 18.3  (26.3 – 
88.6) ** 
       Spring  (%) 
Mean ± SE (95% 
CI 
12.0 ± 6.6 (3.8 – 
32.0)  
19.4 ± 6.7 (9.4  – 
35.9) 
20.0 ± 10.7 (6.3 – 
48.3) 
19.6 ± 5.4 (11.1 – 
32.3) †† 
38.5 ± 14.0  
(16.2 – 66.9) 
27.3 ± 14. (8.5 – 
60.4) 
No observations 
       Summer  (%) 
Mean ± SE (95% 
CI 
12.0 ± 6.6  (3.8 – 
32.0 )  
27.8  ± 7.6  (15.4 
– 44.8 ) 
26.7 ± 11.8  (9.9 – 
54.5) 
25.0  ± 5.8  (15.3  – 
38.1 ) †† 
No observations 9.1 ± 9.1  (1.1 – 
46.7) 
12.5 ± 12.5  (1.5 – 
57.7)  
       Fall (%) 
Mean ± SE (95% 
CI 
24.0  ± 8.7  (10.9  
– 44.8 )  
25.0 ± 7.3  (13.4 – 
41.9) 
20.0 ± 10.7  (6.3 – 
48.3) 
35.7  ± 6.5  (24.2  – 
49.2) ** 
30.7 ± 13.3  
(11.5 – 60.5 ) 
18.2  ± 12.2  (4.2  
– 52.9) 
25.0  ± 16.4  (5.6 – 
65.1) 
*†‡§Same superscript symbols denote statistically significant differences (p<0.05) for 25(OH)D concentrations by disease category  
**†† Denotes statistically significant different by season within disease category. 
 Significance established when the point estimates did not lie within the estimated 95% confidence intervals for parameters from the 








Evaluation of Nutritional Status through Anthropometric Measurements 
6.1. Introduction 
Nutrition and Juvenile Idiopathic Arthritis (JIA)  
Children with JIA often experience nutrition-related concerns, such as protein-energy 
malnutrition, micronutrient deficiencies and growth abnormalities (Dinardo, Dwyer, Goldberg, 
& Holland, 1991). While it is not the sole cause, nutritional impairment can contribute to reduced 
growth, osteoporosis, anemia and suboptimal body composition in children with JIA (Cleary et 
al., 2004). As new medications and treatments have become available, it is important to monitor 
and update the expected growth outcomes of children with JIA. Currently, no standard 
recommendations for nutrition therapy or specific diet for children with JIA exists, however 
nutrition does play a role in disease treatment. Current nutrition recommendations are the same 
as they are for all children and specific recommendations are made based on individual projected 
outcomes and requirements (Dinardo, Dwyer, Goldberg, & Holland, 1991).  
Waist circumference is a measure of central adiposity and body composition.  Children 
with JIA weigh less than healthy children; they may have lower muscle mass and greater central 
adiposity (Jednacz, & Rutkowska-Sak, 2014, Sousa et al., 2006). Few longitudinal studies 
comparing JIA patients to healthy controls exist. Central obesity during childhood increases the 
risk of cardio metabolic risk in young adulthood (Barbour-Tuck, Erlandson, Muhajarine, Foulds, 
& Baxter-Jones, 2018). Concern over increased cardiovascular risk in patients with rheumatoid 
arthritis and impaired nutritional status in children with JIA, warrant the further research to 
explore cardio metabolic risk factors in children wit JIA (Jednacz, & Rutkowska-Sak, 2014).  
 
Vitamin D and JIA 
Nutrition in children with JIA may be improving as more effective treatments for the 
underlying disease become available.  The correlation between body fatness and vitamin D status 
has been found in children (Wakayo et al., 2015). Overweight children were found to have lower 





for-age and triceps skinfold-for-age percentile (Wakayo et al., 2015). Thus, overweight and 
obese children may require additional vitamin D.   
Rooney et al. reported that the degree of growth retardation is associated with the 
duration of the disease activity (longer duration of disease activity reduces growth potential) in 
children with JCA, and that disease remission can improve growth (Rooney, Davies, Reeve, 
Preece, Ansell, 2000). It was concluded that normal height can be achieved through catch-up 
growth after 2-3 years of disease remission unless the epiphyseal growth plate had already fused. 
Vitamin D may play a role in suppressing inflammation (Cutolo et al., 2011) therefore 
establishing appropriate target concentrations for children with JIA considering their body 
composition may suppress inflammation and assist in optimizing growth.  
Endocrine Society has published clinical practice guideline as well for patients at risk of 
vitamin D deficiency. They have included recommendations for a number of at-risk populations, 
including: “obese children and adults and children and adults on anticonvulsant medications, 
glucocorticoids, antifungals such as ketoconazole, and medications for AIDS be given at least 
two to three times more vitamin D for their age group to satisfy their body's vitamin D 
requirement” (Holick et al., 2011)  
To date and to our knowledge, no study has investigated the relationship between vitamin 
D status, growth outcomes and JIA from the time of the first presentation. This research 
compares at a population level whether there are significant differences in growth between 
healthy children and those recently diagnosed with JIA. We compared the vitamin D status and 
growth outcomes for children and adolescents with JIA to a healthy age-matched population of 
children and adolescents. The objectives of this research were to evaluate vitamin D status and 
growth in newly diagnosed children with JIA compared to healthy children. 
6.2. Methodology 
Data from the BBOP study A (n=136) and the CHMS were used. BBOP data from 
children, aged 3-16 years with new onset JIA, were compared to age-matched healthy children 
from CHMS cycle 1 and 2 after weighting and bootstrapping to be able to generalize data at 
population level. As 3 to 5 years olds only participated in cycle 2 of CHMS they were analyzed 
separately from the 6-16 year olds so that the appropriate bootstrap variables could be applied. 





(age and sex specific) and maturation offset were calculated. Means and 95% confidence 
intervals were calculated to determine significance. Anthropometric z-scores and percentiles 
were calculated using the Center for Disease Control reference data (Fryar, Gu, & Ogden, 2012), 
and maturation offset to explore the impact of puberty on growth and disease development were 
calculated using the equation by Mirwald et al. (Mirwald, Baxter-Jones, Bailey, & Beunen, 
2002). 
6.3. Results 
Growth parameters  
The proportion of children in each BMI class did not differ between the two groups, and 
there was no difference in BMI z-score as shown in Table 6.1 (JIA 0.14 ± 0.10, healthy 0.24 ± -
2.40). Weight and height were higher in healthy children both as measured and based on weight 
and height for age z-scores (weight z-score JIA 0.06 ± 0.11, healthy 0.37 ± 0.03, height JIA -0.11 
± 0.10, healthy 0.28 ± 0.03). There were a greater proportion of children with JIA who had a 
waist circumference above the 90th percentile for their age and sex (9.0 ± 3%) than healthy 
children (4.1 ±1%). No difference was found in the proportion of children by maturity offset 
classification. There was a significantly greater proportion of children ages 14-16 years with JIA 
who were underweight compared to healthy children (JIA 13 ± 5%, healthy 3 ± 1%).  
 
25(OH)D by body composition.  
There was a significant difference in vitamin D concentrations for children based on 
weight category with normal and underweight children from both groups having higher vitamin 
D than the children in the overweight and obese categories from both groups. While 25(OH)D 
concentrations were lower in children who had a waist circumference >90th percentile the results 
were not significant.  
 
3 to 5 year olds 
Children with JIA had statistically significantly higher BMI that healthy children. Other 
than that, they did not differ. Waist circumference was not measured on 3 to 5 year olds in 






This is the first study in Canada to investigate the relationship between vitamin D status, 
growth outcomes and JIA from the time of the first presentation and also the first to make 
comparisons at a population level to children who are free of chronic disease. In comparison to 
children free of chronic disease, children with JIA are more likely to be shorter and weight less. 
7% of children 6-16 years old  from our study were underweight based on BMI compared to 11-
41% of patients with JIA reported by Gaspari et al. (Gaspari et al., 2011). Growth failure is 
reported to occur most often in children with systemic and polyarticular JIA and, although less 
severe,  also in children with oligoarticular JIA (Marcovecchio et al., 2012). 
Body composition may also impact vitamin D status as vitamin D is readily taken up by 
adipose tissue. Obese individuals have lower serum 25(OH)D concentrations than normal weight 
individuals (Tsiaras & Weinstock, 2011).  A study with the goal of characterizing the dose-
response relationship of vitamin D supplementation and 25(OH)D concentration was conducted 
in a large sample of healthy volunteers. Specifically the aim was to quantify the dose-response 
relationship for different BMIs and for absolute body weight. The authors found that BMI was a 
better determinant of 25(OH)D concentrations than absolute weight. When compared to subjects 
with a BMI in the healthy range, obese and overweight adults have serum 25(OH)D 
concentrations that are on average 19.8 nmol/L and 8.0 nmol/L lower than normal weight adults, 
respectively (P<0.001) (Ekwaru et al., 2014). The correlation between body fatness and vitamin 
D status has also been found in children (Wakayo et al., 2015). Overweight children were found 
to have lower 25(OH)D concentrations than non-overweight children, based on classification of 
both BMI-for-age and tricepskinfold-for-age percentile (Wakayo et al., 2015).  
While the proportion of children in each BMI class did not differ between the two groups 
(healthy children and children with JIA), weight and height z-scores were not the same, with z-
scores being higher in healthy children. A greater proportion of children in the JIA group were 
above the 90th percentile for age and sex-adjusted waist circumference. As waist  circumference 
is an indicator of central adiposity and body composition, these results  suggests that while 
children with JIA weigh less than healthy children they may have lower muscle mass. These 
results highlight that at disease onset children with JIA already differ from healthy children in 
terms of growth characteristics and that discussion and monitoring of body composition and 





 Other studies have reported mixed results on the impact of JIA on body weight with both 
evidence of under and over nutrition available (Caetano et al., 2009; Cleary et al., 2004; Dey et 
al., 2014; Markula-Patjas et al., 2014). These mixed results are most likely due to an individual’s 
response to the disease activity either through reduced intake, reduced physical activity, and/or 
increased caloric requirement.  In 1990, when Bacon et al. investigated the relationship between 
growth and dietary intake in children with JRA, it was found that one-third of the children 
studied were at or below the tenth percentile in height for age (Bacon et al., 1990). Overall, meal 
caloric and nutrient intakes were found to be adequate when compared to the RDA of the 
National Academy of Science. Biochemical measurements showed abnormalities amongst the 
subtypes of JRA and discrepancies between dietary intake and blood values. It was hypothesized 
that this was due to increased energy utilization due to chronic inflammation (Bacon et al., 
1990). 
6.5. Conclusion 
   Children with JIA are shorter and weigh less than healthy children weigh; they are at 
increased risk of having a waist circumference above the 90th percentile. Vitamin D, which was 
adequate in the JIA population, is not likely to be a factor accounting for impeded growth. 
Further research into strategies to minimize inflammation and optimize nutritional status 









Table 6.1. Anthropometric measures and adjusted anthropometric measures 
  Overall 6-16 3-5 
  Healthy JIA Healthy JIA 
  Mean ± SE (95% CI) Mean ± SE (95% CI) Mean ± SE (95% CI) Mean ± SE (95% CI) 
Weight (kg)   47 ±  0.63 (46-48) 43±  1.6 (40 - 46) 33.5 ± 15.6 (-0.15-67.15) 17.2 ± 0.76 (15.7-18.8) 
 




 67 ±  0.44 (66-68) 68 ±  1.7 (65 - 71) 75.5±16.2(40.5-110.4) 55.3 ± 1.8 (51.5-60.0) 
 
Body Mass Index  20 ± 0.16 (19.9-20.3)    19 ± 0 .40 (18.45 - 20.05) 17.7±1.4 (14.7-20.6) 16.2 ± 0.39 (15.4-17.0) 
Waist Circumference (%) < 90th percentile 96.4 ± 0.70 (94-97) 91.1 ± 3 (83-96.1) Not available 77 ± 12 (43-94) 
 > 90th percentile 4.1 ± 0.70 (02.7-5.6) 9.0 ± 3 (4.5-17) Not available 23 ± 1.2 (6-57) 
Weight Category (%) Under weight 3.8 ± 0.8 (2.2-5.5) 6.9 ± 2.2 (3.6-13) 3-5 combined normal and 
under weight 
 
 Normal Weight 71 ± 1.6 (68-74) 72 ± 3.9 (64-79) 75±4(67-83) 88 ± 7 (66-96) 
 Overweight   14 ± 1.2 (12-17) 11 ± 2.7 (6.4-17) 18±3(10-25) 13 ± 7 (4-34) 
 Obese 11 ± 0.94 (8.8-13) 10 ± 2.6 (5.9-17) 7±2(3-12) none 
Maturation offset Before puberty  49 ± 1 (47 - 51) 41 ±  4 (33 - 50) N/A N/A 
 During puberty  21 ±  1 (18 - 23)  19 ± 3 (13 - 26) N/A N/A 
 After   30 ±  1 (28  - 32) 40 ±  4 (32 - 49) N/A N/A 
Weight for age z-score  0.37 ± 0.03 (0.30-0.43) 0.06 ±  0.11 ( -0.15- 0 .27) 0.37 ± 0.12 (0.12-0.63) 0.19 ± 0.11 (-0.05-0.43) 
Height for age z-score     0.28 ± 0.03 (0.21-0.34) -0.11 ± 0.10 (-0.31-0.08) 1.26 ± 0.92 (-0.73-3.25) -0.23 ± 0.11 (-0.47-0.01) 
BMI for age z-score  0.24 ±  0.02 (0.20 - 0.28) 0.14 ± 0.10 (-0.06-0.35)   0.25 ± -2.02 (0.13-0.37)    0.50 ± 0.10 (0.27-  0.72) 
*Bold font represent statistically significant (p<0.05) differences between healthy children and those with JIA. Significance 



















Table 6.2. 25(OH)D concentration and vitamin D-related variables in healthy children and children with JIA 
  Overall 6-16 3-5 
  Healthy  JIA Healthy  JIA 
25(OH)D nmol/L  68.0 ± 1.8 (65.2-72.4) 
 
 79.1 ± 3.1 (73.2-85.1) 
 
77.8±1.2(75.2-80.4) 100.5 ± 8.5 ( 83.3 -117.8) 
Vitamin D by waist 
circumference nmol/L 
<90% 68.6±1.8(64.8-72.4) 79.0±3.9(71.4-86.7) Not available  
 >90% 62.1±2.9(56.2-68.0) 61.4±10.2(41.0-8.7)   
Vitamin D by BMI group nmol/L Under and normal 
weight 
 73.5±4.9(63.4-83.7) 83.3±3.4(76.6-90.1) 79.3±1.6(75.9-82.8) 103.2 ± 11.3(79.5-126.8) 
 Overweight 62.9±1.7(59.4-66.3) 51.9±6.0(40.1-68.8) 73.1±4.9(62.4-83.7) 73.7 ± 9.4(53.9-93.4 
 Obese 62.5±2.8(56.8-68.2)b 59.3±6.7(45.9-72.6) 72.8±4.5(63.0-82.5) 90.3 ± 19.4(49.7-131.0) 
*Bold font represent statistically significant (p<0.05) differences between healthy children and those with JIA. 
 Differing superscript letters denote statistically significant differences (p<0.05) for 25(OH)D concentrations by waist circumference 
category or BMI category. Significance established when the point estimates did not lie within the estimated 95% confidence intervals 





















 CHAPTER 7 
OBJECTIVE 2 
Vitamin D is associated with markers of disease activity among children with Juvenile 
Idiopathic Arthritis 
 
To address objective 2 of this thesis, I examined the association between plasma levels of 
25(OH)D and disease activity and outcomes as determined by clinical and biomarker profiles in 
JIA. 
Abstract 
Introduction: While the role of vitamin D in other autoimmune disorders has been established, 
less is known about its association with Juvenile Idiopathic Arthritis (JIA). Low vitamin D levels 
could be associated with inflammation. We aimed to determine associations between vitamin D 
and inflammatory markers in newly diagnosed JIA patients. 
Methods: Data from the Biologically-based Outcome Predictors (BBOP) in JIA prospective 
multi-centre study was used (n=186). Environmental and clinical data were collected every 6 
months for 2 years and blood samples were obtained at baseline (treatment-naive) and 6 months 
(receiving treatment). Longitudinal analysis then explored whether 25(OH)D and related factors 
could predict disease activity in BBOP children. 
Results: No difference was found in 25- hydroxy vitamin D (25(OH)D) concentrations between 
baseline and 6 months (84.5 ± 37.7 vs. 84.4 ± 43.7 nmol/L). Overall, 36% of children achieved 
remission on continuing medications; 25% had sustained remission after discontinuing 
medication. Increased 25(OH)D or its associated factors predicted lower ESR, CRP and cytokine 
concentrations. Remission was predicted by increasing 25(OH)D concentrations at the 6 month 
time point. 
Conclusion: Serum 25(OH)D concentrations and factors that influence 25(OH)D status such as 
season and daily milk consumption are associated with measures of disease activity. 25(OH)D 
predicted remission suggesting that it may play a role in suppressing inflammatory-related 





Vitamin D has been implicated in the pathogenesis of certain autoimmune diseases 
(Holick, 2012).  The mechanism by which this occurs is believed to be through vitamin D’s 
effect on non-calciotropic immune and inflammatory pathway functions (Trochoutsou, Kloukina, 
Samitas, & Xanthou, 2015). Cytokines mediate the inflammatory response in humans; during 
inflammation, pro-inflammatory cytokine concentrations increase and anti-inflammatory 
cytokines decrease (Armon, 2014).  
The association of vitamin D with cytokine mediators of inflammation have not been 
explored in children with JIA. Pelajo et al. (2012) found that children with JIA were more likely 
to be vitamin D deficient than healthy controls (Pelajo, Lopez-Benitez, & Miller, 2011). A 2013 
meta-analysis, of vitamin D in JIA reported the prevalence of vitamin D insufficiency in this 
population to be 82%. There was, however, no information available to elucidate if the reduced 
vitamin D concentrations were a consequence of reduced dietary intake, medication effect, or 
increased utilization due to the disease status. Additionally, there was no information reporting 
the relationship between vitamin D status and disease courses and outcomes (Nisar et al., 2013). 
 The objectives of this present study were to examine the association between 
plasma concentrations of 25-hydroxyvitamin D (25(OH)D) and vitamin D associated 
factors (as examples, vitamin D intake, the season of measurement, and the use of 
corticosteroids) and relationships with disease activity outcomes. Outcomes were 
determined by composite scores of disease activity, disease remission, and biomarker 
profiles in a JIA inception cohort of over a two-year period. This is the first cohort study 
to explore the association of vitamin D with disease outcomes in newly diagnosed 
children with JIA.  
7.2. Methods 
 We used data from the Biologically Based Outcome Predictors (BBOP) in Juvenile 
Idiopathic Arthritis study, a prospective, inception cohort study. Recruitment of 186 participants 
aged 1-17 years with new-onset JIA were recruited from 11 Canadian pediatric rheumatology 
centers (Appendix A). Enrollment criteria included conforming to ILAR classification criteria 




with DMARDs or biologically-based anti-cytokine therapies  (biologics),  and providing consent 
to be enrolled in the study. To achieve a reasonable number of participants in each of the seven 
JIA categories rather to achieve a typical JIA category distribution, only participants with 
polyarthritis or systemic JIA, the least prevalent categories, were eligible during the first six 
months of the enrollment period; after six months and until the end of the two-year enrollment 
period participants with any JIA category were eligible. Each participating institution provided 
ethics approval. 
7.2.1. Data and Sample Collection  
Demographic and clinical data were collected at enrollment and every six months for two 
years. Clinical data included variables required for the American College of Rheumatology 
pediatric core set of measures of disease activity (Giannini et al., 1997). These variables include 
the physician global assessment (PGA) of disease activity, acute phase reactants (ESR and/or 
CRP), and the CHAQ-JIA (Giannini et al., 1997). Inactive disease (remission on or off 
medication) was defined by criteria proposed by Wallace et al. (Wallace et al., 2004). 
Additionally, data was collected using the Juvenile Arthritis Quality of Life Questionnaire 
(JAQQ). Participant pain status was assessed using the CHAQ question “how much pain do you 
think your child has had because of his/her illness in the past week?”. 
 
Laboratory-Based Assays 
Sample Collections and Handling:  
From plasma samples collected at baseline and at six months, 25(OH)D, pro- and anti-
inflammatory mediators IL-2, IL-1α, IL-1rα, IL-1β, IFN-ɤ,  IL-6, IL-8,  IL-17, TNFα, IL-4, and 
IL-10 were measured (Matheson, Duong, Rosenberg, & Yeung, 2008).  ESR and CRP measures 
were derived from results generated by the clinical service laboratories in each of the respective 
participating centers and reported for all time points.  Table 7.1 shows the inflammatory 
biomarker measurements analyzed. 
 
Cytokine Measurements: 
At enrollment and at six months, blood was collected in P100 Blood Collection and 
Preservation tubes (BD Biosciences, San Jose, CA) (Matheson, Duong, Rosenberg, & Yeung, 




(Fluorokine® Multi-Analyte Profiling, Multiplex human cytokine panel A {R&D Systems}using 
a Luminex analyzer (Luminex Corp.) at the Toronto University Health Network Microarray 
Centre (www.mircoarray.ca). Forty-six cytokines were analyzed for the BBOP study. We chose 
to focus on the cytokines listed above because they are most commonly listed in the literature as 
having been explored in participants with JIA or other autoimmune diseases and have been 
studied in the context of vitamin D. (Cutolo et al., 2011; Dankers et al., 2017; Hayes et al., 
2015). 
 
Vitamin D Assay 
25(OH)D was measured from a plasma sample obtained at enrollment and at six months 
after enrollment using a competitive binding enzyme-linked immunoassay (EIA 
Immunodiagnostic Systems ) as previously described (Matheson et al., 2008). All biochemical 
measures were log-transformed, as they did not follow normal distribution. 
To assess vitamin D intake over the  month prior to blood sample collection, the 
frequency of milk intake (two categories every day, and never/sometimes) and vitamin D 
containing supplement use (two categories every day/sometimes, and never) were collected for 
analysis.  Medications were documented at every time-point and categorized by medication class 
(non-steroidal anti-inflammatory [NSAID], corticosteroid [steroids], DMARD or biologic). 
A method to standardize, compare and combine inflammatory biomarkers developed by 
Tabung et al.  was used (Tabung et al., 2015). Z-scores of the log-transformed. CRP, IL-6, and 
TNFα concentrations were then added together to create the overall pro-inflammatory biomarker 
score. The same method was applied to create an anti-inflammatory score where the anti-
inflammatory cytokines IL-4 and IL-10 were standardized then combined.  Since CRP is used in 
defining remission, we used the pro and anti-inflammatory scores to include other measures of 
inflammation that are not included in the definition of remission.  
 
Statistical Analysis 
Descriptive statistics (means and standard deviations for continuous variables and 
percentages for categorical variables) were used to summarize the data at the five-time points of 
measurements. Multi-Level Mixed-Effects (MLM) Modeling  and backwards methodology with 




utilized to determine if there is association between factors associated with vitamin D status 
(milk intake, supplement intake, season) and markers of inflammation /disease outcomes in the 
presence of potential covariates, such as socioeconomic status, sex, age, ethnicity. The repeated 
measures across time points had unstructured covariance structure. STATA 15 (StataCorp LP 
2015) was used for both the descriptive and inference statistics; alpha was set at p<0.05.  
7.3. Results 
The mean age of participants at recruitment was 9.34 ± 4.78 years. One-hundred and 
twenty-eight (69%) of the 186 patients recruited were female. Demographic data and clinical 
characteristics are presented in Table 7.2. Mean 25(OH)D concentrations did not change from 
baseline to 6 months (84.48 ± 37.54  nmol/L vs 84.38 ± 43.68nmol/L) (Table 7.1). Forty-five 
percent of JIA patients were vitamin D insufficient (< 75 nmol/L) (Holick et al., 2011). 
Measurements taken at all time points (baseline to 24 months) are presented in Table 7.3.  
 
Baseline and six months  
As most biochemical measurements including 25(OH)D, were analyzed at only baseline 
and at six months, separate models were made to include 25(OH)D concentrations.  
 
Measures of inflammation 
CRP concentrations decreased between the baseline visit and  the visit  at six months.  
The average CRP levels decrease when 25(OH)D increases if  on a steroid (β=-0.95) (Appendix 
A Table 7.4); average CRP levels increase when 25(OH)D increased, if  not on a steroid (β 0.04 
= -0.95+0.99). Reporting consuming milk every day also predicted a reduction in average CRP 
(β= -0.52, p=0.028).  Average between the baseline visit and  the visit  at six months (Table A.4). 
There was an interaction between milk consumption and supplement use (p=0.033).  For children 
who drank milk everyday and did not take a supplement, the average ESR concentration 
decreased (β= -0.25).  For those who did drink milk and did take a supplement, the average ESR 
concentrations increased (β 0.47= -0.25+0.72).With respect to ESR, there was an interaction 
between age and supplement intake (p=0.019). For those who did not take a supplement the 
average ESR concentration increased with age (β=0.02). For those who are taking a supplement 






Follow up measurement at the six month time point was not associated with any of the 
inflammatory cytokines (Table A.5). The only predictive variables to impact IL-1α were being 
prescribed a biologic and milk intake. Those who had not received biologics had lower average 
concentrations of IL-1α than those who had been prescribed biologics (β= -0.88, p=0.012). 
Taking a supplement every day predicted an average positive association with IL-1α compared to 
children not taking a supplement (β= 0.31, p=0.03). Drinking milk every day predicted higher 
average concentrations of IL-1rα (β= 0.75, p=0.024). Increasing age predicted lower average IL-
1rα  concentrations (β= -0.09, p=0.099). Not being prescribed a biologic predicted lower average 
IL-1rα  concentrations (β= -2.02, p <0.001). There was an interaction between steroid used and 
25(OH)D concentrations (p=0.017); 25(OH)D predicted lower average IL-1rα concentrations in 
children prescribed a steroid (β= -1.44). Those not prescribed a steroid had higher average IL-1ra 
concentrations as their 25(OH)D increased (β 0.07= -1.44+ 1.51). Average IL-1β was higher in 
the summer compared to the winter (β=0.64, p=0.008). The average IL-2 concentrations decrease 
when 25(OH)D increases if  on a steroid (β=-0.-1.31); average IL-2 concentrations increase 
when 25(OH)D increased, if  not on a steroid (β 0.15 = -1.31+1.46). Taking a supplement every 
day predicted higher average IL-2  concentrations (β= 0.57, p=0.002).  Average IL-6 
concentrations were higher in the summer than winter (β= 0.54, p=0.013).  There was an 
interaction between age and milk intake ( p= 0.018).  The average IL-6 concentrations increased 
when age increases if children reported not drinking milk every day (β=0.008); average IL-6 
concentrations increased when age increased, if children reported drinking milk every day (β 
1.19= 1.31+- 0.12).  Average IL-8 concentrations were predicted to be higher in the spring (β= 
1.25, p= <0.001) and summer (β= 2.25, p= <0.001) compared to the winter.  With respect to IL-
8, there was an interaction between age and milk intake (p= 0.002). The average IL-8 
concentrations increased when age increases if children reported not drinking milk every day 
(β=0.08); average IL-6 concentrations decreased when age increased, if children reported 
drinking milk every day (β -0.09= 0.08 +-0.17). Average 25(OH)D plasma concentration 
outcomes decreased with age  for children less than 11 and increased with age for children older 
that 11 (β -1.7= -1.87 + 0.17).  With respect to IL-17, there was an interaction between milk and 




reported drinking milk every day and not taking a supplement. (β=0.-0.15); average IL-17 
concentrations decreased further in children who reported not drinking milk and taking a 
supplement every day (β -1.6= -0.15+-1.45). Older children have lower average TNFα than 
younger children (β= -0.05, p=0.008). There was negative association between 25(OH)D 
concentrations and average INFƴ concentrations (β= -1.20, p=0.008). Older children were 
predicted to have higher average IFN concentrations than younger children (β= 0.10, p=0.016).  
Children taking a supplement containing vitamin D had an average INFƴ  concentration that was 
lower than children who reported not taking a supplement (β= -0.51, p=0.007). With respect to 
the pro-inflammatory index,  there was an interaction between steroid use and 25(OH)D 
(p=0.010). For those taking a steroid higher vitamin D levels resulted in lower average pro-
inflammatory index values (β= -1.67); however, for those not taking a steroid having higher 
vitamin D concentrations resulted in higher inflammation than those taking a steroid with higher 
vitamin D concentrations (β 0.31=-1.67+1.98)  
 
Anti-Inflammatory Cytokines 
Significant main effects and significant interactions with associated main effects for anti-
inflammatory cytokines are presented in (Table A.6). There was no change in average IL-4 
between the two visits (β=0.23, p=0.078).   With respect to Il-4 there was an interaction between 
age and 25(OH)D (p=0.034). For children less than 13 years of age having a higher 25(OH)D 
concentration lowers average IL-4 concentrations and after 13 years of age having higher 
25(OH)D increases average IL-4 concentrations (β -1.53= -1.66 +0.13). Females were predicted 
to have higher average IL-4 than males (β= 0.94, p=0.013). Average IL-10 did not statistically 
change from baseline to the six-month follow up. There was seasonal variation in average IL-10 
concentrations with spring (β= 0.41, p=0.036) and summer (β= 0.39, p=0.005) predicting higher 
average IL-10 concentrations than winter. Those who identified as non-white had higher average 
IL-10 concentrations than those who identified as white (β=0.065, p=0.04). Those in the highest 
income group (>$100,000) also had higher average IL-10 than the comparison group (<51,000( 
(β= 0.63, p=0.036).  As BMI percentile increased so did average IL-10 (β=0.01, p=0.044). There 
was an interaction between milk intake and supplement use (p=0.019).The average IL-10 
concentrations increased when children reported drinking milk every day and not taking a 




not drinking milk and taking a supplement every day (β 0.73 = 0.09+0.64). There was no change 
in the average anti-inflammatory index between baseline and the six month follow up. The 
average anti-inflammatory index was predicted to be higher in the summer compared to the 
winter (β=0.44, p=0.029).  With respect to the anti-inflammatory index, there was an interaction 
between age and 25(OH)D (p=0.033). For children less than 12 years of age having a higher 
25(OH)D concentration lowers average anti-inflammatory index and after 13 years of age having 
higher 25(OH)D increases average anti-inflammatory index (β -1.62 = -1.76 +0.14). 
 
Objective and Self-reported Measures of Disease Outcomes 
PGA scores fell from the baseline to the six month visit (Table A.7). There was an 
association between higher 25(OH)D and a higher average PGA score (β=0.55, p=0.044) Those 
in the middle-income category had a lower average PGA score than those in the lowest income 
category (β= -0.91, p=0.007).   
 
All visits (baseline through 24 months) 
Laboratory measures of inflammation 
Over the five study visits CRP decreased (Table A.8) (β= -0.34, p= <0.001)  Children 
who reported drinking milk every day, had decreased average CRP concentrations (β= -0.44, 
p=0.007).  Those who reported not taking a steroid had decreased average CRP concentrations 
(β=0.48, p=0.007). Children who reported drinking milk every day milk had lower average ESR 
than those who did sometimes or never (β= -0.49, p=0.006) (Table A.8). There was an 
interaction between supplement and age (p=0.033). The average ESR concentrations increased 
when age increases if children reported not taking a supplement (β=0.82); average ESR 
concentrations increased to a lesser degree when age increased, if children reported taking a 
supplement every day (β 0.75 = 0.082 +-0.07).    
Objective and self-reported measures of disease outcomes  
Objective and self-reported measures of disease outcomes over the five study visits are 
presented in Table A.9. Average CHAQ scores decreased from visit one through five (β= -0.43, 
p= <0.001). Children who reported drinking milk every day had on average less disability and 
discomfort than those who sometimes or never did (β= -0.25, p=0.014). Average JAQQ score 




JAQQ score over the five visits (β=0.26, p= <0.001). Increasing age predicted a higher JAQQ 
score(β= 0.06, p= 0.004).  With respect to the JAQQ scores, the relationship between not taking 
an NSAID and a reduction in average JAQQ score remained (β= -0.4, p=0.018).   Average pain 
reduced with time (β=-1.54, p= <0.001). The average pain score decreased in the spring than in 
the winter (β= -1.25, p=0.014). Younger children also reported less average pain than older 
children (β= 0.13, p=0.028) With respect to the pain score, there was an interaction between milk 
intake and supplement use (p=0.021). On average pain decreased when children reported 
drinking milk every day and not taking a supplement. (β=-0.37); the average pain score increased 
in children who reported drinking milk and taking a supplement every day (β= -0.37+1.92). PGA 
values decreased on average with time (β= -0.74, p=<0.001). The only predictive variables for 
the model were time and ethnicity. Those who identified as non-white (β= 0.56, p=0.016) and 
those who self-identified as Indigenous (β= 0.72, p=0.008) had a higher PGA than those who 
identified as white.  
 
Remission 
When using CRP in the model 25(OH)D did not predict remission on or off medications 
(Table A.10). 25(OH)D predicted remission while a higher pro-inflammatory score predicted 
active disease (β= 0.016, p=0.019) (Table A.11).  Vitamin D associated factors did not predict 
remission in the model for all five time points (Table A.12). 
 
7.4. Discussion 
This prospective inception cohort study is the first to investigate the relationship between 
vitamin D status and JIA from the time of first presentation. Mean 25(OH)D status in Canadian 
children with JIA appears to meet the Endocrine Society optimal concentrations at both baseline 
and after six months of disease (Holick et al., 2011). 25(OH)D and factors that impact vitamin D 
status impact biological markers of disease activity. Vitamin D status was shown to predict 
disease remission when pro- and anti-inflammatory cytokine scores were included in the model 
suggesting that 25(OH)D and associated factors are associated with a reduction in important 




We found that higher 25(OH)D concentrations and factors associated with improving 
vitamin D status predicted a reduction in measures of inflammation. Thus far all previous studies 
but one  have been conducted with participants who were being treated for JIA, many of whom 
were receiving corticosteroids (Szymańska-Kałuża et al., 2013). This cross-sectional study 
compared children newly diagnosed with JIA to children hospitalized due to circulatory system 
functional disorders. The groups of children had statistically similar mean 25(OH)D 
concentrations of 17.35ng/mL which is lower than the optimal 30ng/mL suggested by the 
endocrine society (Holick et al., 2011). No correlation was found between disease activity, JIA 
type or vitamin D metabolite (25(OH)D or 1,25(OH)D. In our recent scoping review, which 
summarized the available literature reporting 25(OH)D concentrations in children with JIA, we 
found that 15 of the  38 studies (39.5%) considered the relationship between vitamin D and 
disease activity (Finch, Rosenberg, & Vatanparast, 2018). Seven studies (46.7%) reported that 
patients with active disease or those with elevated inflammatory biomarkers had lower 25(OH)D 
concentrations than those patients who were in remission or who had less disease activity (Finch 
et al., 2018).    
The impact of 25(OH)D on cytokines has been studied at the cellular level and in other 
disease models (Cutolo et al., 2011; Gubatan et al., 2018; Han, Forno, Boutaoui, Canino, & 
Celedón, 2018; Pappa et al., 2014). This is the first study to explore the association of vitamin D 
with of inflammatory cytokines in children with JIA. Our results suggest that 25(OH)D and 
factors related to vitamin D status prevent inflammation in children with JIA. Further studies are 
required to confirm this relationship. The few studies that have explored the impact of vitamin D 
on cytokines in children have found higher vitamin D status is associated with a reduced 
inflammatory profile (Batmaz, Arikoglu, Tamer, Eskandari, & Kuyucu, 2018; Gubatan et al., 
2018; Han et al., 2018; Pappa et al., 2014). One study exploring the relationship of vitamin D 
with cytokine concentrations in children with inflammatory bowel disease found a lower 
incidence of inflammatory markers and cytokines in children receiving higher doses of vitamin 
D2 (Pappa et al., 2014). In children with ulcerative colitis who were in remission higher vitamin 
D concentrations correlated with a higher anti-inflammatory ratio of IL-4+ IL-10/ IL-17+TNFα 
and IL-4+ IL-10/ IL-6+TNFα suggesting that vitamin D may be protective against relapse 
(Gubatan et al., 2018). Vitamin D insufficiency modified the effect of IL-5 and IL-13 on IgE by 




asthma (Han et al., 2018). Seasonal variations in vitamin D status were also shown to impact 
cytokine concentrations in children with asthma (Batmaz et al., 2018). Like our study, higher 
vitamin D concentrations were associated with lower IL-4. They also found that concentrations 
of IL-10 were significantly lower in the winter than the fall and summer (Batmaz et al., 2018). 
Identifying an association of vitamin D with cytokines that mediate inflammation is an important 
step in understanding the underlying mechanism and clinical implications of vitamin D in 
inflammatory diseases such as JIA. 
There is no single, universally accepted tool to assess JIA outcomes (van Mater, 
Williams, Coeytaux, Sanders, & Kemper, 2012). We used a variety of tools to assess the 
potential for vitamin D status, together with other metrics, to predict JIA outcomes. Plasma 
25(OH)D concentrations did not predict a reduction in composite outcome scores explored in our 
study.  There was a negative relationship between  25(OH)D and PGA. Bouaddi et al. found a 
significant association between a reduction in Disease Activity Score-28 (DAS-28) and 
increasing 25(OH)D as well as the same relationship between the Patient Global Assessment and 
25(OH)D (Bouaddi et al., 2014). Similar to our study, de Sousa et al. found no association 
between 25(OH)D and CHAQ. We did, however, find an association between drinking milk 
every day and predicting a reduction in CHAQ (de Sousa Studart et al., 2015). A further 
understanding of vitamin D’s role in the inflammatory pathway will help to establish the 
appropriate evaluation score to assess its impact on disease activity. 
The most commonly used composite score for disease activity improvement 
measurement is the ARC Pediatric 30 (Giannini et al., 1997). A limitation of the ACR Pediatric 
30 Criteria is that it does not quantify the disease activity of an individual in a way that allows 
for comparison between individuals or JIA categories (Giannini et al., 1997). Due to this 
limitation, we decided to use the remission criteria established by Wallace et al. instead (Wallace 
et al., 2004). Plasma 25(OH)D and associated factors did not predict remission in the model that 
included CRP. The only factors that did were medication use and a reduction in CRP, which are 
part of the remission definition. However, 25(OH)D did predict remission when CRP was 
replaced by the pro- and anti-inflammatory scores in the model.  CRP is a general indicator of 
inflammation and possibly does not fully describe the factors associated with remission. 




indicators exists. This is the first time that 25(OH)D has been explored in the prediction of 
remission and further studies are required to confirm this association. 
 
Limitations  
Some limitations of this study include that there was no individual measurement of sun 
exposure or sunscreen use. We did include the season of measurement in our model as a 
consideration of UVB exposure.  Milk intake was measured by food frequency questionnaire as a 
measure of vitamin D intake instead of through a 24-hour recall;  however, milk is the most 
common source of vitamin D for this age group (Whiting et al., 2011). While an estimated 20% 
of newly diagnosed children with JIA in Canada were recruited to the study, this was not enough 
to explore 25(OH)D by JIA categories with our models. This cohort study also did not have a 
control group for comparison to healthy children; however, we did compare baseline data for age 
and sex-matched  children older than three years who are free of chronic disease from the 
Canadian Health Measures Survey in a previous publication (Finch, Rezaei, Whiting, Rosenberg, 
& Vatanparast, 2017). 25(OH)D, pro- and anti-inflammatory cytokines were only measured at 
two time points and not throughout the entire study. Additionally, we tried to explore if factors 
associated with vitamin D could predict disease activity measured by JIA category, using all 
seven categories, then by inflamed joint count > four and < four. However, there was an 
inadequate sample size for predictions even through bivariate analysis.  
7.5. Conclusion 
Serum 25(OH)D concentrations and factors that influence 25(OH)D status such as season 
and daily milk consumption are associated with measures of disease activity. 25(OH)D predicted 
remission suggesting that it may play a role in suppressing inflammatory-related factors of JIA 
outcomes. Being able to suggest specific targets for vitamin D status as a potential adjunct 
therapy or specific actions to reduce inflammation in the treatment of JIA will enhance the 
quality of life of patients and their families. Intervention studies exploring 25(OH)D and factors 
associated with vitamin D status will help in the development of actionable/ feasible 




Table 7.1. Biomarker measures collected at baseline and 6 month follow up 
Outcome Baseline (mean ± SD) 6 month (mean ± SD) 
Interleukin-1a pg/mL 133.88 ± 708.62   121.81 ± 691.33             
Interleukin-1b pg/mL 134.71 ± 432.51   171.06 ± 478.01             
Interleukin-1ra pg/mL 1462.73 ± 6495.19     2074.51 ± 7892.50             
Interleukin-2 pg/mL 421.64 ± 5191.54   41.33 ± 265.40             
Interleukin-6 pg/mL 76.66 ± 412.22   99.46 ± 695.01             
Interleukin-17 pg/mL 143.91 ± 1290.05   44.20 ± 312.07             
Interferon-ƴ  IU/mL 250.11 ± 2174.51   83.50 ± 476.06             
Tumor necrosis factor-α pg/mL 125.92 ± 1160.66   51.89 ± 231.82             
Pro-Inflammatory Score† 0.48 ± 0.19      0.11 ± 0.24      
Interleukin-4  pg/mL 126.99 ± 686.07   106.46 ± 620.41             
Interleukin-10 pg/mL 142.86 ± 1204.55   61.22 ± 363.62             
Anti-Inflammatory Score† 0.24 ± 0.18      0.35 ± 0.19     
25(OH)D nmol/L 84.48 ± 37.54   84.38 ± 43.68             
Proportion by 25(OH)D  Cut-off Category*, (% ± SD) 
       < 30 nmol/L 3.68 ± 1.48       6.38 ± 2.07       
          30-50 nmol/L 7.36 ± 2.05       11.35 ± 2.68       
          50-75 nmol/L 33.74 ± 3.71       25.53 ± 3.69       
          75-100 nmol/L 33.74 ± 3.71       31.91 ± 3.94       
       >100 nmol/L 21.47 ± 3.23       24.82 ± 3.65       
25(OH)D (25-hydroxyvitamin D), SD (standard deviation), % (percent) 
*Cut-off categories based on the Institute of Medicine categories (Institute of Medicine, 2010) of 
deficient < 30 nmol/L, insufficient 30-50 nmol/L, and sufficient>50nmol/L as well as the 
Endocrinology Society’s definition of optimal >75 nmol/L (Holick et al., 2011). 25(OH)D > 100 
represents a greater risk of adverse events with higher 25(OH)D concentrations (Institute of 
Medicine, 2010)  
† A method of standardization to compare and combine biochemical markers was developed by 
Tabung et al. (Tabung et al., 2015). The standardized values were combined to create the overall 
pro-inflammatory biomarker score (C-Reactive Protein + Tumor Necrosis Factor –α + 
Interleukin (IL)- 6). The same method of standardization was used to calculate an anti-


















Table 7.2. Sociodemographic information of BBOP participants 
Sociodemographic measure (% ± SD) 
Sex,  % (N)  
       Male  31.18 (58)     
       Female  68.82 (128)     
Family Income, (% ± SD)  
       < $50,000/ year  27.21 ± 3.68 
       $50,000- $100,000/year  36.73 ± 3.99 
       >$100,000/year  36.05 ± 3.97 
Ethnicity, (% ± SD)  
       White  71.01 ± 3.50 
       Non-White  17.75 ± 2.95 
       Indigenous  11.24 ± 2.44 
Age (mean ± SD) 9.34 ± 4.78   
Age Category, (% ± SD)  
       0-2 years old  11.83 ± 2.37 
       3-5 years old  30.11 ± 3.37 
       6-8 years old  14.52 ± 2.59 
       9-13 years old  30.11 ± 3.37 
       14-16 years old  28.49 ± 3.32 
Smoker in home, (% ± SD)  
       No %  67.53 ± 3.79 
       Yes %  32.47 ± 3.79 
JIA subtype, (% ± SD)  
       Psoriatic arthritis  6.45 ± 1.81 
       Rheumatoid-factor-negative 
polyarthritis  
34.41 ± 3.49 
       Rheumatoid-factor- positive 
polyarthritis  
9.14 ± 2.12 
       Systemic  14.52 ± 2.59 
       Oligoarthritis  24.19 ± 3.15 
       Undifferentiated  4.30 ± 1.49 







Table 7.3. Variables measured at all-time points 
   Baseline (mean 











 C-Reactive Protein (mean 
± SD) 
 18.40 ± 27.64§  7.89 ± 18.89†   5.28 ± 9.14   6.05 ± 13.08   2.23 ± 3.06† 
 Erythrocyte Sedimentation 
Rate (mean ± SD) 
 29.35 ± 26.58§   16.68 ± 18.77  14.31 ± 15.74  12.39 ± 13.27   10.45 ± 8.65 
Objective and Self-reported Assessments 
 Physician Global 
Assessment (mean ± SD) 
 3.75 ± 2.20§  1.51 ± 1.67†‡   1.15 ± 1.75   0.91 ± 1.60†  0.71 ± 1.54‡ 
 Child Health Assessment 
Questionnaire (CHAQ) 
(mean ± SD) 
 0.82 ± 0.71§     0.43 ± 0.47   0.40 ± 0.50   0.34 ± 0.49   0.41 ± 0.51 
 Pain assessment (mean ± 
SD) 
 4.12 ± 2.78§   2.54 ± 2.72   2.56 ± 2.68   1.75 ± 2.36   1.94 ± 2.89 
 Juvenile Arthritis Quality 
of Life Questionnaire  
(JAQQ) (mean ± SD) 
 3.19 ± 1.60§  2.62 ± 1.26   2.32 ± 1.25   2.29 ± 1.39   2.11 ± 1.30 
 Milk intake (% ± SD)       
  Every day 71.81 ± 3.70       75.97 ± 3.78       76.19 ± 4.18       78.26 ± 4.32       72.06 ± 5.48       
      
Never/sometimes 
     
 Taking a vitamin D 




45.95 ± 4.75 47.52 ± 4.99 43.75 ± 4.71 43.48 ± 4.64 49.54 ± 4.81 
 Season of measure (% ± 
SD) 
      
  Winter 22.58 ± 3.07       21.30 ± 3.16       19.72 ± 3.35       22.13 ± 3.77        
 
 
 Spring 19.89 ± 2.93       34.32 ± 3.66        22.54 ± 3.52       31.15 ± 4.21        
  Summer 27.42 ± 3.28       23.08 ± 3.25      22.54 ± 3.52       24.59 ± 3.91        




 BMI percentiles (mean ± 
SD) 
 54.22 ± 2.35       60.60 ± 2.44      56.96 ± 2.76      54.46 ± 2.79       54.24 ± 3.45       
Prescribed Medications  
 NSAID (% ± SD)  28.50 ± 3.31§§ 32.54 ± 3.61 45.07 ± 4.19† 56.91 ± 4.48 60.22 ± 5.10
† 
 DMAR (% ± SD)  25.27 ± 3.19§ 49.70 ± 3.86 50.00 ± 4.21 52.85 ± 4.52 49.46 ± 5.21 
 Steroids (% ± SD)  26.88 ± 3.26§§ 24.26 ± 3.31 8.45 ± 2.34 11.38 ± 2.88 6.52 ± 2.5 
 Biologics (% ± SD)  32.26 ± 1.30§ 8.28 ± 2.13† 14.79 ± 2.99
‡
 19.51 ± 3.59†
‡
 20.43 ± 4.20 
Remission Category* 
 Active disease (% ± SD)  
96.13 ± 1.44 §§ 68.29 ± 3.64 52.21 ± 4.3 40.34 ± 4.52 39.08 ± 5.26 
 With medication (% ± SD)  3.31 ± 1.33 § 23.78 ± 3.33† 32.35 ± 4.03 39.50 ± 4.50
† 35.63 ± 5.16 
  Without medication (% ± 
SD) 
 
0.55 ± 0.55 § 7.93 ± 2.12
 ʬ  15.44 ± 3.11 20.17 ± 3.69 25.29 ± 4.69 
Continuous variables were analyzed using linear regression and Tukeys post-hoc test. Categorical variable were analyzed using χ2 and 
linear comparison post estimation command for post-hoc testing of significant variables.  
* Remission category defined by criteria proposed by Wallace et al. (Wallace et al., 2004). 
SD (standard deviation), % (percent), BMI (Body Mass Index), NSAID (non-steroidal anti-inflammatory), Biologics (biologically-
based anti-cytokine therapies), Steroids (corticosteroid), DMARD (disease-modifying anti-rheumatic drug)  
§ Superscript indicates statistically significant difference (p<0.05) in baseline value from other time points. 
§§ Superscript indicates baseline and 6-month follow up values statistically similar (p>0.05) with statistically significant difference 
from other time points. 
†‡ Same superscripts indicate statistically significant difference by time point (p<0.05). 




       CHAPTER 8 
OBJECTIVE 3 
 
Vitamin D pathway-related genes relate to the association between 25(OH)D and disease 
activity in children with juvenile idiopathic arthritis 
 
To address objective 3 of this thesis, I evaluated the association between vitamin D 
pathway gene polymorphisms, vitamin D levels, and JIA disease activity. 
 
Abstract 
Background:  Both genetic and environmental factors influence Juvenile Idiopathic Arthritis 
(JIA) development. Factors that influence vitamin D status and their interactions might be 
associated with vitamin D effects on immune and inflammatory responses in children with JIA. 
Objective: To evaluate the association between vitamin D pathway gene polymorphisms, vitamin 
D levels, and JIA disease activity. 
Methods: We analyzed data from the Biologically-Based Outcome Predictors (BBOP) Study, a 
prospective multi-center study of newly diagnosed Canadian children with JIA (n=186). Blood 
samples were obtained at baseline and 6 months follow up, 25(OH)D, CRP, ESR, Interleukin 
(IL)-2, IL-4, IL-1ra, IL-10, IL-6, and TNFα were measured. Vitamin D related factors (milk 
intake, season, supplement and steroid use) and clinical data defining remission (no active 
arthritis, fever, uveitis, normal ESR and CRP, best possible physician’s global assessment score) 
were collected every 6 months for 2 years. Genome-Wide Association Studies (GWAS) 
techniques were applied to identify frequent gene polymorphisms of potential relevance to the 
vitamin D pathway in JIA. Longitudinal analysis explored whether 25(OH)D and related factors 
could predict disease activity in BBOP children. Significant variables from linear regressions, 
genes identified through GWAS, vitamin D pathway genes and gene-gene interactions were 
selected for further analysis.  
Results: GWAS-identified genes were NOTCH4, c6orf9, HLA-DQA1, LEP, IGFBP4, and 
GPS1. When genes were not included in the model there was an inverse association of 25(OH)D 
to  disease activity.  Genes, when included, modified the association between 25(OH)D and 




25(OH)D and disease activity markers.  Drinking milk every day predicted a reduction in 
indicators of disease activity as measured by CRP, ESR, and IL-6.   
Conclusions: A negative association of 25(OH)D and inflammation is influenced by vitamin D-
related genetic polymorphisms. Milk intake, as a source of dietary vitamin D, is associated with 
suppression of inflammation in children with JIA. 
8.1. Introduction 
As with other immune-mediated inflammatory diseases, the pathogenies of JIA  is 
believed to be a consequence of  interaction of  environmental factors with disease susceptibility 
genes (Gowdie, 2012). Vitamin D has been suggested to play a role in JIA development at both 
the environmental (season, sun exposure, dietary intake, medication use) and genetic (vitamin D 
pathway gene polymorphisms) levels (Berkun et al., 2015; Berkun & Padeh, 2010; Ellis et al., 
2010; Ellis et al., 2015; Falcini et al., 2013). Vitamin D is also being explored for its potential to 
suppress inflammation in children with active JIA (Stagi et al., 2014). Low levels of vitamin D 
are implicated as an environmental factor influencing JIA occurrence and course; children with 
JIA tend to have suboptimal vitamin D levels and low vitamin D levels in JIA are associated 
with more active disease (Finch et al., 2018).  It is vitamin D’s influence on gene expression, 
including expression of genes governing immune and inflammatory processes, which may best 
explain vitamin D’s  putative role in the pathogenesis of diseases such as JIA (Cutolo et al., 
2011; Ellis et al., 2015).   
The active form of vitamin D, 1, 25 hydroxyvitamin D (1,250D), influences expression of 
hundreds of genes involved in an array of biologic systems including bone mineralization and 
immune function. (Fuleihan et al., 2015; Holick, 2012).   The action of 1,25OHD is mediated by 
its binding to  VDR in bone,  muscle, immune, intestinal, cardiac and endocrine cells (Haussler 
et al., 1998; Souberbielle et al., 2010). The 1,25(OH)D-liganded VDR dimerizes with nuclear 
RXR.  The VDR-RXR heterodimer  binds to the VDRE of target DNA sequences to turn gene 
transcription  on or off (Jolliffe, Walton, Griffiths, & Martineau, 2016). The influence of 
1,25(OH)D on gene expression and associated cell functions can be modulated by factors that 
determine the body’s vitamin D levels including, as examples, exposure to ultra-violet B 
radiation, dietary intake of vitamin D , use of vitamin D supplements, and certain medications 




expression is influenced by SNPs and epigenetic alteration of genes involved in the vitamin D 
pathway  (Knight, Wong, Cole, Lee, & Parra, 2017; Saccone, Asani, & Bornman, 2015).  
Polymorphisms of the rs11568820 SNP (specifically the GG genotype and G alleles), 
located in the promotor region of  the VDR gene, are more frequent in patients with JIA and are 
hypothesized to be associated with  reduction in VDR activity and a related blunting of response 
to vitamin D (Falcini et al., 2013). The idea of investigating epistasis (gene-gene interactions) 
amongst genes in the inflammatory and vitamin D pathways in the context of JIA was explored 
by Ellis et al. (2015). They reported various  interacting SNPs involving the PTPN2 gene with 
the vitamin D binding protein gene contirbuted to JIA risk ( Ellis et al., 2015). This suggests that 
the role of vitamin D may be through its interaction with the inflammatory pathway. 
Vitamin D’s benefits  as adjunctive therapy to favorably affect disease activity has been 
explored in a variety of immune and inflammatory-mediated disease including,  as examples, 
rheumatoid arthritis, diabetes, asthma, and inflammatory bowel disease  (Hu et al., 2018; 
Ishikawa et al., 2017; Jeffery, Raza, & Hewison, 2015; Kerley, Elnazir, Faul, & Cormican, 2015; 
Tabatabaeizadeh, Tafazoli, Ferns, Avan, & Ghayour-Mobarhan, 2018).  However, to our 
knowledge,  there are no reports of vitamin D’s influence on disease outcomes in the context of  
genes governing the vitamin D pathway.  The objectives of this study were to investiage vitmain 
D pathway gene polymorphisms in JIA and ascertain elements of the vitamin D pathway that 
predict disease activity outcomes in children with JIA.  
8.2. Methods 
8.2.1. Data and Sample Collection  
 
We analyzed data from the Biologically-Based Outcome Predictors (BBOP) in Juvenile 
Idiopathic Arthritis study, a prospective multi-center study of newly diagnosed Canadian 
children with JIA (n=186, aged 1-16 years old). Enrollment criteria included meeting the ILAR 
classification criteria for JIA (Petty et al., 2004), being within six months of disease onset,  
having not been treated previously with DMARDs or biologically-based anti-cytokine therapies  
(biologics),  and consenting to be enrolled in the study.  Each participating institution provided 
ethics approval. 
Demographic and clinical data were collected from December 2007 to December 2012 at 




remission and included variables required for the American College of Rheumatology pediatric 
core set of measures of disease activity (Giannini et al., 1997) including PGA of disease activity, 
acute phase reactants ESR and/or CRP, and the CHAQ-JIA (Giannini et al., 1997). Inactive 
disease (remission) was established using criteria  defined by Wallace et al. (Wallace et al., 
2004) and categorized as remission on medication or remission off medication.  
 Markers of inflammation ESR and CRP were generated by the clinical service 
laboratories in each of the respective participating centers and reported for all time points. Blood 
was collected in P100 tubes (BD Biosciences, San Jose, CA) obtained at baseline and six  and 
the plasma stored at -80oC until assayed for levels of 25(OH)D as previously described (McNally 
et al., 2008), and the following cytokines: IL-2,  IL-4, IL-6, IL-10, and TNFα (Eng et al., 2014) 
(cytokine analysis is described in Chapter 4). Biomarker variables were log transformed for 
statistical analysis because they did not follow normal distribution. Forty-six cytokines were 
analyzed for the BBOP study. We chose to focus on the cytokines listed above because they are 
most commonly listed in the literature as having been explored in participants with JIA or other 
autoimmune diseases and are associated with vitamin D (Cutolo et al., 2011; Dankers et al., 
2017; Hayes et al., 2015). We used a method of standardization developed by Tabung et al. to 
compare inflammatory biomarker concentrations (Tabung et al., 2015). This method takes the 
log-transformed biomarker concentration then computing a z-score for each inflammatory 
biomarker. Tabung et al. combined  (added together) the standardized values for CRP, IL-6, and 
TNFα to create a pro-inflammatory index score (Tabung et al., 2015). Using the same method of 
standardization, we created an anti-inflammatory score that combined the anti-inflammatory 
cytokines IL-4 and IL-10.  
CRP, ESR, vitamin D-related factors (milk consumption, season of measurement, vitamin 
D supplementation, and steroid use) and clinical data to define remission were recorded every six 
months for two years. To assess vitamin D intake over the last month, information on the 
frequency of milk intake (every day, never/sometimes) and vitamin D containing supplement use 
(every day/sometimes, never) were collected.   Medication use was assessed at every time-point 
and categorized by medication class including NSAID, steroid, disease-DMARD, or biologic 
agents. Demographic data included age, sex, family income and self-identified ethnicity. 
At the second visit, a saliva sample was collected for genotyping. DNA was extracted to 




polymorphisms. For the BBOP study single nucleotide polymorphism (SNP) gene testing was 
done using Human 12-sample Immuno BeadChip 11419691 B (Illumina®). The data were 
analyzed using Genome Studio 2011.1. Genetic testing was done at the Genetic Analysis 
Facility, The Centre for Applied Genomics, The Hospital for Sick Children, Toronto. 
Genome-Wide Association Studies (GWAS) were applied to identify SNPs of potential 
relevance to the vitamin D pathway in JIA. GWAS was performed by the University of 
Saskatchewan Bioinformatics Lab. In addition to BBOP, two other genetic datasets were used 
for GWAS. 1) The “Better Outcomes for Children: GWAS from Cincinnati Children's Hospital 
Medical Center (CCHMC) - eMERGE Phase II” dataset (dbGaP Study Accession: 
phs000494.v1.p1).  This dataset includes genotyping data from six cohorts. Cohort D of the 
dataset comprises  Caucasian patients with JIA. The dataset includes 814 JIA cases and 658 
controls of self-reported non-Hispanic European American (EA) ancestry (Thompson et al., 
2012). 2) The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 
healthy control genetic dataset were merged to build a case/control dataset, where BBOP 
samples were used as cases and control samples from the NIDDK Dataset were used as controls. 
PLINK: Whole genome data analysis toolset software version v1.90b4.4 was used for the 
analysis (http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell, Neale, Todd-Brown, Thomas et 
al., 2007).  This approach was used to replicate the results achieved from the analysis of the 
cohort D of the Cincinnati dataset. After applying quality control for these two datasets by 
following the procedure suggested by Anderson et al. (Anderson et al., 2011), there was a small 
overlap between SNPs in these datasets. This was mainly because NIDDK and BBOP used two 
different platforms with a small overlap between their results; therefore, we avoided extracting 
control samples from NIDDK dataset and conducting a case-control study.  
A subset of markers was assembled based on the following criteria: 
 Markers suspected to be involved in JIA extracted from the literature  
 Markers associated with the vitamin D pathway 
Markers extracted from the analysis of the Cincinnati  cohort D, the genotype data were 
extracted for the candidate SNPs for all samples, in the BBOP dataset, that passed the quality 
control procedure. The step-by-step protocol described by Anderson et al. was followed to 





Genetic predictors of disease activity 
Univariate analysis was performed to explore what individual genes identified through 
GWAS as well as genes from the vitamin D pathway (Table 8.1) predict disease activity. Any 
genes identified to have a p<0.05 were included in the full model building process. Next, 
analysis of epistasis of genes identified through GWAS and those in the vitamin D pathway was 
performed. Those with a p-value <0.01 were included in the full model building process. 
Variables that were significant in the previous steps were included in the full model building 
process. 
Environmental, genetic and interactions that predict disease activity 
Linear regressions identified significant gene-environment interactions associated with 
disease activity measures for inclusion in the final model.  Significant variables from linear 
regressions performed in Chapter 7, as well as those genes identified through GWAS, vitamin D 
pathway genes, gene-gene interactions were included in the final analysis to identify what 
environmental and genetic factors associate with disease activity.  
Statistical Analysis 
Descriptive statistics (means and standard deviations for continuous variables and 
percentages for categorical variables) were used to summarize the data at five time-points.  
Multi-Level Mixed-Effects (MLM) Modeling  and backwards methodology with patients set as a 
random effect factor (individual patient change by time/visit number), was utilized to determine 
if there is an association between genes potentially related to the vitamin D pathway and markers 
of inflammation /disease outcomes in the presence of potential covariates, such as 
socioeconomic status, sex, age, ethnicity. The repeated measures across time points had 
unstructured covariance structure. Intreactions with a p-value > 0.01 were not selected for the 
final model to adjust for the increased false discovery rate of multiple comparisons. All vitamin 
D pathway gene*GWAS identified gene interaction and environment*gene interaction were 
explored in the model however only significant interactions are presented in the tables. STATA 








8.3.1. Genome-Wide Association Studies (GWAS) 
 
Genes identified through GWAS were NOTCH4, C6orf10, HLA-DQA1, LEP, IGFBP4, 
GPS1. SNPs and allele frequencies are shown in Table 8.1. Environmental factors influencing 
vitamin D as well as biochemical and remission variables are summarized in Chapter 7.3. 
Multivariate analysis was performed to explore the epistasis of differing polymorphisms of genes 
identified through GWAS and those in the vitamin D pathway found to predict significant 
differences in disease activity measures. All SNPs in Table 8.1 predicted a variation in disease 
activity with the exception of those for LEP rs 2071045 and VDR rs4516035. Additionally, the 
VDR SNP rs3890733 was only significant in the genetics models and not in the gene-
environment models. 
Analysis of both genetic and environmental factors to predict disease activity in children 
with JIA reveals that overall the interaction between differing SPN allelic variations in vitamin D 
pathway genes, IGFBP4, HLA-DQA1 or GPS1 and environmental factors associated with 
vitamin D predict differences in disease activity. While the other GWAS genes predicted gene-
gene interactions, they did not predict significant gene-environment interactions. Interaction 
between 25(OH)D and VDR rs731236, VDR rs7975232, GC, GSP1 or HLA-DQA1 was present 
in a number of inflammatory models ( ESR, IL-1α, IL-2, IL-6) as well as the model that 
predicted remission. 
8.3.2. Genetic Predictors of Disease Activity 
 
Biochemical measures of inflammation 
Differences in the prediction of CRP concentrations based on allelic variation were found 
in the following genetic SNPs and genetic interactions ([variable name] *[variable name] 
represents interaction term): VDR rs4760648, CYP24A1 rs4809959, C6orf10 rs6907322, HLA-
DQA1 rs9272219, IGFBP4 rs584438, VDR rs4760648* IGFBP4 rs584438, CYP24A1 
rs4809959 * IGFBP4 rs584438 (Table 8.2). CRP was also predicted to decrease over the five 
study visits. In comparison to their reference alleles, differences in the prediction of ESR 
concentrations were ovserved in the following genetic SNPs and genetic interactions: VDR 




IGFBP4 rs584438, and CYP24A1 rs4809959 * IGFBP4 rs584438 (Table 8.3). ESR was also 
predicted to decrease over the five study visits.  
 
Pro-Inflammatory Cytokines 
In comparison to their reference alleles, differences in the prediction of IL-1ra 
concentrations were found in the following genetic SNPs and genetic interactions: VDR 
rs11568820, VDR rs4760648, IGFBP4 rs584828, NOTCH4 rs415929, VDR rs4760648 * 
NOTCH4 rs415929, VDR rs11568820* IGFBP4 rs584828, VDR rs2238136* NOTCH4 
rs2071286 (Table 8.4). IL-1ra was not predicted to change over time. Differences in the 
prediction of IL-2 concentrations based on allelic variations were seen in the following genetic 
SNPs and genetic interactions: VDR rs1540339, VDR rs3890733, rs731236, rs7975232, 
CYP24A1 rs2248359, VDR rs1540339 * NOTCH4 rs415929, VDR rs3890733 * IGFBP4 
rs584828, VDR rs7975232 * GPS1 rs9916764, CYP24A1 rs4809959* HLA-DQA1 rs9272219, 
CYP24A1 rs2248359* IGFBP4 rs584438 (Table 8.5). IL-2 concentration did not change over 
time. Predicted IL-6 concentrations differed based on allelic variations in the following genetic 
SNPs and genetic interactions: IL-6 VDR rs1544410, rs4760648, rs2238136, GC rs7041/rs4588, 
IGFBP4 rs584438, GPS1 rs9916764, VDR rs1544410 * GPS1 rs9916764, VDR rs4760648* 
GPS1 rs9916764, VDR rs2238136* IGFBP4 rs584438. IL-6 was predicted to decrease from 
baseline to the first follow-up visit (Table 8.6). Differences in the prediction of TNF-α 
concentrations based on allelic variations were found in the following genetic SNPs and genetic 
interactions: VDR rs731236, VDR rs2238136, CYP24A1 rs4809959, IGFBP4 rs584438, 
CYP24A1 rs4809959* IGFBP4 rs584828. There was no statistically significant difference in 
TNF-α concentration between the two visits (Table 8.7). In comparison to their reference alleles, 
differences in the prediction of the Pro-Inflammatory Index Score were observed in the 
following genetic SNPs and genetic interactions: VDR rs10783219, CYP24A1 rs4809959, 
IGFBP4 rs584828, GPS1 rs9916764, VDR rs1544410 * GPS1 rs9916764, VDR rs10783219* 
GPS1 rs9916764 (Table 8.8). This score significantly decreased between baseline and the six-
month follow-up visit. 
 




Predicted IL-4 concentrations differed based on allelic variations in the following genetic 
SNPs and genetic interactions: VDR rs2238136, IGFBP4 rs584828, VDR rs1544410 * GPS1 
rs9916764 (Table 8.9). There was no statistically significant difference in IL-4 concentrations 
between the two visits. There was differences in the prediction of IL-10 concentrations based on 
allelic variations in the following genetic SNPs and genetic interactions: IGFBP4 rs584828, 
VDR rs7975232* GPS1 rs9916764 (Table 8.10). IL-10 did not change over time. In comparison 
to their reference alleles differences in the prediction of the Anti-Inflammatory Index Score (IL-
10+IL-4) were found in the following genetic SNPs and genetic interactions: VDR rs731236, 
VDR rs7975232, VRD rs2248098, VDR rs2238136, GC rs7041/rs4588, CYP24A1 rs4809959, 
HLA-DQA1 rs9272219, IGFBP4 rs584438, IGFBP4 rs584828, VDR rs11568820 * GPS1 
rs9916764, VDR rs731236* GPS1 rs9916764, 
VDR rs2238136 * NOTCH4 rs2071286, CYP24A1 rs4809959* HLA-DQA1 rs9272219, 
CYP24A1 rs4809959* IGFBP4 rs584438 (Table 8.11). This score did not change between the 
baseline and the six-month follow-up visit.   
 
Remission 
In comparison to their reference alleles, differences in the prediction of achieving 
remission were seen in the following genetic SNPs and genetic interactions: VDR rs10783219, 
CYP24A1 rs2248359, CYP24A1 rs2248359 * NOTCH4 rs415929 (Table 8.12). Achieving 
remission was also predicted to increase over the five study visits. 
8.3.3. Genetic and Environmental Predictors of Disease Activity 
 
Baseline and six-month follow up (first follow-up) 
Biochemical measures of inflammation 
CRP concentrations decreased from baseline to the six-month follow-up (Table 8.13). 
Children who were not prescribed a steroid were predicted to have lower CRP than those that 
were prescribed. Differences in the prediction of CRP concentrations based on allelic variation 
were found in the following genetic SNPs and genetic interactions: VDR rs4760648, VDR 
rs10783219, NOTCH4 rs415929, VDR rs4760648 * NOTCH4 rs415929.  The following gene-
environment interactions were associated with differences in CRP concentrations: Season* VDR 




from baseline by the first follow-up. Significant environmental variables included 25(OH)D, 
Milk Intake and Season. Significant environmental interaction occurred between Milk Intake and 
supplement use. Differences in the prediction of ESR concentrations based on allelic variation 
were seen in the following genetic SNPs and genetic interactions: VDR rs4760648, C6orf10 
rs6907322 HLA-DQA1 rs9272219, IGFBP4 rs584438, VDR rs4760648* IGFBP4 rs584438 
(Table 8.14). The following gene-environment interactions were associated with differences in 
ESR concentrations: 25(OH)D* GPS1 rs9916764 and Season*CYP24A1 rs4809959. 
 
Pro-Inflammatory Cytokines 
There was no difference in IL-1ra between baseline and the first follow-up (Table 8.15). 
Significant environmental variables included 25(OH)D, age (years), use of a steroid or biologic 
agent. There was a significant interaction between 25(OH)D and steroid use. Genes and gene-
gene interactions of significance include VDR rs4760648, VDR rs1544410, VDR rs7975232, 
VDR rs2248098, VDR rs731236, GC rs7041/rs4588, CYP24A1 rs2248359, IGFBP4 rs584828, 
NOTCH4 rs2071286, NOTCH4 rs415929, VDR rs4760648 * NOTCH4 rs415929, VDR 
rs11568820*IGFBP4 rs584828.  Gene-environment interactions that were significant included 
25(OH)D*VDR rs7975232, 25(OH)D*GC rs7041/rs4588, 25(OH)D*VDR rs2248098, Season* 
VDR rs1544410, Season* VDR rs731236, and Season*VDR rs2238136. 
There was no significant reduction in IL-2 from baseline to the six-month follow-up 
(Table 8.16). 25(OH)D, Milk Intake, Vitamin D containing supplement use and Season predicted 
variations in IL-2 concentrations. The genetic factors that predicted differing IL-2 concentrations 
were: VDR rs731236, VDR rs7975232, VDR rs11568820, CYP24A1 rs4809959, CYP24A1 
rs2248359, GC rs7041/rs4588, IGFBP4 rs584438, IGFBP4 rs584828, VDR rs1540339 * 
NOTCH4 rs415929, VDR rs7975232 * GPS1 rs9916764, CYP24A1 rs4809959* HLA-DQA1 
rs9272219, CYP24A1 rs2248359* IGFBP4 rs584438. Gene-environment interactions that 
significantly predicted varying IL-2 were: 25(OH)D *VDR rs731236, 25(OH)D*GC 
rs7041/rs4588, Season* VDR rs1544410, Season* VDR rs7975232, Milk Intake *VDR 
rs11568820 Taking a supplement containing vitamin D * VDR rs4760648, and taking a 
supplement containing vitamin D* CYP24A1 rs2248359. 
IL-6 concentrations did not significantly change over time (Table 8.17). The 




and Season. The following genes and genetic interactions were significant: GC rs7041/rs4588, 
GC rs7041/rs4588 * GPS1 rs9916764. The following gene-environment interactions were 
significant:  25(OH)D*GPS1 rs9916764, Season* VDR rs1544410, Season* VDR rs7975232, 
Season* CYP24A1 rs2248359, Milk Intake*VDR rs1544410, Milk Intake * VDR rs7975232   
TNF-α did not change over time (Table 8.18). There was an association with age (years), 
and Season, as well as the following genetic factors: VDR rs731236, VDR rs11568820, 
CYP24A1 rs4809959, IGFBP4 rs584438, IGFBP4 rs584828, CYP24A1 rs4809959* IGFBP4 
rs584828, The genetic and environmental interactions that predicted differences in TNF-α were: 
Milk Intake *VDR rs11568820, and Season*VDR rs2238136.  
There was a decrease in the pro-inflammatory index score between the baseline and six-
month follow-up visits (Table 8.19). 25(OH)D concentrations, Milk Intake, taking a supplement 
containing vitamin and Season predicted variations in the pro-inflammatory index score. The 
following genes and genetic interactions were significant: VDR rs1544410, VDR rs10783219, 
GPS1 rs9916764, IGFBP4 rs584438.The following gene-environment interactions predicted 
variations in the pro-inflammatory index concentrations:  25(OH)D* GPS1 rs9916764, Season* 
VDR rs7975232, Season* VDR CYP24A1 rs2248359, Season* IGFBP4 rs584438, Milk Intake 
* VDR rs7975232,  and taking a supplement containing vitamin D * GC rs7041/rs4588.  
 
Anti-Inflammatory cytokines 
There was an association with age, sex, and Milk Intake that predicted differenced in IL-4 
concentrations (Table 8.20). In addition, the following genes and genetic interactions were 
significant:  VDR rs1544410, VDR rs2238136, IGFBP4 rs584828, GPS1 rs9916764, VDR 
rs1544410 * GPS1 rs9916764. The following gene-environment interactions were significant: 
Season* VDR rs1544410, Season* GC rs7041/rs4588, Milk Intake * VDR rs7975232. The 
variables that predicted variations in IL-10 were: taking a supplement containing vitamin D, 
Season, VDR rs11568820, CYP24A1 rs2248359, IGFBP4 rs584828, Season* VDR rs731236, 
Season* VDR rs7975232, taking a supplement containing vitamin D * VDR rs11568820 (Table 
8.21). IL-10 also decreased from the baseline to the first follow-up. Age, Milk Intake, and 
Season predicted variations in the anti-inflammatory index score. The following genes and 
genetic interactions were significant: VDR rs731236   VDR rs7975232, VRD rs2248098, VDR 




GPS1 rs9916764, The following gene-environment interactions predicted variations in the anti-
inflammatory index concentrations:  VDR rs11568820* GPS1 rs9916764, VDR rs731236 * 
GPS1 rs9916764, VDR rs2238136* NOTCH4 rs2071286, CYP24A1 rs4809959* HLA-DQA1 
rs9272219, CYP24A1 rs4809959* IGFBP4 rs584438 (Table 8.22). The following gene-
environment interactions were significant: Season* VDR rs7975232, Milk Intake * VDR 
rs11568820, Milk Intake * VDR rs7975232. 
 
Remission 
At the six-month follow-up, a significant number of patients had achieved remission 
(Table 8.23). The following genes and genetic interactions were significant: CYP1R1 
rs17116978, NOTCH4 rs415929, HLA-DQA1 rs9272219, GPS1 rs9916764, CYP1R1 
rs17116978* NOTCH4 rs415929. The following gene-environment interactions were significant: 
25(OH)D*HLA-DQA1 rs9272219, and 25(OH)D*GPS1 rs9916764. 
 
All time points: Baseline to 24-month follow-up 
Biochemical measures of inflammation 
CRP concentrations decreased over the two-year follow-up period (Table 8.24). 
Significant environmental variables included milk intake, using a steroid and having a smoker in 
the home. The following genes and genetic interactions were significant: VDR rs4760648 VDR 
rs10783219, VDR rs4760648*NOTCH4 rs415929, as well as the gene-environmental interaction 
of Season* VDR rs1544410. ESR decreased through the follow-up visits (Table 8.25). 
Significant environmental variables included age, taking a supplement containing vitamin D, and 
Season. Significant environmental interaction occurred between Milk Intake and supplement use.  
There was also a significant interaction of Season*CYP24A1 rs4809959. 
 
Remission 
There was an increase in patients achieving remission over the two-year follow-up period 
(Table 8.26). Significant environmental variables included CRP, taking a supplement containing 
vitamin D, being prescribed an NSAID or biologic. The following genes and genetic interactions 





This is the first study to explore the association of gene, environment and biochemical 
factors in the vitamin D pathway on disease activity and outcomes in children with JIA. None of 
the genes identified through GWAS were direct vitamin D pathway genes. Vitamin D pathway 
genes and their interactions with GWAS identified genes did predict differing disease outcomes 
based on the gene polymorphisms. When the environmental and biochemical information factors 
were added to the statistical models, disease outcomes were modulated by genetic 
polymorphism, milk intake, and 25(OH)D along with key GWAS gene-environment interactions 
and gene-biochemical interactions.   
No direct vitamin D pathway genes were identified through GWAS in this study, 
suggesting that the impact of vitamin D in autoimmune disease is through the impact on 
25(OH)D or the interaction of vitamin D pathway genes with genes identified to be associated 
with JIA. There is evidence of over 100 genes targeted by 1,25(OH)D in immune cells (Maruotti 
& Cantatore, 2010). Understanding the contribution of genes to disease development, treatment 
response and outcome is an important step in the development of personalized medicine and 
furthering our comprehension of molecular pathways (Hersh & Prahalad, 2015). Our GWAS 
found variations in the polymorphisms of HLA-DQA1 between healthy controls and children 
with JIA. This gene has been confirmed to be associated with JIA (Chiaroni-Clarke et al., 2014; 
Hersh & Prahalad, 2015). The other GWAS genes identified in Table 8.1 will require further 
study to validate the association with JIA development.    
Except for the LEP gene, all other genes identified by GWAS were associated with 
differences in selected disease activity measures. Additionally, SNPs of VDR, GC, and 
CYP24A1 were also associated with differing disease activity status in both models including 
only genes and gene-environment. Vitamin D pathway genes have been found both singly and 
collectively to be risk factors for other autoimmune diseases (Jolliffe, Walton, Griffiths, & 
Martineau, 2016; Maruotti & Cantatore, 2010). Interactions between vitamin D pathway genes 
and PTPN2 (rs2542151) a gene confirmed in the heritability of JIA has been explored (Ellis et 
al., 2015). However, this is the first time that this concept has been explored in relation to disease 
outcomes. The identified interactions will need to be confirmed in a validation cohort.  
 Analysis of modifiable and environmental risk factor without the inclusion of genetic 




two GWAS identified genes and between 25(OH)D and genes in the vitamin D pathway over the 
six-month period during which cytokine data was collected. This is the first time that this has 
been explored in JIA. Young et al. found a combined role of vitamin D status and CYP24A1 in 
the transition to Systematic Lupus Erythematosus (SLE) (Young et al., 2016). Where the 
association between the development of SLE and 25(OH)D was modified for each minor allele 
of CYP24A1 rs4809959, increased 25(OH)D concentrations decreased the risk of developing 
SLE in participants who have family member already diagnosed with SLE. While we did not 
find the same association with CYP24A1 rs4809959 as found in the study on SLE, we did find 
the association to be present with another vitamin D pathway gene, the VDR polymorphisms of 
rs7975232 and rs731236 presented such association.   
 Milk intake was also shown to interact with genetic polymorphisms and correlate with 
disease outcomes. Milk, with mandatory fortification in Canada,  is the most common source of 
vitamin D for this age group (Whiting et al., 2011) and suggests an actionable way to improve 
vitamin D concentrations in children with JIA. A systematic review of clinical trials exploring 
dairy product intake and inflammation demonstrated that dairy products might have anti-
inflammatory properties in humans (Bordoni et al., 2017). Our study suggests that genetic factors 
may modify this relationship. 
This is the first study to explore the association of the vitamin D pathway (environmental, 
biochemical and genetic factors) and JIA over time in newly diagnosed individuals. Investigating 
the genetic and environmental role, that vitamin D plays in the prevention and control of JIA in 
the same children helps to tease out the multifaceted role played by vitamin D in this disease.  
 
Limitations 
While this study has many strengths, it has limitations. Limitations include the lack of 
measurement of seasonal sun exposure or sunscreen use. This could explain why we did not see 
the same pattern for the Season of measurement and genetic variables as we did for milk intake. 
This cohort study did not have a control group for comparison to healthy children. To mitigate 
the impact of this we used additional available data for GWAS analysis by exploring two 
additional datasets. 25(OH)D, pro- and anti-inflammatory cytokines were only measured at two 
time-points and not throughout the entire two years of the study. Another limitation is that we 




analysis using the Bonferoni correction.  Instead, we chose to include only interactions with a p-
value < 0.01 to adjust for the increased false discovery rate of multiple comparisons. To explore 
the association of vitamin D in the later time points we used surrogate measures such as Season, 
milk intake and supplement. Our sample size was not large enough to explore 25(OH)D by JIA 
categories with our models. We explored factors associated with vitamin D that could predict 
disease activity measured by JIA category, using all seven categories, then by inflamed joint 
count > four and < four. However, there was an inadequate sample size to perform the analysis 
using MLM even when the participants were divided into two groups for bivariate analysis. 
Investigation of differing environmental and genetic factors impacting individual JIA categories 
will require large multi-country studies. 
8.5. Conclusion 
Genes identified through GWAS (HLA-DQA1, and GPS1) and VRD polymorphisms 
(rs7975232 and rs731236) modified the association between 25(OH)D and indicators of disease 
activity; only certain genotypes maintained the negative association of 25(OH)D and disease 
activity markers. Disease activity measures were also modified by the interaction of milk 
consumption and VDR polymorphisms (rs1544410, rs7975232 and rs11568820) where drinking 
milk in children with certain SNPs of these genes predicted a reduction in indicators of disease 
activity as measured by CRP, ESR, and IL-6. Our findings indicate a negative association of 
25(OH)D and inflammation was modified by vitamin D-related genetic polymorphisms. Milk 
intake as a source of dietary vitamin D, modified by VDR polymorphisms SNPs, was associated 
with suppression of inflammatory markers in children with JIA. Understanding how genetic 
variants interacting with environmental and biochemical factors increase the risk of disease 
development or alter disease outcomes will enhance the quality of life of patients and their 
families. 
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Table 8.1. The allele frequency of genes found through Genome-Wide Association Studies 
(GWAS) and vitamin D pathway genes 
Gene  Single Nucleotide 
Polymorphism  
Allele Frequency (%) 
Vitamin D Pathway Genes 
VDR     
 rs4516035 CC (20.2) CT (39.3) TT (40.5)   
 rs11568820 AA (6.5) AG (31.1) GG (62.5) 
 rs1544410 AA (14.9) AG (49.4) GG (35.7) 
 rs1540339 AA (10.7) AG (43.5) GG (45.8) 
 rs3890733 TT (8.9) TC (38.7) CC (52.4) 
 rs4760648 TT (23.2) TC (50.0) CC (26.8) 
 rs731236 CC (13.7) CT (50.0) TT (36.3) 
 rs7975232 CC (21.7) CA (51.2) AA (27.1) 
 rs2248098 TT (21.0) TC (52.7) CC (26.3) 
 rs10783219 TT (14.9) TA (42.9) AA (42.3) 
 rs2238136 AA (5.4) AG (32.9) GG (61.7) 
GC rs7041/rs4588 TT (19.2) TG (46.7) GG (34.1) 
CYP24A1     
 rs4809959 TT (22.8) TG (53.9) GG (23.3) 
 rs2248359 TT (11.9) TC (49.4) CC38.7 
CYP1R1     
 rs17116978 CC (0.6) CT (7.7) TT (91.7) 
 rs1035798 TT (8.9) TC (44.6) CC (46.4) 
Genes Identified through GWAS 
NOTCH4     
 rs2071286 AA (7.8) AG (41.0) GG (51.2) 
 rs415929 GG (13.7) GA (46.6) AA (40.0) 
C6orf10 rs6907322 AA (3.6) AG (46.7) GG (50.0) 
HLA-DQA1 rs9272219 TT (19.6) TG (42.3) GG (38.1) 
LEP rs2071045 CC (7.7) CT (37.50 TT (54.8) 
IGFBP4     
 rs584438 TT (20.2) TG (48.8) GG (31.0) 










Genetic variables and their interactions 
 
Biochemical measures of inflammation 
 
Table 8.2. SNPs allelic variations and interactions that predict differing C-Reactive Protein 
concentrations 
Variable C-Reactive Protein 
 Coefficient  (95% 
Confidence Interval) 
p-value 
VDR rs4760648, reference value (TT) 
       TC  0.76 ( 0.0 , 1.6 ) 0.062 
       CC  1.61 ( 0.5 , 2.8 ) 0.006 
VDR rs7975232, reference value (CC) 
       CA -0.57 ( -0.9 , -0.2 ) 0.002 
       AA -0.64 ( -1.0 , -0.2 ) 0.002 
VDR rs10783219, reference value (TT) 
       TA -0.38 ( -0.8 , 0.1 ) 0.087 
       AA -0.74 ( -1.2 , -0.3 ) 0.001 
NOTCH4 rs415929, reference value (GG) 
       GA  1.01 ( 0.2 , 1.8 ) 0.01 
       AA  1.77 ( 1.0 , 2.5 ) < 0.001      
VDR rs4760648 * NOTCH4 rs415929, reference value (TT/GG) 
       TC/AA -1.25 ( -2.2 , -0.3 ) 0.012 
       CC/GA -1.49 ( -2.8 , -0.2 ) 0.026 
       CC/AA -2.24 ( -3.5 , -1.0 ) 0.001 
Follow ups -0.39 ( -0.5 , -0.3 ) p < 0.001 
cons  2.22 ( 1.4 , 3.0 ) p < 0.001 
Random Effects  Standard Error 
Participant  0.38 ( 0.2 , 0.8 ) 0.132 
Residual  1.12 ( 1.0 , 1.2 ) 0.0578 
SNP (Single Nucleotide Polymorphism),  












Table 8.3. SNPs allelic variations and interactions that predict differing Erythrocyte 
Sedimentation Rates 
Variable Erythrocyte Sedimentation Rate 
Fixed Effects Coefficient  (95% 
Confidence Interval) 
p-value 
VDR rs4760648, reference value (TT)  
       TC -1.2 ( -1.8 , -0.5 ) 0.001 
       CC -1.0 ( -1.8 , -0.2 ) 0.019 
CYP24A1 rs4809959 TT 
 -0.1 ( -0.9 , 0.6 ) 0.743 
C6orf10 rs6907322, reference value (AA) 
       AG -0.6 ( -1.4 , 0.2 ) 0.114 
       GG -0.9 ( -1.7 , -0.1 ) 0.03 
HLA-DQA1 rs9272219, reference value (TT) 
       TG -0.4 ( -0.8 , -0.1 ) 0.024 
       GG -0.2 ( -0.6 , 0.2 ) 0.265 
IGFBP4 rs584438, reference value (TT) 
       TG -0.6 ( -1.3 , 0.2 ) 0.133 
       GG -1.4 ( -2.2 , -0.6 ) 0.001 
VDR rs4760648* IGFBP4 rs584438, reference value (TT/TT) 
       TC/GG  1.3 ( 0.4 , 2.2 ) 0.003 
       CC/GG  1.4 ( 0.3 , 2.4 ) 0.01 
CYP24A1 rs4809959 * IGFBP4 rs584438, reference value (GG/TT) 
       TT/GG  1.5 ( 0.4 , 2.6 ) 0.008 
Follow ups -0.3 ( -0.3 , -0.2 ) < 0.001 
Constant  4.7 ( 3.7 , 5.8 ) < 0.001 
Random Effects  Standard Error 
Participant  0.6 ( 0.5 , 0.7 ) 0.100 
Residual  0.8 ( 0.8 , 0.9 ) < 0.001 
SNP (Single Nucleotide Polymorphism) 





















Table 8.4. SNPs allelic variations and interactions that predict differing Interleukin-1ra 
concentrations 
Variable Interleukin-1ra 
   
Fixed Effects Coefficient  (95% 
Confidence Interval)  
p-value 
VDR rs2238136, reference value (AA) 
       AG -2.28 ( -6.6 , 2.0 ) 0.298 
       GG -1.69 ( -3.6 , 0.2 ) 0.082 
VDR rs11568820, reference value (AA) 
       AG -3.28 ( -6.4 , -0.2 ) 0.036 
       GG -2.05 ( -4.5 , 0.5 ) 0.108 
VDR rs4760648, reference value (TT) 
       TC -2.37 ( -4.3 , -0.4 ) 0.017 
IGFBP4 rs584828, reference value (AA) 
       AG -5.51 ( -8.7 , -2.3 ) 0.001 
       GG -3.23 ( -6.4 , -0.1 ) 0.046 
NOTCH4 rs415929, reference value (GG) 
       GA -1.89 ( -3.7 , 0.0 ) 0.045 
       AA -1.81 ( -3.7 , 0.1 ) 0.067 
NOTCH4 rs2071286, reference value (AA) 
       AG -2.59 ( -5.4 , 0.2 ) 0.072 
       GG  0.81 ( -0.8 , 2.4 ) 0.316 
VDR rs4760648 * NOTCH4 rs415929, reference value (TT/GG) 
       TC/GA  2.30 ( 0.0 , 4.6 ) 0.046 
       TC/AA  2.96 ( 0.6 , 5.3 ) 0.013 
VDR rs11568820* IGFBP4 rs584828, reference value (AA/AA)  
AG/AG  6.08 ( 2.3 , 9.9 ) 0.002 
AG/GG  4.76 ( 0.9 , 8.6 ) 0.016 
GG/AG  4.34 ( 1.0 , 7.7 ) 0.01 
VDR rs2238136* NOTCH4 rs2071286, reference value (AA/AA) 
       GG/AG  3.15 ( 0.5 , 5.8 ) 0.02 
Follow ups  0.08 ( -0.2 , 0.4 ) 0.621 
Constant  10.22 ( 6.5 , 13.9 ) 0.00 
Random Effects  Standard Error 
Participant   1.42 ( 0.1 , 1.2 ) 1.717 
Residual  1.23 ( 0.1 , 1.1 ) 1.415 
SNP (Single Nucleotide Polymorphism) 








Table 8.5. SNPs allelic variations and interactions that predict differing Interleukin-2 
concentrations 
Variable Interleukin-2 
 Coefficient (95% 
Confidence Interval) 
p-value 
Fixed Effects   
VDR rs1540339, reference value (AA) 
       AG  2.89 ( 0.9 , 4.9 ) 0.005 
       GG  1.21 ( -0.2 , 2.6 ) 0.086 
VDR rs3890733, reference value (TT) 
       TC -1.45 ( -3.8 , 0.9 ) 0.223 
       CC -2.79 ( -5.0 , -0.5 ) 0.015 
VDR rs731236, reference value (CC) 
       CT -1.30 ( -2.3 , -0.3 ) 0.010 
       TT -1.38 ( -2.6 , -0.2 ) 0.022 
VDR rs7975232, reference value (CC) 
       CA -1.31 ( -3.5 , 0.9 ) 0.250 
       AA -1.68 ( -3.2 , -0.2 ) 0.029 
CYP24A1 rs4809959, reference value (TT) 
       TG  0.05 ( -1.5 , 1.6 ) 0.950 
       GG  0.33 ( -1.4 , 2.0 ) 0.709 
CYP24A1 rs2248359, reference value (TT) 
       TC  3.54 ( 1.9 , 5.2 ) < 0.001 
       CC  3.87 ( 2.1 , 5.6 ) < 0.001      
NOTCH4 rs415929, reference value (GG) 
       GA  0.38 ( -1.8 , 2.5 ) 0.733 
       AA  0.43 ( -0.7 , 1.5 ) 0.443 
HLA-DQA1 rs9272219, reference value (TT) 
       TG  0.60 ( -0.9 , 2.1 ) 0.445 
       GG -0.18 ( -1.5 , 1.2 ) 0.793 
IGFBP4 rs584438, reference value (TT) 
       TG  0.62 ( -3.0 , 4.2 ) 0.735 
       GG -0.39 ( -3.3 , 2.5 ) 0.792 
IGFBP4 rs584828, reference value (AA) 
       AG -1.77 ( -4.6 , 1.1 ) 0.223 
       GG (omitted)  
GPS1 rs9916764, reference value (GG) 
       GT -0.98 ( -2.9 , 0.9 ) 0.313 
       TT -0.48 ( -1.8 , 0.9 ) 0.483 
VDR rs1540339 * NOTCH4 rs415929, reference value (AA/GG) 
       AG/GA -2.86 ( -5.4 , -0.4 ) 0.025 
VDR rs3890733 * IGFBP4 rs584828, reference value (TT/AA) 
       CC/AG  2.96 ( 0.3 , 5.6 ) 0.027 
VDR rs7975232 * GPS1 rs9916764, reference value (CC/GG) 




CYP24A1 rs4809959* HLA-DQA1 rs9272219, reference value 
(TT/GG) 
       GG/TT  2.21 ( 0.1 , 4.3 ) 0.036 
CYP24A1 rs2248359* IGFBP4 rs584438, reference value (TT/TT) 
       TC/TG -3.34 ( -5.5 , -1.2 ) 0.002 
       TC/GG -2.56 ( -4.9 , -0.2 ) 0.030 
       CC/TG -3.00 ( -5.1 , -0.9 ) 0.005 
       CC/GG -3.15 ( -5.3 , -1.0 ) 0.005 
Follow ups  0.01 ( -0.2 , 0.2 ) 0.920 
Constant  2.33 ( -1.0 , 5.7 ) 0.175 
Random Effects  Standard Error 
Participant   1.05 ( 0.9 , 1.3 ) 0.092 
Residual  0.67 ( 0.6 , 0.8 ) 0.052 
SNP (Single Nucleotide Polymorphism) 
[variable name] *[variable name] represents interaction term 
 
 
Table 8.6. SNPs allelic variations and interactions that predict differing Interleukin-6 
concentrations 
Variable Interleukin-6 
 Coefficient  (95% 
Confidence Interval) 
p-value 
Fixed Effects   
VDR rs1544410, reference value (AA) 
       AG  3.51 ( 0.9 , 6.2 ) 0.009 
       GG  4.55 ( 1.7 , 7.4 ) 0.002 
VDR rs4760648, reference value (TT) 
       TC -4.31 ( -6.7 , -1.9 ) < 0.001      
       CC -3.64 ( -6.3 , -1.0 ) 0.007 
VDR rs2238136, reference value (AA) 
       AG -2.19 ( -3.8 , -0.6 ) 0.007 
       GG -0.89 ( -2.4 , 0.7 ) 0.260 
GC rs7041/rs4588, reference value (TT) 
       TG 3.37 ( 1.2 , 5.5 ) 0.002 
       GG 4.52 ( 2.1 , 7.0 ) < 0.001      
IGFBP4 rs584438, reference value (TT) 
       TG -1.40 ( -3.5 , 0.7 ) 0.190 
       GG -2.15 ( -4.2 , -0.1 ) 0.036 
GPS1 rs9916764, reference value (GG) 
       GT  4.42 ( 1.7 , 7.1 ) 0.001 
       TT  3.48 ( 0.7 , 6.2 ) 0.014 
VDR rs1544410 * GPS1 rs9916764, reference value (AA/GT) 
       AG/GT -5.17 ( -8.0 , -2.4 ) < 0.001 
       AG/TT -2.85 ( -5.6 , -0.1 ) 0.045 




       GG/TT -3.69 ( -6.7 , -0.7 ) 0.017 
VDR rs4760648* GPS1 rs9916764, reference value (TT/GG) 
       TC/GT  4.90 ( 2.4 , 7.4 ) < 0.001 
       TC/TT  3.81 ( 1.3 , 6.3 ) 0.003 
       CC/GT  3.34 ( 0.5 , 6.1 ) 0.019 
       CC/TT  3.03 ( 0.2 , 5.8 ) 0.035 
VDR rs2238136* IGFBP4 rs584438, reference value (AA/TT)  
       AG/GG  3.16 ( 0.9 , 5.4 ) 0.006 
       GG/GG  2.15 ( 0.0 , 4.3 ) 0.052 
GC rs7041/rs4588* GPS1 rs9916764, reference value (TT/GG)  
       TG/GT -3.42 ( -5.7 , -1.1 ) 0.003 
       TG/TT -3.92 ( -6.3 , -1.6 ) 0.001 
       GG/GT -5.14 ( -7.7 , -2.6 ) < 0.001      
       GG/TT -5.19 ( -7.8 , -2.6 ) < 0.001      
Follow ups -0.29 ( -0.6 , 0.0 ) 0.045 
Constant  1.19 ( -1.6 , 4.0 ) 0.411 
Random Effects  Standard Error 
Participant 0.84 ( 0.6 , 1.1 ) 0.115 
Residual 1.10 ( 1.0 , 1.3 ) 0.074 
SNP (Single Nucleotide Polymorphism) 
[variable name] *[variable name] represents interaction term 
 
 
Table 8.7. SNPs allelic variations and interactions that predict differing Tumor Necrosis Factor-
α (TNF- α) concentrations 
Variable TNF-α 
 Coefficient  (95% 
Confidence Interval) 
p-value 
Fixed Effects   
VDR rs731236, reference value (CC) 
       CT -0.90 ( -1.4 , -0.4 ) < 0.001      
       TT -1.04 ( -1.6 , -0.5 ) < 0.001      
VDR rs2238136, reference value (AA) 
       AG -1.04 ( -1.8 , -0.3 ) 0.007 
       GG -0.60 ( -1.3 , 0.1 ) 0.113 
CYP24A1 rs4809959, reference value (TT) 
       TG -1.59 ( -2.5 , -0.7 ) < 0.001      
       GG -1.19 ( -2.1 , -0.3 ) 0.013 
IGFBP4 rs584438, reference value (TT) 
       TG -0.65 ( -2.3 , 1.0 ) 0.454 
       GG -1.63 ( -2.6 , -0.7 ) 0.001 
 IGFBP4 rs584828, reference value (AA) 
       AG -1.10 ( -2.7 , 0.5 ) 0.191 
CYP24A1 rs4809959*  IGFBP4 rs584828,  reference value (TT/AA) 




GG/GG  2.23 ( 0.9 , 3.6 ) 0.001 
Follow ups  0.11 ( -0.1 , 0.3 ) 0.200 
Constant  5.59 ( 4.5 , 6.7 ) < 0.001      
Random Effects  Standard Error 
Participant   0.87 ( 0.7 , 1.0 ) 0.070 
Residual  0.67 ( 0.6 , 0.8 ) 0.042 
SNP (Single Nucleotide Polymorphism) 




Table 8.8. SNPs allelic variations and interactions that predict differing Pro-Inflammatory Index 
Score† 
 Pro-Inflammatory Index 
Variable Coefficient  (95% 
Confidence Interval) 
p-value 
Fixed Effects   
   
VDR rs1544410, reference value (AA) 
       AG  1.11 ( -1.9 , 4.1 ) 0.465 
       GG  2.31 ( -2.4 , 7.0 ) 0.336 
VDR rs10783219, reference value (TT) 
       TA  4.21 ( 0.9 , 7.5 ) 0.014 
       AA  2.35 ( -1.5 , 6.2 ) 0.227 
CYP24A1 rs4809959, reference value (TT) 
       TG -1.18 ( -2.0 , -0.4 ) 0.005 
       GG -0.81 ( -1.8 , 0.2 ) 0.099 
IGFBP4 rs584828, reference value (AA) 
       AG -1.30 ( -2.2 , -0.4 ) 0.003 
       GG -0.29 ( -1.2 , 0.6 ) 0.543 
GPS1 rs9916764, reference value (GG) 
       GT  5.24 ( 1.0 , 9.5 ) 0.015 
       TT  2.67 ( -1.5 , 6.9 ) 0.214 
VDR rs1544410 * GPS1 rs9916764, reference value (AA/GG)  
       AG/GT -4.06 ( -7.3 , -0.8 ) 0.015 
       AG/TT -0.99 ( -4.2 , 2.2 ) 0.546 
       GG/GT -4.60 ( -9.5 , 0.3 ) 0.067 
       GG/TT -1.58 ( -6.4 , 3.3 ) 0.523 
VDR rs10783219* GPS1 rs9916764, reference value (AA/GG)  
       TA/GT -4.54 ( -8.2 , -0.9 ) 0.015 
       TA/TT -4.89 ( -8.4 , -1.3 ) 0.007 
Follow ups -0.66 ( -1.1 , -0.2 ) 0.006 
Constant  0.44 ( -3.7 , 4.6 ) 0.833 
Random Effects  Standard Error 




Residual  1.36 ( 1.1 , 1.6 ) 0.132 
SNP (Single Nucleotide Polymorphism) 
 
† A method of standardization to compare and combine biochemical markers was developed by 
Tabung et al. (Tabung et al., 2015). The standardized values were combined to create the overall 
pro-inflammatory biomarker score (C-Reactive Protein + Tumor Necrosis Factor –α + 
Interleukin (IL)- 6). The same method of standardization was used to calculate an anti-
inflammatory score to combine the concentrations of cytokines IL-4 and IL-10.   
 





Anti- Inflammatory Cytokines 
 
Table 8.9. SNPs allelic variations and interactions that predict differing Interleukin-4 
concentrations 
Variable Interleukin-4 
 Coefficient (95% 
Confidence Interval) 
p-value 
Fixed Effects   
VDR rs1544410, reference value (AA) 
       AG -1.82 ( -4.1 , 0.4 ) 0.115 
       GG  2.01 ( -0.8 , 4.8 ) 0.164 
VDR rs2238136, reference value (AA) 
       AG -2.14 ( -3.7 , -0.6 ) 0.007 
       GG -0.99 ( -2.5 , 0.5 ) 0.194 
IGFBP4 rs584828, reference value (AA) 
       AG -1.11 ( -1.9 , -0.3 ) 0.005 
       GG -0.27 ( -1.1 , 0.6 ) 0.516 
GPS1 rs9916764, reference value (GG) 
       GT  0.83 ( -1.3 , 2.9 ) 0.443 
       TT -1.63 ( -3.8 , 0.5 ) 0.131 
VDR rs1544410 * GPS1 rs9916764, reference value (AA/GT) 
       AG/TT  3.05 ( 0.4 , 5.7 ) 0.024 
       GG/GT -3.54 ( -6.7 , -0.4 ) 0.028 
Follow ups  0.13 ( -0.1 , 0.4 ) 0.338 
Constant  5.08 ( 2.7 , 7.4 ) < 0.001      
Random Effects  Standard Error 
Participant  1.42 ( 1.2 , 1.7 ) 0.125 
Residual  0.83 ( 0.7 , 1.0 ) 0.069 
SNP (Single Nucleotide Polymorphism) 






Table 8.10. SNPs allelic variations and interactions that predict differing Interleukin-10 
concentrations 
 Interleukin-10 
Variable Coefficient (95% 
Confidence Interval) 
p-value 
Fixed Effects   
VDR rs7975232, reference value (CC) 
       CA -0.56 ( -2.5 , 1.4 ) 0.582 
       AA -0.08 ( -1.8 , 1.6 ) 0.924 
NOTCH4 rs415929, reference value (GG) 
       GA -1.07 ( -2.4 , 0.2 ) 0.111 
       AA  0.76 ( -0.6 , 2.1 ) 0.263 
IGFBP4 rs584828, reference value (AA) 
       AG -0.97 ( -1.6 , -0.4 ) 0.001 
       GG -0.37 ( -1.0 , 0.3 ) 0.247 
GPS1 rs9916764, reference value (GG) 
       GT -1.18 ( -2.7 , 0.4 ) 0.136 
       TT -0.64 ( -1.8 , 0.5 ) 0.267 
VDR rs7975232* GPS1 rs9916764, reference value (CC/GG)  
       AA/GT  2.20 ( 0.8 , 3.6 ) 0.003 
       AA/TT (omitted)  
Follow ups -0.16 ( -0.3 , 0.0 ) 0.057 
Constant  4.09 ( 2.4 , 5.7 ) < 0.001      
Random Effects  Standard Error 
Participant  1.20 ( 0.1 , 1.0 ) 0.086 
Residual  0.60 ( 0.0 , 0.5 ) 0.042 
SNP (Single Nucleotide Polymorphism) 
[variable name] *[variable name] represents interaction term 
 
 
Table 8.11. SNPs allelic variations and interactions that predict a differing Anti-Inflammatory 
Index Score† 
 Anti-Inflammatory Index 
Variable Coefficient (95% 
Confidence Interval) 
p-value 
Fixed Effects   
VDR rs11568820, reference value (AA) 
       AG  0.41 ( -2.6 , 3.5 ) 0.794 
       GG  2.86 ( -0.5 , 6.2 ) 0.096 
VDR rs731236, reference value (CC) 
       CT -4.88 ( -7.4 , -2.4 ) < 0.001      
       TT -6.31 ( -9.8 , -2.9 ) < 0.001      
VDR rs7975232, reference value (CC) 




       AA  2.96 ( 0.8 , 5.1 ) 0.008 
VRD rs2248098, reference value (TT) 
       TC -3.81 ( -5.6 , -2.0 ) < 0.001      
       CC -3.03 ( -5.1 , -1.0 ) 0.003 
VDR rs2238136, reference value (AA) 
       AG -7.52 ( -10.7 , -4.4 ) < 0.001      
       GG -3.16 ( -4.7 , -1.6 ) < 0.001      
GC rs7041/rs4588, reference value (TT) 
       TG -0.84 ( -1.6 , -0.1 ) 0.026 
       GG -0.72 ( -1.6 , 0.1 ) 0.095 
CYP24A1 rs4809959, reference value (TT) 
       TG -0.17 ( -1.7 , 1.4 ) 0.835 
       GG -2.57 ( -4.5 , -0.6 ) 0.010 
NOTCH4 rs2071286, reference value (AA) 
       AG -1.74 ( -4.3 , 0.8 ) 0.183 
       GG -0.47 ( -1.7 , 0.8 ) 0.458 
HLA-DQA1 rs9272219, reference value (TT) 
       TG  1.92 ( 0.4 , 3.5 ) 0.016 
       GG  1.13 ( -0.1 , 2.4 ) 0.070 
IGFBP4 rs584438, reference value (TT) 
       TG -0.46 ( -2.9 , 2.0 ) 0.714 
       GG -2.52 ( -3.9 , -1.2 ) < 0.001      
IGFBP4 rs584828, reference value (AA) 
       AG -2.68 ( -4.8 , -0.6 ) 0.012 
       GG (omitted)  
GPS1 rs9916764, reference value (GG) 
       GT  0.68 ( -1.9 , 3.3 ) 0.608 
       TT -2.53 ( -6.4 , 1.3 ) 0.199 
VDR rs11568820 * GPS1 rs9916764, reference value (AA/GG)  
       AA/GT -4.01 ( -7.6 , -0.4 ) 0.029 
VDR rs731236* GPS1 rs9916764, reference value (CC/GG)  
       CT/GT  3.29 ( 0.5 , 6.1 ) 0.022 
       CT/TT  5.33 ( 2.7 , 8.0 ) < 0.001 
       TT/GT  4.38 ( 0.7 , 8.1 ) 0.019 
       TT/TT  6.05 ( 2.7 , 9.5 ) < 0.001      
VDR rs2238136 * NOTCH4 rs2071286, reference value (AA/AA)  
       AG/AG  4.73 ( 1.1 , 8.3 ) 0.010 
       AG/GG  3.70 ( 1.0 , 6.4 ) 0.007 
CYP24A1 rs4809959* HLA-DQA1 rs9272219, reference value (TT/TT)  
       TG/TG -3.30 ( -5.3 , -1.3 ) 0.001 
       TG/GG -2.19 ( -3.9 , -0.5 ) 0.011 
CYP24A1 rs4809959* IGFBP4 rs584438, reference value (TT/TT)  
       TG/TG  2.85 ( 1.3 , 4.4 ) < 0.001      
       TG/GG  1.91 ( 0.2 , 3.6 ) 0.028 
       GG/TG  3.15 ( 1.2 , 5.1 ) 0.001 




Follow ups  0.11 ( -0.1 , 0.3 ) 0.257 
Constant  7.55 ( 4.1 , 11.0 ) < 0.001      
Random Effects  Standard Error 
Participant  0.98 ( 0.8 , 1.2 ) 0.089 
Residual  0.60 ( 0.5 , 0.7 ) 0.051 
SNP (Single Nucleotide Polymorphism) 
† A method of standardization to compare and combine biochemical markers was developed by 
Tabung et al. (Tabung et al., 2015). The standardized values were combined to create the overall 
pro-inflammatory biomarker score (C-Reactive Protein + Tumor Necrosis Factor –α + 
Interleukin (IL)- 6). The same method of standardization was used to calculate an anti-
inflammatory score to combine the concentrations of cytokines IL-4 and IL-10.   





Table 8.12. SNPs allelic variations and interactions that predict differing Remission Categories 
 Remission Category  
Variable Coefficient  (95% 
Confidence Interval) 
p-value 
Fixed Effects   
VDR rs10783219, reference value (TT) 
       TA  0.22 ( 0.0 , 0.4 ) 0.029 
       AA  0.17 ( 0.0 , 0.4 ) 0.096 
CYP24A1 rs2248359, reference value (TT) 
       TC  0.26 ( -0.3 , 0.8 ) 0.329 
       CC  0.62 ( 0.1 , 1.2 ) 0.021 
NOTCH4 rs415929, reference GG 
       GA  0.03 ( -0.6 , 0.6 ) 0.936 
       AA  0.29 ( -0.3 , 0.8 ) 0.300 
CYP24A1 rs2248359 * NOTCH4 rs415929, reference value (TT/GG)  
       CC/AA -0.75 ( -1.4 , -0.1 ) 0.021 
Follow ups  0.22 ( 0.2 , 0.3 ) < 0.001 
Constant -0.56 ( -1.0 , -0.1 ) 0.016 
Random Effects  Standard Error 
Participant  0.30 ( 0.2 , 0.4 ) 0.031 
Residual  0.51 ( 0.5 , 0.5 ) 0.017 
SNP (Single Nucleotide Polymorphism) 











Full Models, Environmental, Biochemical and Genetic variables as well as Interactions 
 
Baseline and First follow up (6 Months) 
 
Biochemical measures of inflammation 
 
Table 8.13. Environmental, biochemical and genetic factors and their interactions that predict a 
differing C-Reactive Protein concentrations 
Variable C-Reactive Protein 
 Coefficient (95% 
Confidence interval) 
p-value 
25(OH)D 0.10 ( -0.3 , 0.5 ) 0.642 
Season, reference value (Winter) 
       Spring  1.30 ( -0.1 , 2.7 ) 0.063 
       Summer  0.82 ( -0.6 , 2.2 ) 0.255 
       Fall  0.32 ( -0.7 , 1.3 ) 0.546 
Steroid Prescribed, reference value (Yes) 
       No -0.96 ( -1.4 , -0.5 ) < 0.001 
Milk Intake, reference value (Never/sometimes) 
       Everyday  0.64 ( -1.3 , 2.6 ) 0.514 
VDR  rs7975232, reference value (CC) 
       CA  0.27 ( -0.5 , 1.1 ) 0.508 
       AA  0.15 ( -0.8 , 1.1 ) 0.763 
VDR rs1544410, reference value (AA) 
       AG -0.17 ( -1.3 , 0.9 ) 0.754 
       GG -0.93 ( -2.3 , 0.4 ) 0.18 
IGFBP4 rs584438, reference value (TT) 
       TG  0.15 ( -0.3 , 0.6 ) 0.527 
       GG  0.44 ( -0.1 , 1.0 ) 0.095 
VDR rs4760648, reference value (TT) 
       TC  4.54 ( 2.7 , 6.3 ) < 0.001 
       CC  3.66 ( 1.9 , 5.4 ) < 0.001 
VDR rs10783219, reference value (TT) 
       TA  0.06 ( -0.5 , 0.6 ) 0.829 
       AA -0.66 ( -1.2 , -0.1 ) 0.023 
NOTCH4 rs415929, reference value (GG) 
       GA -1.63 ( -3.0 , -0.3 ) 0.018 
       AA -1.98 ( -3.3 , -0.7 ) 0.003 
Season* VDR rs1544410, reference value (Fall*GG) 
       Spring*GA -1.56 ( -2.6 , -0.5 ) 0.005 
Milk Intake*VDR rs1544410, reference value (Every day*AA) 
       Never/sometimes*AG  3.27 ( 1.5 , 5.0 )  < 0.001 
       Never/sometimes*GG  2.65 ( 0.9 , 4.4 )  0.003 
Milk Intake* VDR rs7975232, reference value (Every day* CC) 




VDR rs4760648 * NOTCH4 rs415929, reference value (CC/AA) 
       TT/GA  3.82 ( 1.9 , 5.7 ) < 0.001 
       TT/AA  4.29 ( 2.5 , 6.1 ) < 0.001 
       TC/GG -3.03 ( -4.6 , -1.5 ) < 0.001 
First follow up -0.68 ( -1.1 , -0.3 )  0.001 
Constant  0.18 ( -2.9 , 3.2 ) 0.909 0.909 
Random Effects  Standard Error 
Participant  < 0.001 ( 0.0 , 0.0 ) 4.78E-11 
Residual  0.94 ( 0.8 , 1.1 ) 0.056821 
25(OH)D (25-hydroxyvitamin D), Steroid (corticosteroid)  
[variable name] *[variable name] represents interaction term 
 
 
Table 8.14. Environmental, biochemical and genetic factors and their interactions that predict 
differing Erythrocyte Sedimentation Rates 
Variable Erythrocyte Sedimentation Rate 
 Coefficient (95% 
Confidence interval) 
p-value 
25(OH)D  1.28 ( 0.3 , 2.3 ) 0.011 
Age (years) -0.04 ( -0.1 , 0.0 )  0.050 
Milk Intake, reference value (Never/sometimes) 
       Everyday -0.50 ( -1.0 , 0.0 ) 0.039 
Taking a supplement containing vitamin D, reference value (Never) 
       Every day/Sometimes -0.48 ( -1.1 , 0.1 ) 0.108 
Milk Intake* Taking a supplement containing vitamin D 
       Milk intake every day* 
supplement 
everyday/sometimes 
 0.76 ( 0.1 , 1.4 ) 0.029 
 
Season, reference value (Winter) 
       Spring -0.25 ( -0.7 , 0.2 ) 0.304 
       Summer -0.58 ( -1.1 , -0.1 ) 0.024 
       Fall  0.46 ( -0.1 , 1.0 ) 0.104 
VDR rs4760648, reference value (TT) 
       TC -1.24 ( -2.0 , -0.5 ) 0.002 
       CC -1.19 ( -2.1 , -0.3 ) 0.008 
CYP24A1 rs4809959, reference value (CC)  
       TT  0.07 ( -0.6 , 0.8 ) 0.845 
C6orf10 rs6907322, reference value (AA) 
       AG -1.39 ( -2.3 , -0.5 ) 0.002 
       GG -1.58 ( -2.5 , -0.7 ) < 0.001 
HLA-DQA1 rs9272219, reference value (TT) 
       TG -0.49 ( -0.9 , -0.1 ) 0.021 
       GG -0.38 ( -0.8 , 0.0 ) 0.075 
IGFBP4 rs584438, reference value (TT) 
       TG -0.66 ( -1.4 , 0.1 ) 0.082 




GPS1 rs9916764, reference value (GG) 
       GT  6.96 ( 2.2 , 11.7 ) 0.004 
       TT  2.54 ( -2.2 , 7.2 ) 0.290 
VDR rs4760648* IGFBP4 rs584438, reference value (TT/TT) 
       TC/GG  1.66 ( 0.6 , 2.7 ) 0.001 
       CC/GG  1.52 ( 0.4 , 2.6 ) 0.007 
25(OH)D* GPS1 rs9916764, reference value (25(OH)D*GG) 
       25(OH)D* GT -1.48 ( -2.6 , -0.4 ) 0.008 
Season*CYP24A1 rs4809959, reference value (Winter*CC) 
       Spring*TT  1.15 ( 0.0 , 2.3 ) 0.043 
First follow up -0.59 ( -0.8 , -0.3 ) < 0.001 
Constant  0.76 ( -3.7 , 5.2 ) 0.737 
Random Effects  Standard Error 
Participant  0.51 ( 0.3 , 0.8 ) 0.118 
Residual  0.73 ( 0.6 , 0.9 ) 0.073 
25(OH)D (25-hydroxyvitamin D)  
[variable name] *[variable name] represents interaction term 
 
 
Pro Inflammatory Cytokines 
 
Table 8.15. Environmental, biochemical and genetic variables and their interactions that predict 
differing Interleukin-1ra concentrations 
Variable Interleukin-1ra 
Fixed Effects Coefficient (95% 
Confidence Interval)  
p-value 
25(OH)D  3.44 ( 0.8 , 6.1 ) 0.012 0.012 
Age (years) -0.11 ( -0.2  0.0 ) 0.006 
Milk Intake, reference value (Never/sometimes) 
       Everyday  0.44 ( -0.2  1.1 ) 0.15 
Season, reference value (Winter) 
       Spring -0.29 ( -1.6  1.1 ) 0.672 
       Summer -0.70 ( -1.8  0.4 ) 0.198 
       Fall  0.53 ( -0.9  2.0 ) 0.474 
Steroid Prescribed, reference value (Yes) 
       No -7.60 ( -13.2  -2.0 ) 0.007 
Biologic Prescribed, reference value (Yes) 
       No -1.15 ( -2.2  -0.1 ) 0.027 
25(OH)D* Steroid Prescribed, reference value (25(OH)D*Yes) 
       25(OH)D*No  1.73 ( 0.5  3.0 ) 0.008 
VDR rs2238136, reference value (AA) 
       AG -0.19 ( -2.8  2.4 ) 0.887 
       GG  2.12 ( -0.4  4.6 ) 0.095 
VDR rs11568820, reference value (AA) 
       AG -0.16 ( -2.4  2.1 ) 0.889 




VDR rs4760648, reference value (TT) 
       TC -2.81 ( -5.6  0.0 ) 0.049 
       CC -2.27 ( -4.9  0.3 ) 0.086 
VDR rs1544410, reference value (AA) 
       AG -8.39 ( -14.4  -2.4 ) 0.006 
       GG -4.70 ( -11.0  1.6 ) 0.146 
VDR rs7975232, reference value (CC) 
       CA -67.13 ( -115.3  -18.9 ) 0.006 
       AA -104.95 ( -175.8  -34.1 ) 0.004 
VDR rs10783219, reference value (TT) 
       TA  0.16 ( -0.8  1.1 )  0.748 
       TT  0.49 ( -0.6  1.6 )  0.383 
VDR rs2248098, reference value (TT) 
       TC  68.21 ( 21.0  115.4 ) 0.005 
       CC  106.56 ( 36.6  176.5 ) 0.003 
VDR rs731236, reference value (CC) 
       CT  6.72 ( 0.9  12.5 ) 0.024 
       TT  3.27 ( -2.7  9.3 ) 0.285 
GC rs7041/rs4588, reference value (TT) 
       TG  8.47 ( 2.4  14.6 ) 0.006 
       GG  5.13 ( -1.9  12.1 ) 0.151 
CYP24A1 rs2248359, reference value (TT) 
       TC  16.78 ( 8.1  25.5 ) < 0.001 
       CC  11.55 ( 2.1  21.0 ) 0.016 
IGFBP4 rs584828, reference value (AA) 
       AG -1.64 ( -2.5  -0.8 ) < 0.001 
       GG -0.40 ( -1.4  0.6 ) 0.438 
NOTCH4 rs2071286, reference value (AA) 
       AG  2.15 ( 0.9  3.4 ) 0.001 
       GG  1.32 ( 0.1  2.5 ) 0.035 
NOTCH4 rs415929, reference value (GG) 
       GA -2.14 ( -4.1  -0.1 ) 0.037 
       AA -0.82 ( -2.9  1.3 ) 0.448 
25(OH)D*VDR rs7975232, reference value (25(OH)D*CC) 
       CA  15.30 ( 4.4  26.2 ) 0.005 
       AA  24.63 ( 8.1  41.2 ) 0.003 
25(OH)D*GC rs7041/rs4588, reference value (25(OH)D*TT) 
       25(OH)D*TG -1.83 ( -3.2  -0.4 ) 0.011 
25(OH)D*VDR rs2248098, reference value (25(OH)D*TT) 
       25(OH)D*TC -15.51 ( -26.3  -4.8 ) < 0.001 
Season* VDR rs1544410, reference value (Fall*GG) 
       Spring*AG  7.41 ( 2.5  12.3 ) 0.003 
Season* VDR rs731236, reference value (Fall*TT) 
       Spring*CT -7.48 ( -12.4  -2.5 ) 0.003 
Season*VDR rs2238136, reference value (Summer*GG) 




       Fall*AA  5.06 ( 2.2  7.9 ) < 0.001 
       Winter*AG  2.60 ( 1.1  4.1 ) 0.001 
       Summer* AG  1.84 ( 0.4  3.3 ) 0.013 
First follow up -0.10 ( -0.6  0.4 ) 0.689 
Constant -7.99 ( -21.2  5.2 ) 0.235 
Random Effects  Standard Error 
Participant  0.69 ( 0.4  1.2 ) 0.195   
Residual  1.12 ( 0.9  1.4 ) 0.111      
25(OH)D (25-hydroxyvitamin D), Steroid (corticosteroid), Biologic (biologically-based anti-
cytokine therapie)   




Table 8.16. Environmental, biochemical and genetic factors and their interactions that predict 
differing Interleukin-2 concentrations 
Variable Interleukin-2 
 Coefficient  (95% 
Confidence interval) 
p-value 
25(OH)D  3.12 ( 1.9 , 4.3 ) < 0.001 
Milk Intake, reference value (Never/sometimes) 
       Every day  3.41 ( 2.1 , 4.7 ) < 0.001 
Taking a supplement containing vitamin D, reference value (Never) 
       Every day/Sometimes  1.14 ( 0.2 , 2.1 ) 0.018 
Season, reference value (Winter) 
       Spring -4.16 ( -6.5 , -1.8 ) 0.001 
       Summer -2.83 ( -5.7 , 0.1 ) 0.055 
       Fall -2.16 ( -3.9 , -0.5 ) 0.013 
VDR rs1540339, reference value (AA) 
       AG -0.03 ( -1.4 , 1.3 ) 0.963 0.963 
       GG  0.31 ( -1.0 , 1.6 ) 0.630 0.630 
VDR rs4760648, reference value (TT) 
       TC -0.55 ( -1.3 , 0.2 ) 0.148 
       CC -0.75 ( -1.7 , 0.2 ) 0.126 
VDR rs731236, reference value (CC) 
       CT  6.26 ( 1.1 , 11.5 ) 0.018 
       TT  5.96 ( -0.2 , 12.1 ) 0.056 
VDR rs7975232, reference value (CC) 
       CA  0.17 ( -1.4 , 1.7 ) 0.833 
       AA -2.12 ( -4.0 , -0.2 ) 0.030 
VDR rs1544410, reference value (AA) 
       AG  0.49 ( -2.8 , 3.8 ) 0.775 
       GG  3.50 ( -1.2 , 8.2 ) 0.142 
VDR rs11568820, reference value (AA) 
       AG -1.52 ( -2.8 , -0.2 ) 0.022 




CYP24A1 rs4809959, reference value (TT) 
       TG  0.35 ( -1.8 , 2.5 ) 0.749 
       GG  2.23 ( 0.5 , 4.0 ) 0.013 
CYP24A1 rs2248359, reference value (TT) 
       TC  3.03 ( 1.0 , 5.0 ) 0.003 
       CC  2.83 ( 1.0 , 4.6 ) 0.002 
GC rs7041/rs4588, reference value (TT) 
       TG  5.92 ( 1.2 , 10.6 ) 0.013 
       GG  8.38 ( 3.9 , 12.9 ) < 0.001 
NOTCH4 rs2071286, reference value (AA) 
       AG  0.45 ( -0.8 , 1.7 ) 0.470 
       GG  0.07 ( -1.1 , 1.3 ) 0.913 
HLA-DQA1 rs9272219, reference value (TT) 
       TG -0.41 ( -1.9 , 1.1 ) 0.599 
       GG  1.04 ( -0.6 , 2.7 ) 0.214 
IGFBP4 rs584438, reference value (TT) 
       TG  2.37 ( -0.1 , 4.9 ) 0.061 
       GG -2.30 ( -3.5 , -1.1 ) < 0.001 
IGFBP4 rs584828, reference (AA) 
       AG -4.83 ( -7.0 , -2.7 ) < 0.001 
       GG  (omitted)  
GPS1 rs9916764, reference value (GG) 
       GT  0.56 ( -0.7 , 1.8 ) 0.373 
       TT -0.47 ( -1.8 , 0.9 ) 0.493 
VDR rs1540339 * NOTCH4 rs415929, reference value (GG/AA) 
       AG/GG  2.42 ( 0.6 , 4.224) 0.008 
       AG/GA -2.03 ( -3.3 , -0.769 ) 0.002 
VDR rs7975232 * GPS1 rs9916764, reference value (AA/TT) 
       CA/GT -2.32 ( -3.8 , -0.838 ) 0.002 
CYP24A1 rs4809959* HLA-DQA1 rs9272219, reference value (GG/GT) 
       TG/GG  2.03 ( 0.6 , 3.511 ) 0.007 
25(OH)D *VDR rs731236, reference value (25(OH)D*CC) 
       CT -1.79 ( -2.8 , -0.8 ) 0.001 
       TT -2.47 ( -3.5 , -1.4 ) < 0.001 
25(OH)D*GC rs7041/rs4588, reference value (25(OH)D*TT) 
       TG -1.53 ( -2.6 , -0.5 ) 0.005 
       GG -2.03 ( -3.0 , -1.0 ) < 0.001 
Season* VDR rs1544410, reference value (Fall*GG) 
       Winter*AG -1.44 ( -2.4 , -0.459 ) 0.004 
       Winter*GG -1.94 ( -3.4 , -0.441 ) 0.011 
       Spring*AA  2.62 ( 1.4 , 3.867 ) < 0.001 
       Spring*AG  1.39 ( 0.5 , 2.258 ) 0.002 
Season* VDR rs7975232, reference value (Fall*AA) 
       Spring*CC  2.19 ( 1.1 , 3.243 ) < 0.001 
       Spring*CA  1.15 ( 0.6 , 1.732 ) < 0.001 




       never/sometimes *AG  3.13 ( 1.6 , 4.665 ) < 0.001 
       never/sometimes *GG  3.15 ( 1.8 , 4.510 ) < 0.001 
Taking a supplement containing vitamin D* CYP24A1 rs2248359, reference 
value (Every day/Sometimes*TC) 
       Never*CC  2.04 ( 1.1 , 3.020 ) < 0.001 
First follow up -0.15 ( -0.3 , 0.0 ) 0.065 
Constant -12.47 ( -18.6 , -6.3 ) < 0.001 
Random Effects  Standard Error 
Participant   1.05 ( 0.9 , 1.2 ) 0.085 
Residual  0.28 ( 0.2 , 0.3 ) 0.030 
25(OH)D (25-hydroxyvitamin D)  





Table 8.17. Environmental, biochemical and genetic variables and their interactions that predict 
differing Interleukin-6 concentrations 
Variable Interleukin-6 
 Coefficient (95% 
Confidence 
p-value 
25(OH)D  1.90 ( 0.7 , 3.1 ) 0.002 
Age -0.07 ( -0.1 , 0.0 )  0.027 
Milk Intake, reference value (Never/sometimes) 
       Every day -0.78 ( -3.0 , 1.4 ) 0.483 
Season, reference value (Winter) 
       Spring -3.00 ( -6.9 , 0.9 ) 0.128 
       Summer -0.44 ( -4.7 , 3.9 ) 0.842 
       Fall -0.83 ( -3.7 , 2.1 ) 0.574 
VDR rs1544410, reference value (AA) 
       AG -0.38 ( -1.7 , 1.0 ) 0.585 
       GG  1.77 ( -0.4 , 3.9 ) 0.111 
VDR rs7975232, reference value (CC) 
       CA  1.72 ( -0.1 , 3.5 ) 0.058 
       AA  1.15 ( -0.9 , 3.2 ) 0.272 
CYP24A1 rs2248359, reference value (TT) 
       TC  0.96 ( -0.3 , 2.2 ) 0.140 
       CC  0.52 ( -0.8 , 1.8 ) 0.436 
GC rs7041/rs4588, reference value (TT) 
       TG  2.62 ( -0.1 , 5.3 ) 0.056 
       GG  2.97 ( 0.4 , 5.5 ) 0.022 
GPS1 rs9916764, reference value (GG) 
       GT  3.82 ( -2.4 , 10.1 ) 0.229 
       TT  4.66 ( -1.6 , 10.9 ) 0.146 
GC rs7041/rs4588 * GPS1 rs9916764, reference value (GG*TT)  




25(OH)D*GPS1 rs9916764, reference value (25(OH)D*GG) 
       GT -1.79 ( -3.125 , -0.5 ) 0.009 
       TT -1.76 ( -3.091 , -0.4 ) 0.010 
Season* VDR rs1544410, reference value (Fall*GG) 
       Spring*AA  2.99 ( 1.1 , 4.919 ) 0.002 
Season* CYP24A1 rs2248359, reference value (Fall*CC) 
       Summer*TC -2.04 ( -2.9 , -1.132 ) < 0.001 
Milk Intake*VDR rs1544410, reference value (Every day* AA) 
       Never/sometimes*AG  1.80 ( 0.4 , 3.215 ) 0.013 
Milk Intake * VDR rs7975232, reference value (Every day* CC) 
       never/sometimes *CA -3.03 ( -4.7 , -1.315 ) 0.001 
First follow up -0.22 ( -0.5 , 0.0 ) 0.109 
Constant -5.29 ( -11.3 , 0.7 ) 0.084 
Random Effects  Standard Error 
Participant  1.13 ( 0.943 , 1.361 ) 0.106 
Residual  0.64 ( 0.528 , 0.769 ) 0.061 
25(OH)D (25-hydroxyvitamin D)  
[variable name] *[variable name] represents interaction term 
 
 
Table 8.18. Environmental, biochemical and genetic variables as well as interactions that predict 
a differing Tumor Necrosis Factor (TNF)-α concentrations 
Variable TNF-α 
   
Fixed Effects Coefficient  (95% 
Confidence Interval)  
p-value 
Age  -0.06 ( -0.1 , 0.0 ) 0.005 
Milk Intake, reference value (never/sometimes) 
       Every day  1.16 ( 0.0 , 2.3 ) 0.052 
Season, reference value (Winter) 
       Spring  1.51 ( 0.3 , 2.8 ) 0.018 
       Summer -0.39 ( -1.9 , 1.1 ) 0.613 
       Fall  1.55 ( 0.5 , 2.6 ) 0.004 
VDR rs731236, reference value (CC) 
       CT -0.94 ( -1.4 , -0.5 ) < 0.001 
       TT -0.90 ( -1.4 , -0.4 ) 0.001 
VDR rs2238136, reference value (AA) 
       AG -0.22 ( -1.2 , 0.7 ) 0.657 
       GG  0.27 ( -0.7 , 1.2 ) 0.573 
VDR rs11568820, reference value (AA) 
       AG  0.55 ( -0.7 , 1.8 ) 0.388 
       GG  1.23 ( 0.1 , 2.4 ) 0.035 
CYP24A1 rs4809959, reference value (TT) 
       TG -1.48 ( -2.4 , -0.6 ) 0.001 




IGFBP4 rs584438, reference value (TT) 
       TG -0.84 ( -2.4 , 0.8 ) 0.307 
       GG -1.58 ( -2.5 , -0.6 ) 0.001 
 IGFBP4 rs584828, reference value (AA) 
       AG -1.03 ( -2.6 , 0.5 ) 0.186 
CYP24A1 rs4809959*  IGFBP4 rs584828,  reference value (TT/AA) 
       TG/AG  1.68 ( 0.6 , 2.736 ) 0.002 
       GG/GG  2.34 ( 1.0 , 3.633 ) < 0.001 
Season*VDR rs2238136, reference value (Winter*AA) 
       Fall*AG -1.64 ( -2.8 , -0.440 ) 0.007 
First follow up  0.15 ( 0.0 , 0.3 ) 0.112 
Constant  4.06 ( 2.4 , 5.7 ) < 0.001 
Random Effects  Standard Error 
Participant  0.80 ( 0.7 , 1.0 ) 0.072 
Residual  0.57 ( 0.5 , 0.7 ) 0.045 
[variable name] *[variable name] represents interaction term 
 
 
Table 8.19. Environmental, biochemical and genetic variables as well as interactions that predict 
differing Pro-Inflammatory Index Scores† 
Variable Pro-Inflammatory Index 
 Coefficient  (95% 
Confidence 
p-value 
25(OH)D  4.54 ( 2.8 , 6.3 ) < 0.001 
Milk Intake, reference value (Never/sometimes) 
       Every day -2.00 ( -3.6 , -0.4  )  0.015 
Taking a supplement containing vitamin D, reference value (Never) 
       Every day/Sometimes -1.92 ( -3.8 , 0.0 ) 0.046 
Season, reference value (Winter) 
       Spring  6.31 ( 2.7 , 9.9 ) 0.001 
       Summer  7.75 ( 4.0 , 11.5 ) < 0.001 
       Fall  4.00 ( 0.9 , 7.1 ) 0.012 
VDR rs1544410, reference value (AA) 
       AG -3.18 ( -4.7 , -1.6 ) < 0.001 
       GG -2.29 ( -4.1 , -0.4 ) 0.015 
VDR rs797523,2 reference value (CC) 
       CA  0.71 ( -1.0 , 2.4 ) 0.422 
       AA -1.55 ( -3.7 , 0.6 ) 0.155 
VDR rs10783219, reference value (TT) 
       TA -1.20 ( -2.4 , 0.0 ) 0.052 
       AA -1.41 ( -2.7 , -0.2 ) 0.027 
GC rs7041/rs4588, reference value (TT) 
       TG  0.96 ( -0.5 , 2.4 ) 0.206 




CYP24A1 rs4809959, reference value (TT) 
       TG  1.19 ( -0.6 , 2.9 ) 0.182 
       GG  0.93 ( -0.9 , 2.8 ) 0.332 
GPS1 rs9916764, reference value (GG) 
       GT  17.83 ( 9.5 , 26.2 ) < 0.001 
       TT  21.16 ( 12.2 , 30.1 ) < 0.001 
IGFBP4 rs584438, reference value (TT) 
       TG -2.02 ( -3.4 , -0.6 ) 0.006 
       GG -1.27 ( -2.7 , 0.1 ) 0.078 
25(OH)D* GPS1 rs9916764, reference value (25(OH)D*GG) 
       GT -4.20 ( -6.1 , -2.3 ) < 0.001 
       TT -5.12 ( -7.1 , -3.1 ) < 0.001 
Season* VDR rs7975232, reference value (Fall*AA) 
       Winter*AA  4.01 ( 1.6 , 6.4 ) 0.001 
       Summer*CC -3.71 ( -6.3 , -1.1 ) 0.006 
       Summer*CA -2.89 ( -4.6 , -1.2 ) 0.001 
Season* CYP24A1 rs2248359, reference value (Fall*CC) 
       Spring*TC -1.82 ( -3.2 , -0.4 ) 0.011 
Season* IGFBP4 rs584438, reference value (Fall*GG) 
       Summer*TT -3.31 ( -5.2 , -1.4 ) 0.001 
Milk Intake * VDR rs7975232, reference value (Every day *CC value 
       never/sometimes *AA -3.89 ( -5.8 , -2.0 ) < 0.001 
Taking a supplement containing vitamin D * GC rs7041/rs4588, reference value 
(Every day/Sometimes*TT) 
       Never*TG -2.99 ( -5.0 , -1.0 ) 0.004 
First follow up -0.72 ( -1.3 , -0.2 ) 0.008 
Constant -14.58 ( -22.9 , -6.3 ) 0.001 
Random Effects  Standard Error 
Participant  1.63 ( 1.3 , 2.0 ) 0.160 
Residual  0.54 ( 0.4 , 0.8 ) 0.096 
25(OH)D (25-hydroxyvitamin D)  
† A method of standardization to compare and combine biochemical markers was developed by 
Tabung et al. (Tabung et al., 2015). The standardized values were combined to create the overall 
pro-inflammatory biomarker score (C-Reactive Protein + Tumor Necrosis Factor –α + 
Interleukin (IL)- 6). The same method of standardization was used to calculate an anti-
inflammatory score to combine the concentrations of cytokines IL-4 and IL-10.   















Table 8.20. Environmental, biochemical and genetic variables as well as interactions that predict 
differing Interleukin-4 concentrations 
Variable Interleukin-4 
 Coefficient (95% 
Confidence 
p-value 
Age -0.13 ( -0.2 , -0.1 ) < 0.001 
Sex, reference value (Male) 
       Female  0.90 ( 0.2 , 1.6 ) 0.009 
Season, reference value (Winter) 
       Spring -1.91 ( -4.136 , 0.3 ) 0.094 
       Summer -1.73 ( -4.324 , 0.9 ) 0.190 
       Fall -1.52 ( -3.563 , 0.5 ) 0.143 
Milk Intake, reference value (Never/sometimes) 
Every day -1.75 ( -3.015 , -0.5 )  0.007 
VDR rs7975232, reference value (CC) 
       CA  0.06 ( -1.191 , 1.3 ) 0.928 
       AA  0.12 ( -1.520 , 1.8 ) 0.890 
VDR rs1544410, reference value (AA) 
       AG  3.99 ( 0.8 , 7.1 ) 0.013 
       GG  3.51 ( 0.5 , 6.5 ) 0.021 
VDR rs2238136, reference value (AA) 
       AG -1.67 ( -3.1 , -0.3 ) 0.017 
       GG -0.64 ( -1.9 , 0.7 ) 0.332 
GC rs7041/rs4588, reference value (TT) 
       TG -0.11 ( -1.485 , 1.3 ) 0.880 
       GG -0.49 ( -1.9 , 0.9 ) 0.501 
IGFBP4 rs584828, reference value (AA) 
       AG -0.83 ( -1.5 , -0.1 ) 0.020 
       GG -0.16 ( -0.9 , 0.6 ) 0.669 
GPS1 rs9916764, reference value (GG) 
       GT -2.94 ( -5.2 , -0.7 ) 0.011 
       TT -3.67 ( -6.1 , -1.2 ) 0.003 
VDR rs1544410 * GPS1 rs9916764, reference value (GG*TT) 
       AG/GG -5.85 ( -8.6 , -3.102 ) < 0.001 
Season* VDR rs1544410, reference value (Fall*GG) 
       Winter*GG -2.54 ( -4.4 , -0.656 ) 0.008 
       Summer*AA  2.81 ( 1.0 , 4.591 ) 0.002 
Season* GC rs7041/rs4588, reference value (Fall*GG) 
       Summer*TG -1.66 ( -2.9 , -0.446 ) 0.007 
Milk Intake * VDR rs7975232, reference value (Every day *CC) 
       never/sometimes *CA -2.18 ( -3.7 , -0.671 ) 0.005 
       never/sometimes *AA -2.65 ( -4.2 , -1.119 ) 0.001 
First follow up  0.04 ( -0.3 , 0.4 )  0.811 




Random Effects  Standard Error 
Participant  1.07 ( 0.8 , 1.3 ) 0.124 
Residual  0.75 ( 0.6 , 0.9 ) 0.082 
[variable name] *[variable name] represents interaction term 
 
 
Table 8.21. Environmental, biochemical and genetic factors and their interactions that predict 
differing Interleukin-10 concentrations 
Variable Interleukin-10 
 Coefficient (95% 
Confidence 
p-value 
Taking a supplement containing vitamin D, reference value (Never) 
       Every day/Sometimes -2.65 ( -4.9 , -0.4 ) 0.021 
Season, reference value (Winter) 
       Spring -2.87 ( -5.4 , -0.4 ) 0.025 
       Summer -3.18 ( -6.0 , -0.4 ) 0.027 
       Fall -1.65 ( -3.5 , 0.2 ) 0.074 
Annual Household Income, reference value (>$51,000) 
       $51,000 – 99,999  0.41 ( -0.2 , 1.0 ) 0.198 
       > $100,000  0.41 ( -0.2 , 1.0 ) 0.183 
VDR rs7975232, reference value (CC) 
       CA  0.28 ( -0.9 , 1.5 ) 0.7 0.655 
       AA  0.62 ( -0.8 , 2.1 ) 0.4 0.401 
VDR rs11568820, reference value (AA) 
       AG  2.21 ( 0.4 , 4.0 ) 0.015 
       GG  2.72 ( 1.0 , 4.5 ) 0.002 
VDR rs731236, reference value (CC) 
       CT  0.52 ( -0.7 , 1.7 ) 0.397 
       TT  1.34 ( -0.3 , 3.0 ) 0.106 
CYP24A1 rs2248359, reference value (TT) 
       TC  0.95 ( 0.2 , 1.7 ) 0.018 
       CC  0.96 ( 0.2 , 1.8 ) 0.018 
IGFBP4 rs584828, reference value (AA) 
       AG -1.07 ( -1.7 , -0.5 ) < 0.001 
       GG -0.50 ( -1.1 , 0.1 ) 0.126 
Season* VDR rs731236, reference value (Fall*TT) 
       Winter*CT -1.75 ( -3.1 , -0.4 ) 0.009 
       Winter*TT -2.56 ( -4.2 , -0.9 ) 0.002 
       Summer*CC  2.83 ( 1.1 , 4.5 ) 0.001 
First follow up -0.20 ( -0.4 , 0.0 ) 0.044 
Constant  2.99 ( 0.6 , 5.4 ) 0.013 
Random Effects  Standard Error 
Participant  1.10 (0.9 , 1.3) 0.088 
Residual  0.44 (0.4 , 0.5) 0.038 





Table 8.22. Environmental, biochemical and genetic factors and their interactions that predict 
differing Anti-Inflammatory Index Scores† 
Variable Anti-Inflammatory Index 
 Coefficient (95% 
Confidence 
p-value 
Age -0.08 ( -0.1 , 0.0 ) 0.005 
Milk Intake, reference 
never/sometimes 
  
Every day  1.16 ( -0.9 , 3.2 ) 0.267 
Season, reference value (Winter) 
       Spring  2.07 ( 0.7 , 3.5 ) 0.004 
       Summer  2.89 ( 1.5 , 4.3 ) < 0.001 
       Fall  1.94 ( 0.7 , 3.2 ) 0.002 
VDR rs11568820, reference value (AA) 
       AG  2.60 ( -0.3 , 5.5 ) 0.077 
       GG  2.49 ( -0.3 , 5.3 ) 0.078 
VDR rs731236, reference value (CC) 
       CT -6.93 ( -9.9 , -3.9 ) < 0.001 
       TT -7.85 ( -10.7 , -5.0 ) < 0.001 
VDR rs7975232, reference value (CC) 
       CA  5.71 ( 3.6 , 7.9 ) < 0.001 
       AA  6.06 ( 3.0 , 9.1 ) < 0.001 
VRD rs2248098, reference value (TT) 
       TC -5.48 ( -7.4 , -3.6 ) < 0.001 
       CC -6.52 ( -9.2 , -3.9 ) < 0.001 
VDR rs2238136, reference value (AA) 
       AG -4.59 ( -6.0 , -3.2 ) < 0.001 
       GG -3.63 ( -5.0 , -2.3 ) < 0.001 
GC rs7041/rs4588, reference value (TT) 
       TG -0.95 ( -1.6 , -0.3 ) 0.004 
       GG -0.46 ( -1.2 , 0.3 ) 0.218 
CYP24A1 rs4809959, reference value (TT) 
       TG -5.14 ( -7.3 , -3.0 ) < 0.001 
       GG -2.41 ( -4.1 , -0.7 ) 0.005 
NOTCH4 rs415929, reference value (GG) 
       GA  0.30 ( -0.8 , 1.4 ) 0.581 
       AA  0.18 ( -0.9 , 1.3 ) 0.745 
HLA-DQA1 rs9272219, reference value (TT) 
       TG -0.58 ( -1.9 , 0.8 ) 0.398 
       GG  1.00 ( -0.4 , 2.4 ) 0.148 
IGFBP4 rs584828, reference value (AA) 
       AG  3.35 ( 1.4 , 5.3 ) 0.001 
       GG  2.46 ( 1.3 , 3.6 ) < 0.001 
IGFBP4 rs584828, reference value (AA) 
       AG -2.70 ( -4.5 , -0.9 ) 0.003 




GPS1 rs9916764, reference value (GG) 
       GT  2.33 ( 0.3 , 4.4 ) 0.028 
       TT  1.89 ( -0.3 , 4.1 ) 0.090 
VDR rs11568820* GPS1 rs9916764, reference value (GG/TT)  
       AG/GT  1.65 ( 0.5 , 2.8 ) 0.005 
VDR rs731236 * GPS1 rs9916764, reference value (TT/TT)  
       CC/GT -7.00 ( -10.3 , -3.7 ) < 0.001 
       CC/TT -6.96 ( -10.0 , -4.0 ) < 0.001 
CYP24A1 rs4809959* HLA-DQA1 rs9272219, reference value (GG/GG)  
       TT/TG  2.68 ( 0.8 , 4.6 ) 0.006 
CYP24A1 rs4809959* IGFBP4 rs584438, reference value (GG/GG)  
       TT/TG -3.46 ( -5.1 , -1.8 ) < 0.001 
       TT/GG -4.97 ( -6.7 , -3.3 ) < 0.001 
       TG/TT  3.31 ( 1.9 , 4.7 ) < 0.001 
Season* VDR rs7975232, reference value (Fall*AA) 
       Winter*AA  2.23 ( 0.7 , 3.7 ) 0.003 
Milk Intake * VDR rs11568820, reference value (Every day *AA) 
       never/sometimes *AG  1.55 ( -0.3 , 3.4 ) 0.103 
       never/sometimes *GG  3.10 ( 1.2 , 5.0 ) 0.001 
Milk Intake * VDR rs7975232, reference value (Every day *CC) 
       never/sometimes *CA -2.53 ( -3.7 , -1.4 ) < 0.001 
       never/sometimes *AA -1.81 ( -3.0 , -0.6 ) 0.004 
First follow up  0.04 ( -0.2 , 0.3 ) 0.768 
Constant  6.37 ( 3.2 , 9.5 ) < 0.001 
Random Effects  Standard Error 
Participant  0.69 ( 0.5 , 0.9 ) 0.089 
Residual  0.53 ( 0.4 , 0.7 ) 0.059 
† A method of standardization to compare and combine biochemical markers was developed by 
Tabung et al. (Tabung et al., 2015). The standardized values were combined to create the overall 
pro-inflammatory biomarker score (C-Reactive Protein + Tumor Necrosis Factor –α + 
Interleukin (IL)- 6). The same method of standardization was used to calculate an anti-
inflammatory score to combine the concentrations of cytokines IL-4 and IL-10.   



















Table 8.23. Environmental, biochemical and genetic factors and their interactions that predict 
differing Remission Categories 
 Remission Category  
Variable Coefficient (95% 
Confidence interval) 
p-value 
Fixed Effects   
C-Reactive Protein -0.04 ( -0.1 , 0.0 ) 0.094 
25(OH)D  0.48 ( 0.0 , 0.9 ) 0.047 
NSAID Prescribed, reference value (Yes) 
       No  0.12 ( 0.0 , 0.2 ) 0.050 
CYP1R1 rs17116978, reference value (CC) 
       CT  0.35 ( -0.1 , 0.8 ) 0.122 
       TT  0.43 ( 0.0 , 0.9 ) 0.046 
NOTCH4 rs415929, reference value (GG) 
       GA -0.33 ( -0.6 , -0.1 ) 0.016 
       AA -0.25 ( -0.5 , 0.0 ) 0.057 
HLA-DQA1 rs9272219, reference value (TT) 
       TG -1.34 ( -2.6 , -0.1 ) 0.040 
       GG -1.23 ( -2.5 , 0.1 ) 0.061 
GPS1 rs9916764, reference GG 
       GT  3.44 ( 1.5 , 5.4 ) 0.001 
       TT  2.56 ( 0.7 , 4.4 ) 0.007 
25(OH)D*HLA-DQA1 rs9272219, reference value (25(OH)D*TT) 
       25(OH)D*TG  0.31 ( 0.0 , 0.6 ) 0.038 
25(OH)D*GPS1 rs9916764, reference value (25(OH)D*GG) 
       25(OH)D*GT -0.81 ( -1.3 , -0.4 ) < 0.001 
       25(OH)D*TT -0.60 ( -1.0 , -0.2 ) 0.006 
First follow up  0.33 ( 0.2 , 0.4 ) < 0.001 
Constant -2.43 ( -4.5 , -0.3 ) 0.023 
Random Effects  Standard Error 
Participant < 0.001 ( 0.0 , 0.0 ) < 0.001 
Residual  0.35 ( 0.3 , 0.4 ) 0.019 
   
25(OH)D (25-hydroxyvitamin D)  













Baseline through 24 months follow ups 
 
Biochemical measures of inflammation 
 
Table 8.24. Environmental and genetic factors and their interactions that predict differing C-
Reactive Protein concentrations 
Variable C-Reactive Protein  
 Coefficient (95% 
Confidence interval) 
p-value 
Milk Intake, reference value (never/sometimes) 
       Every day -0.39 ( -0.7 , -0.1 ) 0.016 
Steroid Prescribed, reference value (Yes) 
       No -0.68 ( -1.0 , -0.3 ) < 0.001 
Season, reference value (Winter) 
       Spring  0.43 ( -0.7 , 1.6 ) 0.461 
       Summer -0.62 ( -1.8 , 0.5 ) 0.291 
       Fall  0.02 ( -0.9 , 1.0 ) 0.969 
Smoker in home, reference value (No) 
Yes  0.45 ( 0.1 , 0.7 ) 0.003 
VDR rs1544410, reference value (AA) 
       AG  0.45 ( -0.4 , 1.3 ) 0.275 
       GG  0.54 ( -0.3 , 1.3 ) 0.193 
VDR rs4760648, reference value (TT) 
       TC  1.84 ( 0.6 , 3.1 ) 0.003 
       CC  1.50 ( 0.4 , 2.6 ) 0.010 
VDR rs10783219, reference value (TT) 
       TA -0.22 ( -0.6 , 0.2 ) 0.292 
       AA -0.63 ( -1.0 , -0.2 ) 0.003 
NOTCH4 rs415929, reference value (GG) 
       GA -0.42 ( -1.4 , 0.5 ) 0.388 
       AA -0.51 ( -1.4 , 0.4 ) 0.274 
VDR rs4760648 * NOTCH4 rs415929, reference value (CC/AA)  
       TT/AA  2.16 ( 0.9 , 3.4 ) 0.001 
Season* VDR rs1544410, reference value (Fall*GG) 
       Spring*AG -0.96 ( -1.8 , -0.1 ) 0.025 
Follow ups -0.33 ( -0.4 , -0.2 ) < 0.001 
Constant  2.02 ( 0.8 , 3.2 ) 0.001 
Random Effects  Standard Error 
Participant  < 0.001 ( 0.0 , 0.0 ) < 0.001 
Residual  1.06 ( 1.0 , 1.2 ) 0.048 








Table 8.25. Environmental and genetic factors and their interactions that predict differing 
Erythrocyte Sedimentation Rates 
Variable Erythrocyte Sedimentation Rate 
 Coefficient  
 (95% Confidence interval) 
p-value 
Age (years) -0.03 ( -0.1 , 0.0 ) 0.043 
Milk Intake, reference value (Never/sometimes) 
       Every day -0.34 ( -0.7 , 0.0 ) 0.062 
Taking a supplement containing vitamin D, reference Never 
       Every day/Sometimes  0.37 ( 0.1 , 0.6 ) 0.006 
Season, reference value (Winter) 
       Spring -0.44 ( -1.4 , 0.5 ) 0.361 
       Summer -0.51 ( -1.5 , 0.5 ) 0.301 
       Fall  0.19 ( -0.7 , 1.0 ) 0.666 
Milk Intake* Taking a supplement containing vitamin D 
       Never/sometimes drink 
milk*never take a supplement 
-0.66 ( -1.2 , -0.2 ) 0.010 
VDR rs4760648, reference value (TT) 
       TC -1.14 ( -2.2 , -0.1 ) 0.034 
       CC -1.31 ( -2.2 , -0.4 ) 0.003 
CYP24A1 rs2248359, reference value (TT) 
       TG  0.41 ( -0.7 , 1.5 ) 0.481 
       GG  0.53 ( -0.5 , 1.5 ) 0.301 
C6orf10 rs6907322, reference value (AA) 
       AG -0.69 ( -1.4 , 0.0 ) 0.067 
       GG -0.82 ( -1.6 , -0.1 ) 0.030 
HLA-DQA1 rs9272219, reference value (TT) 
       TG -0.51 ( -0.9 , -0.1 ) 0.006 
       GG -0.29 ( -0.7 , 0.1 ) 0.132 
IGFBP4 rs584438, reference value (TT) 
       TG  0.37 ( -0.5 , 1.2 ) 0.379 
       GG -0.06 ( -0.9 , 0.8 ) 0.890 
GPS1 rs9916764, reference value (GG) 
       GT  0.65 ( 0.2 , 1.1 ) 0.005 
       TT  0.45 ( 0.0 , 0.9 ) 0.052 
VDR rs4760648* IGFBP4 rs584438, reference value (TT/TT) 
       TT/TG -1.51 ( -2.6 , -0.4 ) 0.005 
       TT/GG -1.31 ( -2.4 , -0.2 ) 0.018 
CYP24A1 rs4809959* IGFBP4 rs584438, reference value (CC/GG)  
       TT/GG  1.41 ( 0.3 , 2.5 ) 0.012 
Season*CYP24A1 rs4809959, reference value (Winter *TC) 
       Summer*TT  0.74 ( 0.2 , 1.3 ) 0.007 
       Fall*TT  0.81 ( 0.2 , 1.4 ) 0.008 
Follow ups -0.25 ( -0.3 , -0.2 ) < 0.001 
Constant  4.72 ( 3.2 , 6.2 ) < 0.001 




Participant  0.52 ( 0.4 , 0.7 ) 0.078 
Residual  0.75 ( 0.7 , 0.8 ) 0.042 





Table 8.26. Environmental and genetic factors and their interactions that predict differing 
Remission Categories 
 Remission Category  
Variable Coefficient (95% 
Confidence interval) 
p-value 
Fixed Effects   
C-Reactive Protein -0.08 ( -0.1 , 0.0 ) 0.001 
Taking a supplement containing vitamin D, reference value (Never) 
       Every day/Sometimes  0.13 ( 0.0 , 0.3 )  0.044 
NSAID Prescribed, reference value (Yes) 
       No  0.32 ( 0.2 , 0.4 ) < 0.001 
Biologic Prescribed, reference value (Yes) 
       No  0.28 ( 0.1 , 0.5 ) 0.003 
CYP1R1 rs17116978, reference value (CC) 
       CT  0.46 ( -0.1 , 1.0 ) 0.103 
       TT  0.44 ( -0.1 , 1.0 ) 0.090 
NOTCH4 rs415929, reference value (GG) 
       GA -0.41 ( -0.7 , -0.1 ) 0.010 
       AA -0.30 ( -0.6 , 0.0 ) 0.073 
Follow ups  0.18 ( 0.1 , 0.2 ) < 0.001 
Constant -0.50 ( -1.0 , 0.0 ) 0.047 
Random Effects  Standard Error 
Participant  0.19 ( 0.1 , 0.3 ) 0.047 
Residual  0.44 ( 0.4 , 0.5 ) 0.025 
NSAID (non-steroidal anti-inflammatory drug), Biologic (biologically-based anti-cytokine 
therapie)   





     CHAPTER 9 
GENERAL DISCUSSION 
 
There is evidence that vitamin D may play a role in both the development and treatment 
of JIA (Berkun et al., 2015; Ellis et al., 2010; Pelajo et al., 2012; Stagi et al., 2014). The role of 
vitamin D has been suggested to have impact at both the environmental level (factors associated 
with 25(OH)D concentrations) (Ellis et al., 2010) and the genetic level (Ellis et al., 2015; Falcini 
et al., 2013). Therefore, understanding how vitamin D affects disease activity in children with 
JIA is important to study further. The Biologically Based Outcomes Predictors (BBOP) in JIA 
study provided mixed longitudinal data allowing for the evaluation of the long-term outcomes in 
children with JIA with the hope of developing better treatment care plans and evaluation method. 
My thesis explored the impact of vitamin D and related factors on disease activity measures in 
BBOP participants 
 In my thesis, I compared healthy children from the Canadian Health Measured Survey 
(CHMS) to children from the BBOP Study to address the objective of evaluating vitamin D 
status and comparing between healthy children/adolescents and patients with JIA (Study 1). 
Then, I explored how environmental factors associated with vitamin D impact biochemical and 
objective measured of disease activity to determine the association of factors that could be 
modified to impact vitamin D status and disease activity in JIA patients. (Study 2). In the next 
step, I investigated if genetic factors related to vitamin D are associated with disease activity 
outcomes. The goal was to identify potential associations of vitamin D pathway gene 
polymorphisms and JIA as well as explore their impact on disease activity (Study 3).  
9.1. Scientific Contributions of Study 1 
This is the first study to compare multiple factors associated with vitamin D status in 
newly diagnosed JIA patients (within 6 months of diagnosis) and healthy children at a national 
level. To date and to our knowledge, no study has investigated the relationship between vitamin 
D status and JIA from the time of the first presentation. This research allowed us to compare at a 
population level whether there are significant differences in factors associated with vitamin D 
and growth outcomes in healthy children and those with JIA. We further compared the vitamin D 




population.  Advancement in medications have been made since these outcomes were last 
documented and compared. In addition, factors associated with vitamin D and growth outcomes 
of children with  newly diagnosed JIA have not been compared to a nationally representative 
population. Findings from this research will provide valuable information on vitamin D and 
growth status of children with JIA.  
Vitamin D status appears to meet current cut-offs in the majority of children with JIA at 
disease onset. However, biochemical measures of inflammation are higher. Mean 25(OH)D 
status was significantly higher for JIA patients (79 ± 3.1 nmol/L vs. 68 ± 1.8 nmol/L). This is in 
contrast to other studies  in which  participants had lower 25(OH)D concentrations than healthy 
children (Dağdeviren-çakır et al., 2016; de Sousa Studart et al., 2015; Nisar et al., 2013; 
Szymanska-Kaluza J., Biernacka-Zielinska M., Stanczyk J., 2013). JIA patients use a supplement 
containing vitamin D more often (50% vs. 7% p <0.05). Prevalence of 25(OH)D deficiency 
(25(OH)D < 30 nmol/L) was 6% for both groups. Children with JIA were more likely to be born 
in the fall and winter and healthy children were more likely to be born in the spring and summer. 
Similar findings were reported by Berkun et al., they found that children with JIA were  more 
likely to be born between November to March compared to birth months for the general 
population peaking in the summer (Berkun et al., 2015). Children with JIA (at disease onset) 
differ from healthy children in terms of growth characteristics. The proportion in each BMI class 
did not vary by group. Weight and height z-scores were higher in healthy children. Daily milk 
intake was associated with a significantly higher 25(OH)D status for both groups.  
In summary, children with JIA are shorter and weigh less than healthy children weigh.  
Vitamin D, which was adequate in the JIA population, is not likely to be a factor accounting for 
impeded growth. Season of birth may reflect vitamin D status in utero or during the first few 
months of life. Further research into what role vitamin D status plays in the development and 
progression of JIA is required.  
9.2. Scientific Contributions of Study 2 
Analyses in this section addressed whether vitamin D and its associated factors are 
negatively associated with inflammatory markers and disease activity among JIA cases. 
We found that serum 25(OH)D concentrations and factors that influence 25(OH)D status 




Consistent with our finding, an association between 25(OH)D concentrations and CRP 
concentrations in JIA patients was found by Stagi et al (Stagi et al., 2014). Dairy products have 
also been shown to suppress inflammation in healthy people;  however,  this is the first time that 
they have been explored in the context of JIA (Bordoni et al., 2017; Stancliffe, Thorpe & Zemel, 
2011). 25(OH)D predicted remission suggesting that it may play a role in a reduction in 
inflammatory-related factors of JIA outcomes. Milk, with mandatory fortification in Canada,  is 
the most common source of vitamin D for this age group (Whiting et al., 2011) and suggests an 
actionable way to improve vitamin D concentrations in children with JIA. No researcher had 
explored milk intake and remission prior to our study and further research is required to develop 
specific recommendations around milk intake and this population. Being able to suggest specific 
targets for vitamin D status as a potential adjunct therapy or specific actions to reduce 
inflammation in the treatment of JIA will enhance the quality of life of patients and their 
families. Further studies exploring 25(OH)D and factors associated with vitamin D status will 
help in the development of actionable/ feasible recommendations for health care professionals 
and families. 
Very recently (December 13, 2018), the results of a prospective multicenter cohort study 
of newly diagnosed (<12 months since diagnosis) children with JIA from Germany was 
published (Senger et al. 2018). Three hundred and sixty patients had 25(OH)D concentrations 
measured twice in the first 2 years of follow up. Disease activity measured using the clinical 
Juvenile Arthritis Disease Activity Score (c-JADAS)-10 which is a composite score that includes 
active joint count in its total. Children from the cohort were also compared to age, sex and month 
of blood collection matched children from the general population. They found that 44% of 
patients with JIA were vitamin D deficient (25(OH)D <20ng.mL) at the first measurement, and a 
quarter were deficient at both measurements (second measure not published). The research group 
speculated that vitamin D status might be changed by the established therapy or treatment. 
Therefore, they only used the first 25(OH)D measure in exploring the association between 
25(OH)D and disease activity. Disease activity was found to be negatively correlated with 
25(OH)D concentrations in their analysis. 
The study by Senger et al. is the publication that most closely resembles my thesis study 
2. However, there are a number of methodological differences that are important to note. As 




tools as measures of disease activity because there is no single measure of disease activity that 
has been deemed the gold standard, especially in the analysis of vitamin D and disease activity. 
Additionally, the measure that the authors use the c-JADAS-10 is a measure that includes joint 
count. Given that the number of joints with active arthritis is a part of the definition of the 
subtypes as well as a measurement of disease activity, the cut-offs are not appropriate for 
comparison between subtypes.  I discuss in my thesis why I chose not to use this as a measure of 
disease activity when there are more than one JIA subtype included in a study. The research 
group included migration pattern that they, defined as mother or father not of German origins to 
represent skin pigmentation, and cultural habits that may influence UVB vitamin D production. 
The authors note that a limitation of their study was that they did not explore vitamin D intake 
from food or supplements. My thesis explored this association and found that both food and 
supplement intake of vitamin D are associated with disease activity. While this study chose to 
explore the role of vitamin D in disease activity using different methodological choices than 
what was explored in the BBOP study it does provide evidence towards the value of our study 
exploring the role of the vitamin D pathway in JIA disease development and disease progression. 
9.4. Scientific Contributions of Study 3 
Analyses of this section addressed whether there are specific polymorphisms of vitamin 
D pathway genes associated with JIA. GWAS-identified genes were NOTCH4, c6orf9, HLA-
DQA1, LEP, IGFBP4, and GPS1. When genes were not included in the multi-level mixed-
effects modeling, there was a negative association of 25(OH)D to disease activity.  Genes, when 
included, modified the association between 25(OH)D and indicators of disease activity. The only 
other exploration of vitamin D genes and their impact on JIA reported by was Ellis et al. (Ellis et 
al., 2015). Epistasis of vitamin D pathway genes and a gene confirmed  in the heritability of JIA 
(PTPN2 rs2542151) was shown to be associated with disease development (Ellis et al., 2015). 
Our study is the first to explore the concept of epistasis in relation to disease outcomes. 
 Genes identified through GWAS (HLA-DQA1, and GPS1) and VRD polymorphisms 
(rs7975232 and rs731236) modified the association between 25(OH)D and indicators of disease 
activity; only certain genotypes maintained the negative association of 25(OH)D and disease 
activity markers. Our study is the first to explore gene-environment and gene-biochemical 




factors and the transition to Systematic Lupus Erythematosus (SLE) (Young et al., 2016). A 
combined role of vitamin D status and CYP24A1 was associated with 25(OH)D and the 
transition to SLE was modified by the genetic polymorphism of the CYP24A1 gene. Disease 
activity measures were also modified by the interaction of milk consumption and VDR 
polymorphisms (rs1544410, rs7975232 and rs11568820) where drinking milk in children with 
certain SNPs of these genes predicted a reduction in indicators of disease activity as measured by 
CRP, ESR, and IL-6. 
Our findings indicate a negative association of 25(OH)D and inflammation that 
influenced by vitamin D-related genetic polymorphisms. Milk intake, as a source of dietary 
vitamin D, is associated with suppression of inflammation in children with JIA. 
This is the first time the potential influence of gene and environment in relation to vitamin D 
were analyzed together in association with JIA disease activity. Environmental, biochemical, and 
genetic factors including interactions of key genetic polymorphism of the vitamin D pathway 
predict disease activity in children with JIA. 
9.5. Strengths 
My study has several strengths. This prospective inception cohort study is the first to 
investigate the relationship between vitamin D status and JIA from the initial diagnosis  and to 
measure disease outcomes over a 2-year period. It is the first time that environmental, 
behavioural and genetic factors associated with vitamin D have been explored in the same JIA 
patient. Also, the first time that interactions of vitamin D associated factors and genetic 
polymorphisms that may differ in children with JIA identified through GWAS have been 
considered.  
To date and to our knowledge, no study has investigated the relationship between vitamin D 
status and JIA over time in newly diagnosed individuals. The ultimate goal of this research is to 
document the vitamin D status in a JIA population and to gain insight into the optimal doses to 
improve the diseases status. We explored the relationship of vitamin D status on markers of 
inflammation and measures of disease activity in children and adolescents with JIA. We explored 
a possible genetic association with vitamin D pathway gene polymorphisms and JIA. We further 




healthy age-matched population of children and adolescents. Findings from this research provide 
valuable information on the role of vitamin D status in relation to disease activity and outcomes. 
9.6. Limitations 
The main limitation of my study was the sample size through the number of children who 
enrolled in the study recruitment period, which did not allow us to explore JIA type in some form 
of sub-group analysis. I explored JIA type using both the seven JIA categories defined by ILAR 
as well as by using inflamed joint count > four and < four. However, sample was too small for 
predictions even through bivariate analysis. An additional limitation was that biochemical 
measurements including 25(OH)D measurements only took place at two time points. This meant 
that milk intake was used as a surrogate measure of dietary 25(OH)D. As mentioned in previous 
chapters, fortified milk is the primary dietary source of vitamin D for Canadians (Whiting et al., 
2011). However, milk is not the only food that contains vitamin D; therefore, it is not an exact 
duplication of total vitamin D intake. Children were also within 6 months of diagnosis and not at 
the date of diagnosis. They (and their parents) may have modified their behaviour already due to 
their disease or disease diagnosis. Lastly, season was used as a proxy for sun exposure and UVB 
vitamin D synthesis. We are not aware if some participants traveled during the winter months or 
used sunscreen in the summer months.  This cohort study also did not have a control group for 
comparison to healthy children. However, we overcame this limitation by the following actions: 
We compared baseline data for age- and sex-matched  children older than three years who are 
free of chronic disease from the Canadian Health Measures Survey and also used The National 
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) healthy control genetic 
dataset and the Better Outcomes for Children: GWAS from Cincinnati Children's Hospital 
Medical Center (CCHMC) - eMERGE Phase II” dataset as genetic controls.  
Serum 25(OH)D and markers of inflammation were only measured at two time points in 
BBOP, therefore we do not have biochemical data to correspond with the outcome of the disease 
beyond this time point.  We did not directly measure the skin pigmentation to control for the 
amount of vitamin D endogenous synthesis. Therefore, we only used ethnicity as a descriptor 
term since skin pigmentation will influence baseline 25OHD values and endogenous synthesis.   
Although this study was able to identify that patients with JIA differ from the healthy 




designed to evaluate the optimal dose of vitamin D or 25(OH)D concentration for children with 
JIA. 
9.7. Future Research 
This study identified some key area for future research around factors associated with 
vitamin D and JIA. First questions around vitamin D and disease development can be further 
explored. We identified that children with JIA are more likely to be born in the fall and winter 
than healthy children. Future research into the intra-uterine environment and maternal behaviour 
surrounding vitamin D practices would help to clarify this. In addition, the role and prevalence of 
vitamin D gene polymorphisms and the interactions of genes associated with the vitamin D 
pathway will help in understanding the causes of JIA. Our study also identified key areas 
associated with vitamin D in the treatment of JIA as well as actions and behaviours of patients at 
diagnosis associated with vitamin D that may influence outcomes. Our models suggest an 
association between 25(OH)D and milk intake and a suppression of inflammation. This might be 
modified in patients with certain polymorphisms of vitamin D pathway genes and genes that 
have polymorphisms that are more frequent in children with JIA that interact with the vitamin D 
pathway. Exploring if there is a dose-dependent relationship between vitamin D intake and 
inflammation and if this is modified by certain genetic polymorphisms will require further 
research. Additionally, research into the impact of milk intake on inflammation in JIA would be 
beneficial. Children with JIA reported drinking milk everyday less than healthy children. If milk 
(the primary dietary source of vitamin D in children) were effective in suppression of 
inflammation, daily milk consumption to reduce inflammation would be a simple 
recommendation for clinicians to make.  
9.8. Conclusion 
25(OH)D was optimal in the JIA population and JIA patients used vitamin D 
supplements more often than healthy children. Children with JIA were more likely to be born in 
the fall and winter, while healthy children were more likely to be born in the spring and summer. 
Being born in seasons with reduced endogenous vitamin D could implicate low vitamin D during 
gestation and early life as a factor influencing JIA pathogenesis. Children with JIA are shorter 




population, is not likely to be a factor accounting for impeded growth. CRP and ESR 
concentrations decreased significantly over the 2 years. Increased 25(OH)D or its associated 
factors predicted lower ESR, CRP and cytokine levels suggesting that vitamin D may suppress 
inflammation in children with JIA. GWAS identified the following genetic components, 
NOTCH4, C6orf10, HLA-DQA1, LEP, IGFBP4, and GPS1. Interactions between frequent gene 
polymorphisms and factors associated with vitamin D including genes in the vitamin D pathway 
(VDR, GC, CYP24A1, and CYP1R1) significantly predicted disease activity-related outcomes.  
This is the first time gene and environment influences in relation to vitamin D were analyzed 
together in association with JIA disease activity. Environmental, biochemical, and genetic factors 
including their interactions predict disease activity in children with JIA. 
Investigating the genetic and environmental role in a cohort of children with JIA over 
years, will help to understand the multifaceted role played of vitamin D in the prevention and 
management of JIA.  Understanding how genetic variants increase the risk of disease 
development will help guide vitamin D management in individual patients and thus contribute to 
improving disease outcomes. The evidence discovered through this thesis suggests that the 
achievement of adequate vitamin D status using environmental factors associated with vitamin D 
(diet, supplement intake and limited UVB exposure) should be included in the comprehensive 
medical plan for children with JIA. 
9.9. Implications for Practice 
This thesis demonstrates that vitamin D is an important nutrient for children with JIA. 
We do not have specific recommendations for the optimal dose required for children with JIA. 
However, applying current daily dosing recommendations for healthy children to the JIA 
population would seem appropriate. Clinicians should establish vitamin D status in their patients 
and work towards achieving or maintaining at minimum adequate 25(OH)D concentrations  (50 
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Tables and Additional Results Related to Chapter 7 
 
Baseline and 6 months 
 
Table A.4. Biochemical measures of inflammation multivariate linear regression analysis at baseline and 6 month follow up 
Variable C-Reactive Protein Erythrocyte Sedimentation Rate 
 Coefficient (95% 
Confidence Interval) 
p-value Coefficient (95% 
Confidence Interval) 
p-value 
Fixed Effects     
25(OH)D -0.95 ( -1.8 , -0.1 ) 0.021      0.29 (  -0.1, 0.7 ) 0.126     
Milk Intake, reference value (Never/Sometimes) 
       Every day -0.52 ( -1.0 , -0.1 ) 0.028     -0.25 ( -0.7, 0.2 ) 0.263     
Taking a supplement containing vitamin D, reference value (Never) 
       Every day/Sometimes  0.07 ( -0.3 , 0.5 ) 0.749      0.64 (-0.09 , 1.37 ) 0.086     
Age  - -  0.02 (  -0.02, 0.1 ) 0.412     
Steroid Prescribed, reference value (Yes) 
       No -5.22 ( -9.4 , -1.0 ) 0.015     - - 
25(OH)D* Steroid prescribed, reference value (25(OH)D* Yes) 
       25(OH)D*No 
 0.99 ( 0.1 , 1.9 ) 0.041      - - 
Age*Taking a supplement containing vitamin D, reference value (Age*Never) 
       Age*Every day/ 
Sometimes 
- - -0.08 ( -0.1, -0.01 ) 0.019      
Milk Intake* Taking a supplement containing vitamin D, reference  value (Never/Sometimes drink 




- -  0.72 (  0.1, 1.4 ) 0.033      







Constant  7.80 ( 4.2 , 11.4 ) < 0.001       2.28 (  0.5, 4.1 ) 0.014      
Random Effects Estimate Standard 
Error 
 Estimate Standard 
Error 
Participant  0.55 ( .2 , 1.2 ) 0.218       0.71 ( 0.5, 1.0 ) 0.106      
Residual  1.01 ( .8 , 1.3 ) 0.124        0.70 ( .6, 0.9 ) 0.081      
25(OH)D (25-hydroxyvitamin D), Steroid (corticosteroid) 
[variable name] *[variable name] represents interaction term 
 
Table A.5. Pro-Inflammatory cytokines multivariate linear regression analysis at baseline and 6 month follow up 
Variable Interleukin-1α Interleukin-1r α Interleukin-1β 
 Coefficient  (95% 
Confidence Interval) 
p-value Coefficient  (95% 
Confidence Interval) 
p-value Coefficient  (95% 
Confidence Interval) 
p-value 
Fixed Effects       
25(OH)D - - -1.44  (-2.5,  -.36)  0.009       
Age - - -0.09 ( -0.2, 0.0 ) 0.009       
Season, reference value (Winter) 
       Spring - - - - -0.04 ( -0.6, 0.5 ) 0.881     
       Summer - - - -  0.64 ( 0.2, 1.1 ) 0.008      
       Fall - - - - -0.26 ( -0.8, 0.3 ) 0.362     
Taking a supplement containing vitamin D, reference value (Never) 
       Every day/Sometimes  0.31 ( 0.03, 0.6 ) 0.030      - - - - 
Milk Intake, reference value (never/sometimes) 
       Every day - -  0.75 ( 0.1, 1.4 ) 0.024      - - 
Biologic Prescribed, reference value (Yes) 
       No -0.88 ( -1.6, -0.2 ) 0.012      -2.02 ( -3.1, -1.0 ) < 0.001      - - 
Steroid Prescribed, reference Yes 
       No - - -6.40 ( -11.9, -0.9 ) 0.021     - - 
25(OH)D*Steroid prescribed, reference value (25(OH)D* Yes) 
       25(OH)D* No - -  1.51 (  0.3, 2.7 ) 0.017      - - 
First follow up 0.002 ( -0.2, 0.2 ) 0.980     -0.15 ( -0.6, 0.3 ) 0.512      0.27 ( -0.05, 0.6 ) 0.097     













Participant  1.55 ( 1.4, 1.8 ) 0.102        1.22 ( 0.9, 1.8 ) 0.223      1.39 ( 1.2, 1.7 ) 0.129       
Residual  0.65 (0.5,0.8)   0.055  1.56 (  1.3, 1.9 ) 0.142         1.34 ( 1.2, 1.5 ) 0.084       
 
 
 Interleukin-2 Interleukin-6 Interleukin-8 
Variable Coefficient (95% 
Confidence Interval) 
p-value Coefficient (95% 
Confidence Interval) 
p-value Coefficient (95% 
Confidence Interval) 
p-value 
Fixed Effects       
25(OH)D -1.31 ( -2.4, -0.3 ) 0.016     - - - - 
Age - -  0.008 ( -0.1, 0.1 ) 0.866      0.08 ( -0.01, 0.2 ) 0.095     
Taking a supplement containing vitamin D, reference value (Never) 
       Every day/Sometimes  0.57 (  0.2, 0.9 ) 0.002      - - - - 
Season, reference value (Winter) 
       Spring - -  0.20 ( -0.3, 0.7 ) 0.457      1.25 ( 0.7, 1.8 ) < 0.001      
       Summer - -  0.54 ( 0.1, 1.0 ) 0.013        2.25 ( 1.7, 2.8 ) < 0.001      
       Fall - -  0.20 ( -0.3, 0.7 ) 0.452      0.43 ( -0.2, 1.0 ) 0.158     
Milk Intake, reference value (Never/sometimes) 
       Every day - -  1.31 (  0.2, 2.4 ) 0.018       1.75 ( 0.5, 3.0 ) 0.007      
Steroid Prescribed, reference value (Yes) 
       No -6.07 ( -11.6, -0.5 ) 0.032      - - - - 
25(OH)D* Steroid prescribed, reference value (25(OH)D* Yes) 
       25(OH)D* No  1.46 ( 0.2, 2.7 ) 0.022      - - - - 
Age*Milk Intake, reference value (Age*Never/sometimes) 
       Age*Every day - - -0.12 ( -0.2, 0.0 ) 0.018     -0.17 ( -0.3, -0.1 ) 0.002      
First follow up  0.17 ( -0.1, 0.4 ) 0.192     -0.21 ( -0.5, 0.1 ) 0.181      -0.38 ( -0.8, 0.02 ) 0.062     
Constant  6.92 ( 2.2 , 11.7 ) 0.004       2.31 ( 1.2, 3.4 ) < 0.001       2.12 ( 0.8, 3.4 ) 0.001      






Participant  1.64 (  1.4, 1.9 ) 0.129       1.29 ( 1.1, 1.6 ) 0.134       1.02 (0.7,1.4)  0.169 









Variable Interleukin-17 TNF-α INF-ƴ 
 Coefficient  (95% 
Confidence Interval) 
p-value Coefficient  (95% 
Confidence Interval) 
p-value Coefficient  (95% 
Confidence Interval) 
p-value 
Fixed Effects       
25(OH)D -1.87 ( -3.2, -0.6 ) 0.004     - - -1.20 ( -2.1, -0.3 ) 0.008     
Age  0.28 ( -1.3, -0.2 ) 0.005     -0.05 ( -0.08 , -0.01 ) 0.008      0.10 ( 0.02, 0.2 ) 0.016      
Milk Intake, reference value (Never/sometimes) 
       Every day -0.15 ( -0.8, 0.5 ) 0.619      - -  0.19 ( -0.1, 0.5 ) 0.170      
Taking a supplement containing vitamin D, reference value (Never) 
       Every day/Sometimes  0.24 ( -0.2, 0.7 ) 0.300     - - -0.51 ( -0.8, -0.1 ) 0.007     
Age*25(OH)D  0.17 ( 0.04, 0.3 )  0.009          




-1.45 ( -2.3, -0.6 ) 0.001     - - - - 
First follow up -0.09 ( -0.4, 0.2 ) 0.549      0.12 ( -.04, 0.3 ) 0.148     -0.13 ( -0.3, 0.1 ) 0.203     
Constant  10.73 ( 4.9, 16.6 ) < 0.001       2.88 ( 2.5, 3.3 ) < 0.001       8.43 ( 4.4, 12.5 ) < 0.001      






Participant  1.57 ( 1.3, 1.9 ) 0.132     1.01 ( 0.9, 1.2 ) 0.070         1.49 ( 1.3, 1.7 ) 0.099        
Residual  0.70 ( 0.6, 0.9 ) 0.086       0.70 ( 0.6, 0.8 ) 0.040        0.62 ( 0.5, 0.7 ) 0.052      
 
 
Variable Pro-Inflammatory Index 
 Coefficient (95% 
Confidence Interval) 
p-value 
Fixed Effects   
25(OH)D -1.67 ( -3.0, -0.3 ) 0.016     
Ethnicity, reference value (White) 







       Indigenous -0.61 ( -1.7, 0.5 ) 0.273     
Milk Intake, reference value (Never/sometimes) 
       Everyday -0.50 ( -1.2, 0.2 ) 0.155     
Taking a supplement containing vitamin D, reference value 
(Never) 
       Every day/Sometimes -0.46 ( -1.1, 0.1 ) 0.131     
Steroid Prescribed, reference value (Yes) 
       No -8.32 ( -14.9, -1.7 ) 0.014      
25(OH)D* Steroid prescribed, reference value (25(OH)D* 
Yes) 
       25(OH)D* No  1.98 ( 0.5, 3.5 ) 0.010      
First follow up -0.40 ( -1.0, 0.2 ) 0.169     
Constant  8.35 ( 2.3, 14.4 ) 0.007      
Random Effects  Standard 
Error 
Participant  1.01 ( 0.6, 1.8 ) 0.293     
Residual  1.23 ( 0.9, 1.7 ) 0.212    
25(OH)D (25-hydroxyvitamin D), Steroids (corticosteroid), Biologic (biologically-based anti-cytokine therapie)   





















Table A.6. Anti-Inflammatory cytokines multivariate linear regression analysis at baseline and 6 month follow up 
Variable Interleukin-4 Interleukin-10 
Fixed Effects Coefficient (95% 
Confidence Interval) 
p-value Coefficient (95% 
Confidence Interval) 
p-value 
25(OH)D -1.66 ( -3.0, -0.4 ) 0.012      - - 
Age -0.72 ( -1.3, -0.2 ) 0.010     - - 
BMI percentile - - 0.01 ( 0.0002 , 0.01 ) 0.044      
Season, reference value (Winter) 
       Spring - - 0.41 ( 0.03, 0.8 ) 0.036      
       Summer - - 0.39 ( 0.1, 0.7 ) 0.005      
       Fall - - 0.37 ( -0.04, 0.9 ) 0.076     
Sex, reference value (Male) 
       Female  0.94 ( 0.2, 1.7 ) 0.013      - - 
Taking a supplement containing vitamin D, reference value (Never) 
       Every day/Sometimes  0.08 ( -0.3, 0.4 ) 0.674     0.09 ( -0.2, 0.4 ) 0.528     
Ethnicity, reference value (White) 
       Non-White - - 0.65 ( 0.03, 1.3 ) 0.040      
       Indigenous - - 0.39 ( -0.3, 1.1 ) 0.283     
Annual Household Income, reference value (>$51,000) 
       $51,000 – 99,999 - - 0.50 ( -0.1, 1.1 ) 0.107     
       > $100,000 - - 0.63 (  0.04, 1.2 ) 0.036       
Milk Intake, reference value (Never/sometimes) 
       Everyday - - 0.27 ( -0.1, 0.7 ) 0.171     
Age*25(OH)D 0.13 ( 0.01 , 0.3 ) 0.034      - - 
Milk Intake* Taking a supplement containing vitamin D, reference value (Never/sometimes drink 




- - 0.64 ( 0.1, 1.2 ) 0.019      
First follow up 0.23 ( -.03, 0.5 ) 0.078     -0.01 ( -0.2, 0.2 ) 0.926     











Participant 1.68 (1.4,2.0)  0.132 1.04 ( 0.9, 1.2 ) 0.087      
Residual 0.63 ( 0.5, 0.8 ) 0.067      0.43 ( 0.3 , 0.5 ) 0.049        
 
 
Variable Anti-Inflammatory Index 
 Coefficient  (95% 
Confidence Interval) 
p-value 
Fixed Effects   
25(OH)D -1.76 ( -3.0, -0.6 ) 0.004     
Age -0.71 ( -1.3, -0.2 ) 0.012     
Season, reference value (Winter) 
       Spring -0.17 ( -0.8, 0.4 ) 0.557     
       Summer  0.44 (  0.0, 0.8 ) 0.029      
       Fall -0.23 ( -0.9, 0.4 ) 0.463     
Milk Intake, reference value (Never/sometimes) 
       Everyday  0.19 ( -0.3, 0.7 ) 0.492     
Taking a supplement containing vitamin D, reference value 
(Never) 
       Every day/Sometimes  0.04 ( -0.3, 0.4 ) 0.814     
Age*25(OH)D    0.14 ( 0.0, 0.3 ) 0.033      
First follow up  0.18 ( -0.1, 0.4 ) 0.190     
Constant  8.57 (  3.1, 14.0 ) 0.002      
Random Effects  Standard 
Error 
Participant  1.75 ( 1.5, 2.1 ) 0.144     
Residual 0 .51 ( 0.4, 0.7 ) 0.065      
25(OH)D (25-hydroxyvitamin D) 










Table A.7. Objective and self-reported measures of disease outcomes multivariate linear regression analysis at baseline and 6 months 
 Child Health Assessment 
Questionnaire 
Juvenile Arthritis Quality of Life 
Questionnaire 
Pain Score 
Variable Coefficient  (95% 
Confidence Interval) 
p-value Coefficient  (95% 
Confidence Interval) 
p-value Coefficient  (95% 
Confidence Interval) 
p-value 
Fixed Effects       
Age - -  0.06 ( 0.03, 0.1 ) 0.001       0.11 ( 0.03, 0.2 ) 0.006      
Milk Intake, reference value (Never/sometimes) 
       Every day -0.25 ( -0.4, -0.1 ) 0.014     - - -0.04 ( -1.1, 1.0 ) 0.937     
Taking a supplement containing vitamin D, reference value (Never) 
       Every day/Sometimes  0.05 ( -0.1, 0.2 ) 0.578     - - -0.40 ( -1.2, 0.4 ) 0.323     
Smoker in home, reference value (No)  
       Yes  0.25 ( 0.1, 0.4 ) 0.010      - - - - 
Annual Household Income, reference value (>$51,000) 
       $51,000 – 99,999 - - -0.39 ( -0.8 , 0.04 ) 0.077     - - 
       > $100,000 - - -0.51 ( -1.0, -0.1 ) 0.023     - - 
NSAID Prescribed, reference value (Yes) 
       No - - -0.36 ( -0.6, -0.1 ) 0.005     - - 




- -    2.34 ( 0.7, 4.0 ) 0.005      
First follow up -0.43 ( -0.6, -0.3 ) < 0.001      -0.27 ( -0.3, -0.2 ) < 0.001      -1.64 ( -2.3, -1.0 ) < 0.001      
Constant  1.38 ( 1.1, 1.7 ) < 0.001       3.20 ( 2.7, 3.7 ) < 0.001       4.92 ( 3.4, 6.4 ) < 0.001      






Participant  0.30 ( 0.2, 0.5 ) 0.082      0.86 ( 0.7, 1.0 ) 0.078        1.09 ( 0.5, 2.2 ) 0.386      
Residual  0.51 ( 0.4, 0.6 ) 0.048        1.04 ( 1.0, 1.1 ) 0.042        2.29 ( 1.9, 2.7 ) 0.0199       
 
 







 Coefficient  (95% 
Confidence Interval) 
p-value 
Fixed Effects   
25(OH)D  0.55 ( 0.01, 1.1 )  0.044      
Age - - 
Ethnicity, reference value (White) 
       Non-White - - 
       Indigenous - - 
Sex, reference value (Male) 
       Female - - 
Annual Household Income, reference value (>$51,000) 
       $51,000 – 99,999 -0.91 ( -1.6, -0.2 ) 0.007     
       > $100,000 -0.59 ( -1.2, 0.0 ) 0.068     
First follow up -2.31 (  2.8, -1.9 ) < 0.001      
Constant  4.27 (  0.8, 6.7 ) 0.001      
Random Effects  Standard 
Error 
Participant  0.74 ( 0.4, 1.4 ) 0.252      
Residual  1.72 ( 1.5, 2.0 ) 0.122      
25(OH)D (25-hydroxyvitamin D), NSAID (non-steroidal anti-inflammatory)  
[variable name] *[variable name] represents interaction term 
 
 
All visits (baseline through 24 months) 
 
Table A.8. Biochemical measures of inflammation multivariate linear regression analysis all visits 
 C-reactive Protein Erythrocyte Sedimentation Rate 
Variable Coefficient  (95% 
Confidence Interval) 
p-value Coefficient  (95% 
Confidence Interval) 
p-value 
Fixed Effects     
Age - -  0.01 ( -0.04, 0.05 ) 0.718     







       Yes  0.38 ( 0.1, 0.7 ) 0.017       0.31 ( -0.04, 0.8 ) 0.083     
     
Milk Intake reference value (Never/sometimes) 
       Every day -0.44 ( -0.8, -0.1 ) 0.007     -0.49 ( -0.8, -0.1 ) 0.006     
Steroid Prescribed, reference value (Yes) 
       No -0.48 ( -0.8, -0.1 ) 0.007       
Taking a supplement containing vitamin D, reference value (Never) 
       Every day/Sometimes - -  0.82 ( 0.1, 1.5) 0.019      
Age*Taking a supplement containing vitamin D, reference value (Age*Never) 
       Age*Every 
day/Sometimes 
- - -0.07 ( -0.1, -0.01 ) 0.033     
Follow ups -0.34 ( -0.4, -0.2 ) < 0.001      -0.66 ( -0.9, -0.4 ) < 0.001      
Constant  2.83 ( 2.4, 3.3 ) < 0.001       3.75 ( 3.1, 4.4 ) < 0.001      




Participant  0.43 (  0.3, 0.7 ) 0.118       0.69 ( 0.5, 0.9 ) 0.104       
Residual  1.12 (  1.0, 1.2 ) 0.060      0.73 ( 0.6, 0.9 ) 0.078      
Steroids (corticosteroid)  
[variable name] *[variable name] represents interaction term 
 
 
Table A.9. Objective and self-reported measures of disease outcomes multivariate linear regression analysis all visits 
 Child Health Assessment 
Questionnaire 
Juvenile Arthritis Quality of Life 
Questionnaire 
Pain Score 
Variable Coefficient  (95% 
Confidence Interval) 
p-value Coefficient  (95% 
Confidence Interval) 
p-value Coefficient  (95% 
Confidence Interval) 
p-value 
Fixed Effects       
Age - -  0.06 ( 0.02, 0.1 ) 0.004       0.13 ( 0.05, 0.2 )  
C-Reactive Protein - - 0.26 ( 0.1, 0.4 ) < 0.001      - - 
Season, reference value (Winter) 
       Spring - - - - -1.25 ( -2.2, -0.3 ) 0.014     







       Fall - - - - -0.38 ( -1.4, 0.6 ) 0.466     
Milk Intake, reference value (Never/sometimes) 
       Everyday -0.25 ( -0.4, -0.1 ) 0.014     - - -0.33 ( -1.4, 0.7 ) 0.546     
Taking a supplement containing vitamin D, reference value (Never) 
       Every day/Sometimes  0.05 ( -0.1, 0.2 ) 0.578     - - -0.37 ( -1.2, 0.4 ) 0.360     
Smoker in home, reference value (No)  
       Yes  0.25 ( 0.1, 0.4 ) 0.010      - -   
Sex, reference value (Male) 
       Female - - - - -0.81 ( -1.6, 0.0 ) 0.053     
NSAID Prescribed, reference value (Yes) 
       No - - -0.40 ( -0.7, -0.1 ) 0.018     - - 
Milk Intake* Taking a supplement containing vitamin D, reference  value (Never/sometimes drink milk*never take a supplement) 
       Never/sometimes drink 
milk* supplement 
everyday/sometimes 
- - - - 1.92 ( 0.3, 3.6 ) 0.021      
Follow ups -0.43 ( -0.6, -0.3 ) < 0.001      -0.19 ( -0.3, -0.1 ) 0.001     -1.54 ( -2.2, -0.9 ) < 0.001      
Constant  1.38 ( 1.1, 1.7 ) < 0.001       2.44 (  1.9, 3.0 ) < 0.001       5.87 ( 4.1, 7.7 ) < 0.001      






Participant  0.30 (0.2,  0.5) 0.082  0.81( 0.1, 1.0)  0.102       1.05 ( 0.5, 2.1 ) 0.384      
Residual  0.51 ( 0.4, 0.6 ) 0.048        1.12 ( 0.0 , 1.3 ) 0.062     2.24 ( 1.9, 2.7 ) 0.195      
 
 
Variable Physician Global Assessment 
 Coefficient  (95% 
Confidence Interval) 
p-value 
Fixed Effects   
Age - - 
Ethnicity, reference value (White) 
       Non-White  0.56 ( 0.1, 1.0 ) 0.016      
       Indigenous  0.72 ( 0.2, 1.3 ) 0.008      







       $51,000 – 99,999 - - 
       > $100,000 - - 
Follow ups -0.74 ( -0.8, -0.6 ) < 0.001      
Constant  3.56 ( 3.2, 3.9 ) < 0.001      
Random Effects  Standard 
Error 
Participant  0.60 ( 0.4, 0.9 ) 0.129      
Residual  1.77 ( 1.7, 1.9 ) 0.060     
NSAID (non-steroidal anti-inflammatory)  
[variable name] *[variable name] represents interaction term 
 
 
Table A.10. Remission prediction multivariate linear regression analysis at baseline and 6 months 
Variable Coefficient (95% 
Confidence Interval) 
p-value 
Fixed Effects   
C-Reactive Protein -0.08 ( -0.1, 0.0 ) < 0.001      
NSAID Prescribed, reference value (Yes) 
       No  0.31 ( 0.2, 0.4 ) < 0.001      
Biologic Prescribed, reference value (Yes) 
       No  0.26 ( 0.1, 0.4 ) 0.002      
First follow up  0.17 ( 0.1, 0.2 ) < 0.001      
Constant -0.26 ( -0.5, 0.0 ) 0.019     
Random Effects  Standard 
Error 
Participant  0.26 ( 0.2, 0.3 ) 0.036       
Residual  0.45 ( 0.4, 0.5 ) 0.021      









Table A.11. Remission prediction using the indexes instead of C-Reactive Protein multivariate linear regression analysis at baseline 
and 6 months 
Variable Coefficient  (95% 
Confidence Interval) 
p-value 
Fixed Effects   
Pro-Inflammatory Index† -0.05 ( -0.1, -0.0 ) 0.006     
Anti-Inflammatory Index†  0.04 ( -0.0, 0.1 ) 0.070     
25(OH)D  0.16 ( 0.0, 0.3 ) 0.019      
First follow up  0.18 ( 0.1, 0.3) 0.002      
Constant -0.82 (-1.5, -0.2)  
Random Effects  Standard 
Error 
Participant  0.13 ( 0.1, 0.3 ) 0.055    
Residual  0.30 ( 0.2, 0.4 ) 0.028  
25(OH)D (25-hydroxyvitamin D) 
† A method of standardization to compare and combine biochemical markers was developed by Tabung et al. (Tabung et al., 2015). 
The standardized values were combined to create the overall pro-inflammatory biomarker score (C-Reactive Protein + Tumor 
Necrosis Factor –α + Interleukin (IL)-6). The same method of standardization was used to calculate an anti-inflammatory score to 
combine the concentrations of cytokines IL-4 and IL-10.   
 
 
Table A.12. Remission prediction multivariate linear regression analysis all visits 
Variable Remission Classification 
 Coefficient  (95% 
Confidence Interval)   
p-value 
Fixed Effects   
C-Reactive Protein -0.08 ( -0.1, 0.0 ) < 0.001      
NSAID Prescribed, reference value (Yes) 
       No  0.31 ( 0.2, 0.4 ) < 0.001      
Biologic Prescribed, reference value (Yes) 







Follow ups  0.17 ( 0.1, 0.2 ) < 0.001      
Constant -0.26 ( -0.5, 0.0 ) 0.019     
Random Effects  Standard 
Error 
Participant  0.26 ( 0.2, 0.3 ) 0.036       
Residual  0.45 ( 0.4, 0.5 ) 0.021    







Recruitment Centres Participating in BBOP Study 
 
British Columbia Children’s Hospital, University of British Columbia, Vancouver, BC  
Alberta Children’s Hospital, Calgary, University of Alberta, AB; Stollery Children’s Hospital, 
Edmonton, University of Alberta, AB 
Royal University Hospital, Saskatoon, University of Saskatchewan, SK 
Children’s Hospital, Winnipeg, University of Manitoba, MB 
The Hospital for Sick Children, University of Toronto, Toronto, ON 
The Montreal Children’s Hospital, McGill University, Montreal, QC 
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC 
Centre Hospitalier de l’universite Laval, Laval, QC; 
 IWK Health Centre, Dalhousie Univeristy, Halifax, NS 
Janeway Children’s Health and Rehabilitation Centre, Memorial University, St. John’s, NL 
 
 
